

27 OCT 2000

FORM PTO-1390U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  
(REV 5-93)

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER

3477-89

U.S. APPLICATION NO. (If known see 37 C.F.R. 1.5)

09/674237

INTERNATIONAL APPLICATION NO.

PCT/CA99/00375

INTERNATIONAL FILING DATE

27 April 1999

PRIORITY DATE CLAIMED

27 April 1998

TITLE OF INVENTION

ESE GENES AND PROTEINS

APPLICANT(S) FOR DO/EO/US

Sean E. EGAN; Wei WANG; Ameet SENGAR

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(l).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☒ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.  
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: International Preliminary Examination Report; International Search Report; PCT Demand; PCT Request; Sequence Listing (paper and computer copy).

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.50) <b>09/674237</b>		INTERNATIONAL APPLICATION NO. PCT/CA99/00375		ATTORNEY'S DOCKET NUMBER 3477-89	
---	--	---	--	-------------------------------------	--

17. <input checked="" type="checkbox"/> The following fees are submitted: <b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Search Report has been prepared by the EPO or JPO . . . . . \$860.00  International preliminary examination fee paid to USPTO (37 CFR 1.482). . . . . \$690.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) . . . . . \$710.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. . . . . \$1,000.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4). . . . . \$96.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00				CALCULATIONS		PTO USE ONLY	

Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	58 - 20 =	38	X \$18.00	\$ 684.00	
Independent Claims	26 - 3 =	23	X \$80.00	\$1,840.00	
Multiple dependent claim(s) (if applicable)				+ \$270.00	\$
TOTAL OF ABOVE CALCULATIONS =				\$3,384.00	
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity statement must also be filed. (Note 37 CFR 1.9, 1.27, 1.28).				\$	
SUBTOTAL =				\$3,384.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$3,384.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +				\$	
TOTAL FEES ENCLOSED =				\$3,384.00	
				Amount to be refunded	\$
				charged	\$

a. ☒ A check in the amount of **\$3,384.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:

Karen A. Magri  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, North Carolina 27627

"Express Mail" mailing label number EL682671390US  
Date of Deposit: October 27, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.

*Margaret J. Pfeiffer*  
Margaret J. Pfeiffer  
Date of Signature: October 27, 2000

*Karen Magri*  
SIGNATURE

\_\_\_\_\_  
Karen A. Magri

41,965  
REGISTRATION NUMBER

Attorney's Docket No. 3477-89

PATENT

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Application of Egan et al.  
Serial No.: To be Assigned  
Filed: Concurrently Herewith  
For: *ESE GENES AND PROTEINS*

Date: October 27, 2000

BOX PCT  
Commissioner for Patents  
Washington, DC 20231

**Preliminary Amendment**

Please amend the above-referenced application as follows prior to substantive examination.

**In the Specification.**

After the title, please insert the following:

**--Related Application Information**

This application claims the benefit under 35 U.S.C. § 371 from PCT Application No. PCT/CA99/00375, filed April 27, 1999, the disclosure of which is incorporated by reference herein in its entirety, which claims the benefit of Canadian Application Serial No. 2,230,201, filed April 27, 1998 and U.S. Provisional Application Serial No. 60/118,739, filed February 5, 1999, the disclosures of which are incorporated by reference herein in their entirety.--

**In the Claims.**

Please amend the claims as follows.

9. (Amended) A recombinant vector comprising the isolated nucleic acid of claim 1 [any of the preceding claims].

19. (Amended) A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising

09/ 674 237

the nucleic acid of claim 2[, 3 or 4] under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

28. (Amended) A recombinant vector comprising the isolated nucleic acid of claim 20 [any of claims 20 to 26].

38. (Amended) A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 20[, 21 or 22] under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

42. (Amended) The method of claim 40[or 41], wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.

Please add the following new claims.

50. A recombinant vector comprising the isolated nucleic acid of claim 7.

51 A host cell comprising the recombinant vector of claim 50.

52. A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 3 under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

53. A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 4 under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.

09674237-072404



54. A recombinant vector comprising the isolated nucleic acid of claim 26.

55. A host cell comprising the recombinant vector of claim 54.

56. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 21 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

57. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 22 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

58. The method of claim 41, wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.

#### Remarks

Claims 9, 19, 28, 38 and 42 have been amended, and new Claims 50-58 added, to remove multiple dependencies from the claims. It is submitted that this application is now in condition for substantive examination, which action is respectfully requested.

Respectfully submitted,




Karen A. Magri

Registration No. 41,965

Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, NC 27627  
Tel. (919) 854-1400  
Fax (919) 854-1401

"Express Mail" mailing label number EL682671390US  
Date of Deposit: October 27, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.



Marjorie J. Pfeiffer  
Date of Signature: October 27, 2000

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**Docket No.  
3206-192/PAR

Serial No.

Filing Date

Patent No.

Issue Date

October 27, 2000

Applicant/ **EGAN, Sean, E. et al.**  
Patentee:Invention: **ESE GENES AND PROTEINS**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: HSC Research and Development Limited PartnershipADDRESS OF ORGANIZATION: 555 University Avenue, Suite 5270Toronto, OntarioM5G 1X8Canada

TYPE OF NONPROFIT ORGANIZATION:

- ☐ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America  
Name of State: \_\_\_\_\_ Citation of Statute: \_\_\_\_\_
- ☒ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  
Name of State: \_\_\_\_\_ Citation of Statute: \_\_\_\_\_

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.
- ☒ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.  
☐ each such person, concern or organization is listed below.

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

TITLE IN ORGANIZATION:

ADDRESS OF PERSON SIGNING:

Anne Marie Christman, President  
Research and Development Limited Partnership

SIGNATURE



DATE:

Nov 3/00

**ESE GENES AND PROTEINS****Field of the Invention**

This invention relates to novel mammalian proteins encoded by the Ese1 and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton.

5

**Background of the Invention**

Endocytosis via clathrin-coated pits is a multipstep process (1, 2). Clathrin heavy and light chains are brought to the plasma membrane through association with a heterotetrameric complex known as clathrin adaptor complex 2, or AP-2. At coated pits, the membrane is bent through the assembly of clathrin triskelion into a caged lattice. The GTPase Dynamin is also recruited to the neck of coated pits where it assembles into a collar for vesicle fission (4, 5). Recruitment of Dynamin to coated pits is believed to require the Amphiphysin I/II heterodimer (6), as these proteins bind Dynamin *in vivo* and amphiphysin proteins are required for endocytosis in yeast (7). In addition, ectopic expression of either Amphiphysin I or II by themselves (6), or the isolated SH3 domain of Amphiphysin I blocks endocytosis (8, 9). Recent data has revealed that the Rab5 small GTPase is required for sequestration of ligands such as transferrin and Epidermal Growth Factor into coated pits *in vitro* (10). The mechanism by which these components interact to regulate coated pit assembly, cargo sequestration, followed by vesicle fission is not yet understood.

From biochemical, cell biological and genetic analysis it is clear that additional components such as kinases, phosphatases, ubiquitin conjugating enzymes as well as lipid modifying enzymes are required for clathrin-coat and vesicle formation (1, 11, 12, 13, 14, 15, 16, 17, 18, 19). Indeed there is also strong evidence for a requirement of the actin cytoskeleton in endocytosis and several proteins which may facilitate this connection (1, 7, 20, 21, 22, 23, 24, 25).

The Eps15 protein was discovered in a search for substrates of the Epidermal Growth Factor Receptor (26). In 1995, Benmerah et. al. reported that Eps15 is constitutively associated with  $\alpha$ -adaptin of the AP2 complex (27). The Eps15 protein has also been localized to the neck of clathrin-coated pits by immunoelectron microscopy (28, 29). Recently, two groups have used dominant inhibitory mutants of Eps15, or antibodies against Eps15 (or the related protein Eps15R), to demonstrate that Eps15 proteins are required for endocytosis via clathrin-coated pits (30, 31). Eps15 contains three large structural domains (26, 32). The N-terminal third contains three copies of an EH domain (for Eps15 Homology domain) (32, 33). The central region of Eps15 forms an extended coiled-coil, which is followed by a complex C-

-2-

terminus containing SH3-binding motifs (34), a large number of DPF repeats (Aspartic acid-Proline-Phenylalanine), and  $\alpha$ -adaptin binding sequences (31, 35, 36). The full length Eps15R protein has a similar overall organization (34). Both Eps15 and Eps15R can be alternatively spliced to produce numerous smaller proteins(37).

5 A protein with similar overall organization has been identified in *Saccharomyces cerevisiae* named Pan1p. Genetic analysis of *PAN1* has revealed that this gene is required for endocytosis and for organization of the actin cytoskeleton (23, 38). Like Eps15 and Eps15R in mammals, the Pan1p protein has N-terminal EH domains followed by a central coiled-coil domain and C-terminal proline-rich  
10 sequences. A second EH domain containing protein, End3p, has also been described in *S. cerevisiae* which is required for endocytosis and regulation of the actin cytoskeleton (21, 39). Co-immunoprecipitation studies have shown that Pan1p and End3p form a complex *in vivo* (40). Indeed, overexpression of End3p can suppress the phenotype of *pan1-4* hypomorphic mutants, and Pan1p is mislocalized in *end3*  
15 mutants indicating that these proteins function together (40). Additional studies have revealed that the EH domains of Pan1p bind to yeast homologues of mammalian clathrin-binding proteins, AP180 and CALM (yAP180A and yAP180B), through NPF motifs (Asparagine-Proline-Phenylalanine) in the yAP180 C-termini(25). These data have led to a proposal that the Pan1p:End3p complex functions as a multivalent  
20 adaptor to coordinate protein-protein interactions during endocytosis (25, 40). At least two additional proteins are predicted to bind to the Pan1p:End3p complex *in vivo*, as strong genetic interactions have been detected between *PAN1* and *SJL1*(25), and between *PAN1* and *RSP5* (41). *SJL1* encodes a phosphatidylinositol polyphosphate-5-phosphatase protein which is related to mammalian synaptojanin  
25 (42) and has a C-terminal NPF motif predicted to bind to EH domains in Pan1p (or End3p) (25, 43). *RSP5* encodes an E3 ubiquitin-protein ligase which may bind to the C-terminal polyproline sequences in Pan1p through one of its three WW domains (25).

30 Numerous SH3 domain containing proteins have been implicated in the regulation of endocytosis (44). These include Amphiphysin I(45) and II (6, 46, 47, 48), Rsv161/Rsv167(7), Actin Binding Protein-1(49), Endophilin/SH3P4/8/13 (50, 51) and Grb2 (52). Kay and coworkers have reported the isolation of several novel SH3 encoding cDNAs (53).

35 The present inventors have identified novel mammalian proteins containing both EH and SH3 domains, which have been named Ese1 and Ese2. Sequence and functional analysis of the full length proteins have implicated these proteins in receptor mediated endocytosis via clathrin coated pits and therefore the proteins have

been named Ese1 and Ese2 respectively (Ese: for EH-domain and SH3 domain regulator of Endocytosis). Also identified are several mammalian alternative transcript proteins two of which are named Ese1L and Ese2L.

5    **Summary of the Invention**

In accordance with one series of embodiments, this invention provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mammalian Ese1 and Ese2 proteins.

10    The invention more specifically provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mouse Ese1 and Ese2 proteins.

15    One of ordinary skill in the art is now able to identify and isolate mammalian Ese protein genes or cDNAs which are allelic variants of the disclosed sequences or are homologues thereof, in other species, including humans, using standard hybridisation screening and PCR techniques. The mammalian polynucleotide may be in the form of DNA, genomic DNA, cDNA, mRNA and various fragments and portions of the gene sequence encoding Ese proteins.

20    Homologues of the mammalian Ese protein genes are generally those sequences which share at least 80% sequence identity, preferably at least 90% sequence identity to the mammalian Ese gene sequence.

In a further embodiment, the invention provides cDNA sequences encoding murine Ese1 and Ese2 proteins comprising the nucleotide sequences of Sequence ID NOS: 1, 2, 4 and 5.

25    In a further embodiment, the invention provides cDNA sequences encoding murine Ese1L and Ese2L proteins comprising the nucleotides sequences of Sequence ID NOS: 22, 23, 25 and 26.

30    Also provided are portions of the Ese gene sequences useful as probes or PCR primers or for encoding fragments, functional domains or antigenic determinants of Ese proteins. The probes can be routinely used to screen and identify homologues of the Ese gene or portions thereof while primers are useful in PCR assays for the amplification of desired portions of the selected Ese gene.

35    The invention also provides portions of the disclosed nucleic acid sequences comprising about 10 consecutive nucleotides to nearly the complete disclosed nucleic acid sequences. The invention provides isolated nucleic acid sequences comprising sequences corresponding to at least 10, preferably 15 and more preferably at least 20 consecutive nucleotides of the Ese genes as disclosed or enabled herein or their complements.

In addition, the isolated nucleic acids of the invention include any of the above described nucleotide sequences included in a vector. Expression vectors comprising the nucleotide sequences are provided along with suitable host cells transfected with such expression vectors.

5 In accordance with a further series of embodiments, this invention provides substantially pure mammalian Ese proteins, fragments of these proteins and fusion proteins including these proteins and fragments.

In accordance with a further series of embodiments, this invention provides substantially pure mutant mammalian Ese proteins, fragments of these proteins and  
10 fusion proteins including these mutant proteins and fragments.

In a further embodiment, the invention provides amino acid sequences encoding murine Ese1 and Ese2 proteins comprising the amino acid sequences of Sequence ID NOS: 3 and 6.

In a further embodiment, the invention provides amino acid sequences  
15 encoding murine Ese1L and Ese2L proteins, which are alternative transcripts, comprising the amino acid sequences of Sequence ID NOS: 24 and 27.

The proteins, fragments and fusion proteins have utility, as described herein, for the preparation of polyclonal and monoclonal antibodies to murine and mammalian Ese proteins, for the identification of binding partners of the mammalian  
20 Ese proteins and for diagnostic and therapeutic methods, as described herein. For these uses, the present invention provides substantially pure proteins, polypeptides or derivatives of polypeptides which comprise portions of the mammalian Ese amino acid sequences disclosed or enabled herein and which may vary from about 4 to 5 amino acids to the complete amino acid sequence of the proteins. The invention  
25 provides substantially pure proteins or polypeptides comprising sequences corresponding to at least 5, preferably at least 10 and more preferably 50 or 100 consecutive amino acids of the mammalian Ese proteins disclosed or enabled herein. Monoclonal antibodies having suitably specific binding affinity for the antigenic regions of a mammalian Ese protein are prepared by the use of corresponding  
30 hybridoma cell lines. In addition, polyclonal antibodies may be prepared by inoculation of animals with suitable peptides which add suitable specific binding affinities for antigenic regions of an Ese protein.

In a further embodiment of the invention, a process is provided for producing mammalian Ese proteins comprising culturing one of the above described transfected  
35 host cells under suitable conditions, to produce the Ese protein by expressing the DNA sequence.

The proteins of the invention may be isolated and purified by any conventional method suitable in relation to the properties revealed by the amino acid sequences of these proteins.

Alternatively, cell lines may be produced which express or over-express the  
5 Ese gene products, allowing purification of the proteins for biochemical characterisation, large-scale production, antibody production and patient therapy.

For protein expression, eukaryotic or prokaryotic expression systems may be generated in which an Ese gene sequence is introduced into a plasmid or other vector which is then introduced into living cells. Constructs in which the Ese cDNA  
10 sequences containing the entire open reading frame is inserted in the correct orientation into an expression plasmid may be used for protein expression. Alternatively, only portions of the sequence may be inserted. Prokaryotic or eukaryotic expression systems allow various important functional domains of the proteins to be recovered as fusion proteins and used for binding, structural and  
15 functional studies and also for the generation of appropriate antibodies.

The present invention includes effective fragments, analogues of the Ese proteins described herein. "Effective" fragments or analogues retain the activity of the described Ese proteins to regulate endocytosis, vesicular trafficking and actin dynamics. The term "analogue" extends to any functional and/or chemical equivalent  
20 of a mammalian Ese protein including mimetics and includes proteins having one or more conservative amino acid substitutions, proteins incorporation unnatural amino acids and proteins having modified side chains.

In accordance with a further embodiment of the invention, antibodies are enabled which bind specifically to the Ese proteins disclosed herein. Polyclonal or  
25 monoclonal antibodies may be prepared using conventional methods. Antibodies may also be prepared to individual selected domains of the Ese proteins, as described herein.

In a further embodiment, the invention provides pharmaceutical compositions containing an Ese protein, fragment or mimetic thereof or a non-functional mutant Ese  
30 protein, fragment or mimetic thereof for the treatment of mammalian disorders which involve abnormal endocytosis, vesicular trafficking and actin dynamics leading to altered cellular functioning. Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result. The  
35 composition comprises an Ese protein and a pharmaceutically acceptable carrier.

In accordance with a further embodiment, the invention provides a method for identifying binding partners of the Ese proteins disclosed herein. Such methods in



general include various assays including those including radiolabelling of the Ese proteins. Other methods may include but are not restricted to phage display, affinity purification techniques, expression cloning and the yeast 2-hybrid system, as described herein.

- 5 In accordance with a further embodiment of the present invention, is a method for identifying proteins which phosphorylate Ese proteins. Such method includes known phosphorylation assays.

- 10 The identification of proteins or peptides interact with or bind to Ese proteins can provide the basis for the design of peptide antagonists or agonists of Ese protein function or for the design of peptide antagonists or agonists of Ese protein binding partners which affect Ese protein function. Further, the structure of these peptides determined by standard techniques such as protein NMR or x-ray crystallography can provide the structural basis for the design of improved small molecule drugs.

- 15 In accordance with a further embodiment, the present invention also provides for the production of mouse models or transgenic non-human animal models for the study of mammalian Ese gene function, for the screening of candidate pharmaceutical compounds, for the creation of *in vitro* mammalian cell cultures which express the Ese proteins or in which an Ese gene has been inactivated by knock-out deletion, and for the evaluation of potential therapeutic interventions.

- 20 The invention enables a transgenic animal, including a transgenic insect, wherein the genome of the animal or of an ancestor of the animal has been modified by introduction of a transgene comprising mammalian Ese genes under the transcriptional control of tissue restricted regulatory elements including the mouse mammary-tumour virus long term repeat sequences.

- 25 Transgenic animals with inappropriate expression of Ese proteins may be examined for phenotypic changes, for example abnormal cellular development or abnormal cellular signalling, vesicular trafficking and actin dynamics and may be used to screen for compounds with potential as pharmaceuticals. Compounds which provide reversal of the phenotypic changes are candidates for development as  
30 pharmaceuticals.

- Transgenic animals in accordance with the invention can be created by introducing a DNA sequence encoding a selected Ese protein either into embryonic stem (ES) cells of a suitable animal such as a mouse, by transfection or  
35 microinjection, or into a germ line or stem cell by a standard technique of oocyte microinjection. Such methods of producing animal models are fully described in the literature.

-7-

In accordance with another aspect of the present invention is a method for screening a candidate compound for effectiveness as an antagonist of an Ese protein comprising:

- 5 (a) providing an assay method for determining the endocytotic regulatory capacity of an Ese protein; and
- (b) determining the endocytotic regulatory capacity of the Ese protein in the presence or absence of the candidate compound, wherein a reduced level of endocytosis in the presence of the candidate compound indicates antagonist activity of the compound.

10 In accordance with another aspect of the present invention is a method for treating in a mammal a disorder associated with an undesired level of endocytotic activity of an Ese protein comprising administering to the mammal an effective amount of a substance selected from the group consisting of:

- 15 (a) an Ese protein antagonist;
- (b) an antibody which binds specifically to an Ese protein;
- (c) an antisense strand comprising a nucleic acid sequence complementary to the sequence or fragment of the sequence and capable of hybridizing to the nucleic acid sequence encoding an Ese protein;
- (d) an agent which down regulates the expression of the Ese gene
- 20 encoding for an Ese protein;
- (e) an antagonist of an Ese protein binding partner; and
- (f) an Ese agonist.

According to another aspect of the present invention is a method for suppressing in a mammal, the abnormal proliferation of a cell capable of being  
25 stimulated to proliferate by a growth factor receptor, the method comprising administering to the mammal an effective amount of a Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein.

According to yet another aspect of the present invention is a method for preventing viral infection in a mammal, said method comprising administering to the  
30 mammal an effective amount of an Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein or an Ese mutant protein not capable of regulating endocytosis.

According to a further aspect of the present invention is a method for promoting endocytosis, vesicular trafficking and/or actin dynamics in selected cells in  
35 a mammal in need of such treatment, said method comprising administering to the mammal an effective amount of an Ese protein or an active analogue, mimic or fragment thereof.

According to a further aspect of the present invention is a method for blocking clathrin-mediated endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising overexpressing Ese1 protein or an active analogue, mimic or fragment thereof.

According to yet a further aspect of the present invention is a method for regulating endocytosis, vesicular trafficking and/or actin dynamics in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising providing an Ese1-Eps 15 complex and further providing a protein binding partner to bind to the complex to regulate components of the endocytic pathway. One such binding partner is dynamin.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **Summary of Tables and Drawings**

A detailed description of the preferred embodiments are provided herein below with reference to the following tables and drawings in which:

Table 1 shows alignment of mouse Ese1 and Ese2 protein sequences. EH, coiled-coil and SH3 domains are as indicated.

Table 2 shows the alignment of protein sequences of the Ese family in mouse, Xenopus and Drosophila. EH and SH3 domains are indicated with overlines. Amino acid identities (bolded) and similarly are boxed.

Figure 1 shows a Northern blot demonstrating expression of Ese1 and Ese2 genes in various adult tissues.

Figure 2A shows Western blots demonstrating the association of Ese and Eps15 proteins *in vivo*. Endogenous Ese1 proteins were precipitated with Rabbit anti-peptide antisera against the N-terminus of Ese1. Immunoprecipitates were then analyzed on western blots for the presence of Ese1/2 with Chicken anti-Ese antisera or for co-precipitation of Eps15 with Rabbit antisera raised against the C-terminus of Eps15.

Figure 2B shows alternative transcripts from the Ese1 and Ese2 genes which code for Ese1L and Ese2L proteins respectively, with C-terminal DBL/PH and C2 domains. Ese1 and Ese2 sequence junctions are indicated in bold red letters.

Figure 3A shows Ese and Eps15 associate *in vivo*. This schematic representation of association of Eps15/Eps15R with Ese1 in the yeast two-hybrid screen. Ese1 coiled-coil domain fused with the Gal4 DNA binding domain (DBD) interacted with Eps15/Eps15R Gal4 activation domain (AD) fusions. The AD-Eps15/Eps15R diagram represents the shortest interacting coding region isolated.

Figure 3B shows association of Ese and Eps15 C-terminal deletion mutants. Cos-1 cells were transfected with pcDNA3Eps15, pcDNA3Ese1 or the C-terminal deletion mutants pcDNA3Ese1 $\delta$ C and pcDNA3Eps15 $\delta$ C-Flag as indicated. Cell lysates were immunoprecipitated with rabbit anti-Ese1 or rabbit anti-Eps15 (left panel); rabbit anti-Ese1, mouse anti-Flag or rabbit anti-Eps15 (right panel). Panels represent western blots to detect the presence of Ese1 in each immunoprecipitation. A 90kDa Ese1 protein exists in the third and sixth lanes on the left panel which is the C-terminally truncated Ese1 protein which is co-immunoprecipitated in a complex with Eps15 in the sixth lane. Also, to be noted is the precipitation of Ese1 with anti-Flag monoclonal antibody in the sixth lane of the right panel experiment. In this case, Ese1 has been precipitated in a complex with the C-terminally truncated Eps15 $\delta$ C protein.

Figure 4 shows confocal immunofluorescent micrographs of Cos cells transfected with myc-Ese1 (A, A'); Eps15 (B); myc-Ese1 + Eps15 (C, C', C'') or myc-Ese1 + Eps15 $\delta$ C (D, D' and D''). Frames C'' and D' represents the overlapping images from frames C/C' and D/D', respectively. Overlap in frames C'' and D'' are indicated in yellow. Scale bar is equal to 10 microns.

Figure 5A and 5B show that Ese1 links to Dynamin and Eps15. Figure 5A is a schematic representation of association between Dynamin and Ese1 in the yeast two-hybrid screen. Ese1 SH3 domains fused with the Gal4 DNA binding domain (DBD) interacted with Dynamin Gal4 activation domain (AD) fusions. The AD-Dynamin diagram represents the shortest interacting coding region isolated. Figure 5B shows confocal immunofluorescent microscopy to detect transfected mycEse1 (frame a), transfected Eps15 (frame d) or endogenous Dynamin (frames b and e) in transfected Cos cells. Frame c and f represents the overlapping images from frames a/b and d/e respectively. Scale bar is equal to 10 microns.

Figure 6 shows Ese1 overexpression blocks endocytosis of Transferrin in Cos-1 cells. Confocal immunofluorescent microscopy was used to detect transfected mycEse1 (frame A), internalized FITC-labeled Transferrin (frame B). Overlapping images are shown in frame C revealing that Ese1 overexpression blocks clathrin-

mediated endocytosis of Transferrin. Mononuclear morphologically normal cells from both transfected and untransfected groups were assessed for internalization of transferrin. Scale bar is equal to 10 microns.

Figure 7 shows a proposed model for Ese regulation of Endocytosis.

In the drawings, preferred embodiments of the invention are illustrated by way of example. It is to be expressly understood that the description and drawings are only for the purpose of illustration and as an aid to understanding, and are not intended as a definition of the limits of the invention.

### **Detailed Description of the Invention**

#### **Sequencing of Murine Ese1 and Ese2 genes**

The full length murine Ese1 cDNA was sequenced (Sequence ID NO:1). It encodes a sequence of 1213 amino acids (Sequence ID NO:3) having a predicted molecular weight of 137 kDa. Murine Ese2 cDNA was also sequenced (Sequence ID NO:4) and encodes a sequence of 1197 amino acids (Sequence ID NO:6) having a predicted molecular weight of 135.7 kDa.

The full length Ese proteins are predicted to encode two N-terminal EH domains followed by a coiled-coil domain and five SH3 domains (Tables 1 and 2). Several Ese1 isolated clones contain only SH3<sub>A</sub>, SH3<sub>B</sub> and SH3<sub>E</sub> domains. Indeed, the SH3<sub>C</sub> domain was not included in the original human SH3P17 partial cDNA. In addition, expressed sequence tags from the Ese1 gene have been found in the public databases which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene is subject to complex alternative splicing and has the potential to encode for many distinct proteins. The predicted Ese2 protein on the other hand encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, suggesting that this gene is also alternatively spliced. The Ese proteins are 53% identical over the full length of Ese1 (645 of 1213 residues in Ese1 line up with identical residues in Ese2) and are related to the Ese protein from *Xenopus* which has recently been submitted to genebank (Accession # AF032118) and *Drosophila* (59) (Table 2). *Xenopus* Intersectin is 81% identical to mouse Ese1 and 54% identical to mouse Ese2 suggesting that Intersectin is an Ese1 orthologue (980/1213 residues of mouse Ese1 and 645/1198 residues of mouse Ese2 line up with identical residues in the *Xenopus* protein). *Drosophila* Dynamin associated protein, Dap160-1 is 32% identical to both mouse Ese proteins (393/1213 residues of mouse Ese1 and 387/1198 residues of mouse Ese2 line up with identical residues in the *Drosophila* protein). These homologies extend over the entire length

-11-

of Dap160-1, except that Dap160-1 has only four SH3 domains corresponding to the first, second, fourth and fifth SH3 domains of the mouse Ese proteins. Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites and at least one SH3-binding consensus (60) in the N-terminus of each Ese protein.

The two EH domains of Ese1 are highly related to the respective EH domains in Ese2 and these Ese EH domains are most closely related those found in Eps15 and Eps15R, two mammalian protein which are required for endocytosis through clathrin-coated pits. EH domains have also been identified in End3 and Pan1p which are yeast partners proteins required for endocytosis. The central third of both Ese proteins are predicted to encode an extended coiled-coil which is a domain typically associated with protein-protein association through dimerization or tetramerization as noted for Eps15 (29, 54). Besides the homology between Ese1 and Ese2, the Ese1 SH3 domains are most closely related to SH3 domains from Myosin IB in *Acanthamoeba* (SH3<sub>A</sub>), Myosin IB in *Entamoeba* (SH3<sub>B</sub>), the YFR024 hypothetical yeast protein (SH3<sub>C</sub>), Myosin IB from *Acanthamoeba* (SH3<sub>D</sub>) and Myosin IC from *Acanthamoeba* (SH3<sub>E</sub>). The same homologies are noted for SH3 domains from Ese2 with the exception of SH3<sub>A</sub> which is most similar to the SH3 domain from  $\beta$ PIX, SH3<sub>C</sub> which is most similar to an SH3 domain from the mouse Ray protein and SH3<sub>D</sub> which is most similar to the SH3 domain from *Dictyostelium* myosin IB. Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites in the Ese proteins and a single SH3 binding consensus in the N-termini of each Ese protein.

With the knowledge of the amino acid sequences for Ese1 and Ese2 proteins and the alternative transcripts Ese1L and Ese2L, there is provided in accordance with the present invention antibodies which recognize epitopes within these proteins and which can be raised to provide information on the characteristics of the protein as well as for any mutant form of these proteins. The generation of antibodies enables the visualization of the protein in mammalian cells and tissues using Western blotting as described herein. Antibodies to the Ese1 or Ese2 proteins also allows for the use of immunocytochemistry and immunofluorescence techniques in which the proteins are visualized directly in cells and tissues as described herein. This is most helpful in order to establish the subcellular location of the protein and the tissue specificity of the protein.

In general, methods for the preparation of antibodies are well known. In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of

-12-

the Ese1 or Ese2 proteins or any of their alternative transcripts can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle. The protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and injected into rabbits or other laboratory animals. Alternatively, protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use, by affinity chromatography. The sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the Ese1 or Ese2 protein, alternative transcript or any mutant thereof. Alternatively, synthetic peptides can be made to the antigenic portions of these proteins and used to inoculate the animals.

Methods to produce monoclonal antibodies which specifically recognize mammalian Ese1 or Ese2 proteins or portions thereof, are known in the art. In general, cells actively expressing the protein are cultured or isolated from tissues and the cell extracts isolated. The extracts or recombinant protein extracts, containing the Ese1 or Ese2 protein, are injected in Freund's adjuvant into mice. After being injected 9 times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened to identify those containing cells making useful antibody by ELISA. These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable lines of clones is established which produce the antibody. The monoclonal antibody can then be purified by affinity chromatography using Protein A or Protein G Sepharose.

The Ese proteins may be isolated and purified by methods selected on the basis of properties revealed by its sequence. Purification can be achieved by protein purification procedures such as chromatography methods (gel-filtration, ion-exchange and immunoaffinity), by high-performance liquid chromatography (HPLC, RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing and hydrophobic interaction chromatography) or by precipitation (immunoprecipitation).

-13-

Polyacrylamide gel electrophoresis can also be used to isolate the Ese proteins based on the molecular weight of the protein, charge properties and hydrophobicity.

Similar procedures to those mentioned can be used to purify the protein from cells transfected with vectors containing an Ese gene (e.g. baculovirus systems, yeast expression systems and eukaryotic expression systems).

The purified proteins can be used in further biochemical analyses to establish secondary and tertiary structure which may aid in the design of pharmaceuticals to interact with the protein, alter the protein charge configuration or charge interaction with other proteins or alter its function.

The Ese proteins can also be purified from the creation of fusion proteins which are expressed and recovered from prokaryotic or eukaryotic cells. The fusion proteins can be purified by affinity chromatography based upon the fusion vector sequence. The Ese protein can then be further purified from the fusion protein by enzymatic cleavage of the fusion protein.

#### Expression of Ese genes

In order to determine where the Ese genes are expressed Northern analysis was performed on mRNA derived from several adult mouse tissues (Figure 1). These genes are both widely expressed and reveal a complex pattern of alternatively spliced transcripts. The highest levels of Ese1 mRNA were noted in brain, heart and skeletal muscle. Brain and skeletal muscle mRNA also contain an unusually large transcript which may be as much as 15kb in length. Interestingly, these tissues express high levels of many proteins involved in synaptic vesicle recycling and endocytosis.

The Northern blot reveals the presence of many alternative mRNA transcripts for both Ese1 and Ese2. In addition, numerous Ese1 expressed sequence tags have been identified which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene has the potential to encode for many distinct proteins. Indeed, the SH3<sub>C</sub> domain was spliced out of the human SH3P17 partial cDNA described by Sparks 1996 (53). The predicted Ese2 protein on the other hand encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, revealing that this gene is also alternatively spliced. Lung, liver and kidney express high levels of a 2.4kb Ese2 transcript which is significantly smaller than the 3591bp sequence required to code for our full Ese2 protein as shown in Table 1 or 2, indicating that a major isoform of Ese2 has only a subset of the domains described above.



Alternative Splicing of Ese1, Ese2 transcripts

Additional transcripts from both Ese1 and Ese2 genes have also been characterized. One of the Ese1 clones isolated from a mouse brain cDNA library contained an extended reading frame. PCR was used from mouse brain cDNA libraries to identify the remaining coding sequences from this transcript. The splicing event which produces this extended protein adds an additional 501 amino acids to Ese1, and codes for a DBL homology domain, a Pleckstrin homology (PH) domain and a C2 domain (Figure 2B). DBL and PH domains are found together in guanine nucleotide exchange factors for the Rho family of small GTPases. This long form of Ese1 is therefore expected to function as an activator of Rho-GTPases, which in turn regulate the actin cytoskeleton and numerous signal transduction pathways (61). C2 domains on the other hand are  $\text{Ca}^{++}$  activated membrane binding domains and protein-protein interaction domains (62). A number of expressed sequence tags which code for a novel C2 domain fused to the sequence coding for the last 11 amino acids of Ese2 have been identified. PCR was used to isolate sequences coding for alternatively spliced exon(s) which can be included C-terminal to the SH3 domains but before the stop codon. The alternatively spliced exon(s) of Ese2 also code for a DBL/PH + C2 domain cassette which can be included within the Ese2 transcript (Figure 2B).

As the Ese genes are subject to complex alternative splicing to produce proteins with novel predicted functions (eg. regulation of the cytoskeleton and membrane-binding), the alternative proteins are named as modifications of Ese. The Ese1 and Ese2 long forms described in Figure 2B are called Ese1L and Ese2L, respectively. In the event that specific domains are spliced out from the transcripts coding for Ese1 and Ese2 proteins as shown in Table 2, then the name is listed as an Ese $\delta$  variant. The protein encoded by the spliced variant in the original SH3P17 clone is designated as Ese1 $\delta\text{S}_c$  to indicate removal of SH3<sub>c</sub>.

In an embodiment of the present invention the knowledge of the Ese1 and Ese2 gene sequences and their expression in heterologous cell systems can be used to demonstrate structure-function relationships as well as provide for cell lines for the purposes of drug screening. Ligating the Ese1 or Ese2 cDNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates, binding partners as well as activators and inhibitors of the proteins. Plasmid expression vectors containing either the entire, or portions thereof, Ese1 or Ese2 can be used in *in vitro* mutagenesis experiments which will identify portions of the protein crucial for regulatory function.

The Ese1 or Ese2 cDNA sequence (or Ese1L and Ese2L cDNA sequence) can

be manipulated in studies to understand the expression of the gene and its product, to achieve production of large quantities of the protein for functional analysis, for antibody production, and for patient therapy. The changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties. Partial or full-length cDNA sequences which encode for the Ese1 or Ese2 protein (or alternative transcripts thereof), modified or unmodified, may be ligated to bacterial expression vectors. *E. coli* can be used using the T7 RNA polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with M13 Phage mGPI-2. *E. coli* vectors can also be used with Phage lambda regulatory sequences, by fusion protein vectors (eg. lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.

Alternatively, the Ese 1 or Ese2 protein or alternative transcripts thereof can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus. For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long-term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin, G418 and purimycin.

Any of the Ese1 or Ese2 cDNA sequences can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.

The cDNA sequence or portions thereof, or a mini gene consisting of a cDNA with an intron and its own promoter, is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. The endogenous Ese1 or Ese2 gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression of the cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid-responsive promoter from the mouse mammary tumor virus.

Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory

-16-

elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.

5 Vectors are introduced into recipient cells by various methods including calcium phosphate, electroporation, lipofection, DEAE dextran, microinjection, or by protoplast fusion. Alternatively, the cDNA can be introduced by infection using viral vectors.

10 Eukaryotic expression systems can be used for many studies of the Ese1 or Ese2 gene and gene product(s) including determination of proper expression and post-translational modifications for full biological activity, identifying regulatory elements located in the 5' region of the Ese1 or Ese2 gene and their role in tissue regulation of protein expression, production of large amounts of the normal and mutant protein for isolation and purification, to use cells expressing the Ese1 or Ese2 protein or alternative transcripts thereof as a functional assay system for antibodies generated  
15 against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring and artificially produced mutant proteins.

20 Using the techniques mentioned, the expression vectors containing the Ese1 or Ese2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells. It is understood that the cDNA sequences for use in the present invention include those sequences disclosed herein encoding Ese1, Ese1L, Ese2 and Ese2L proteins.

25 The recombinant cloning vector, according to this invention, comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that Ese1 or Ese2 proteins or alternative transcripts thereof can be expressed. The expression control sequence may be selected from the group consisting of sequences that control the expression of genes  
30 of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be selected from the group consisting of the lac system, the trp system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.  
35

The host cell which may be transfected with the vector of this invention may

-17-

be selected from the group consisting of *E.coli*, *pseudomonas*, *bacillus subtilus*, *bacillus stearothermophilus*, or other bacilli; other bacteria, yeast, fungi, insect, mouse or other animal, plant hosts, or human tissue cells.

5     Subcellular localisation of Ese proteins

To determine the subcellular localization of Ese1, a myc-epitope tagged version of this protein (mycEse1) was engineered. This tagged protein was expressed in Cos cells and detected by confocal immunofluorescence using the mouse anti-myc monoclonal antibody 9E10 (Figure 4). Interestingly, the transfected Ese1 protein is  
10     highly concentrated into circular domains (Figure 4A and 4A') which are present throughout transfected cells (compare single optical section in Figure 4A with the projection of all sections through the same cell shown in 4A'). In some optical sections rings of fluorescent staining surrounding a non-staining area were observed suggesting that the Ese1 induced structures are vesicles rather than inclusion bodies  
15     (data not shown and Figure 6). Ese1 overexpressed in 10T1/2, BHK and Hela cells using the vaccinia virus T7 expression system is also localized to large circular domains (data not shown). This concentration of ectopically expressed Ese1 contrasts with the localization of Eps15 in transiently transfected cells, Eps15 being dispersed throughout the cell (Figure 4B). Ese1 and Eps15 proteins form a complex *in vivo* and  
20     yet localize to distinct subcellular compartments in transfected Cos cells. We therefore determined the localization of both mycEse1 and Eps15 in Cos cells co-transfected with both genes. In co-transfected cells, mycEse1 is still found in circular domains (Figure 4C). Interestingly, the transfected Eps15 is now also partially co-localized with Ese1 in the same circular domains (Figure 4C' and C'').

25     The C-terminal third of Eps15 contains several regions which are required for association with  $\alpha$ -adaptin of the AP2 clathrin adaptor complex (31). It has been shown that this region of Eps15 is not required for its association with Ese1 (Figure 4). In order to test whether Eps15 function may be required for Ese localization, mycEse1 and Eps15 $\delta$ C have been co-transfected. Interestingly, mycEse1 localization  
30     is still partially colocalized with Eps15 $\delta$ C (Figure 4D, D' and D'') but is no longer found to be concentrated within circular structures, indicating that Ese1 requires Eps15 function for distinctive subcellular localization in transfected cells. In addition, these data suggest that the Ese1:Eps15 complex may require association with AP2 which binds to the Eps15 C-terminus in order to form the large circular  
35     domains in Ese1 transfected cells.

Identification of binding partners of Ese proteins

In order to identify Ese partners, a systematic analysis was initiated of each domain for binding partners using the yeast two hybrid system. The central coiled-coil domain of Ese1 from amino acid 330 to 732 was fused to the GAL4 DNA binding domain and transformed into the Y190 reporter strain together with plasmid cDNA libraries from several tissue sources. Yeast colonies were selected for growth on Histidine minus plates in the presence of 40mM 3-amino triazole to select for interaction between library encoded GAL4 activation domain fusions and the GAL4 DNA binding domain Ese1 coiled-coil bait. Yeast colonies which survived selection for expression of the His3 gene were also tested for induction of the integrated LacZ gene which is GAL4 responsive in Y190. Prey plasmids were recovered from 37 positive yeast colonies which were selected for expression of both His3 and LacZ. Several classes of cDNA were recovered in this screen. One class included Eps15 which was isolated twice and Eps15R which was isolated from four yeast colonies. Interestingly these clones were all partial cDNA fusions which minimally included C-terminal sequences from the central coiled-coil domain to the 3'UTR (Figure 3A). In the case of Eps15, the positive clones start from amino acid 306 and 376 whereas in Eps15R the N-terminal boundary of clones were amino acid 4, 10, 222 and 386. These data indicate that minimal sequences required for interaction between the Ese1 coiled-coil domain and Eps15(R) include either or both of the central coiled-coil and/or the C-terminal third of these proteins.

The Ese proteins were analyzed *in vivo* to test for their association with Eps15 or Eps15R. Polyclonal antisera were raised in chickens against a GST fusion containing the C-terminus of Ese1 from amino acid 665 to the stop codon. This region of Ese1 contains all five of the SH3 domains. In addition, polyclonal antisera were generated in rabbits against a peptide representing the first 21 amino acids of Ese1. Cell lysates were prepared from A431, PC12, MDCK and Hela cells which represent cell lines from several distinct tissue types and species. The rabbit anti-peptide antisera were used to precipitate Ese1 from each lysate and precipitates were analyzed by western blotting using the chicken anti-Ese sera. In each cell line the presence of several specific bands in the range of 150kDa were observed which were precipitated in the absence but not in the presence of the peptide to which the sera was generated (Figure 3A). Thus the Ese1 protein is expressed in many tissue culture cells and runs in a range consistent with the predicted molecular weight of 137kDa. The same samples were also analyzed for co-immunoprecipitation of Eps15 proteins. In each case multiple Eps15 proteins were detected which co-purify with Ese1. The anti-Ese1 peptide antisera and commercially available anti-Eps15 antisera which were

used were raised against epitopes which are not shared by these proteins indicating that Ese1 and Eps15 are constitutively associated partners *in vivo*. This association is reminiscent of the previously detected complex between two EH domain containing yeast proteins, End3p and Pan1p.

5       Ese1 and Eps15 proteins both contain central coiled-coil motifs. In addition, Ese1 contains multiple C-terminal SH3 domains while Eps15 contains SH3-binding motifs. In order to map the regions of each protein which are required for their association *in vivo*, C-terminal truncations of each (Eps15 $\delta$ C and Ese1 $\delta$ C) were generated. Full length Eps15 was co-transfected into Cos-1 cells together with either  
10   full length Ese1 or C-terminally truncated Ese1 $\delta$ C. Cell lysates were precipitated with either rabbit anti-Eps15 or with rabbit anti-Ese1, and precipitates were western blotted with chicken anti Ese1 antisera. Interestingly, the C-terminally truncated Ese1 protein was efficiently immunoprecipitated in a complex with Eps15 using anti-Eps15 sera. In a reciprocal experiment Cos-1 cells were transfected with Ese1 alone or together  
15   with Eps15 or C-terminally truncated Eps15 which had been Flag-epitope tagged (Eps15 $\delta$ C-Flag). Cell lysates were prepared and immunoprecipitated with either rabbit anti-Ese1, mouse anti-Flag, or rabbit anti-Eps15 antibodies. These immunoprecipitations were also western blotted to analyze for the presence of Ese1 (Figure 3B). The anti-Flag antibody efficiently precipitated Ese1 from cells  
20   expressing Flag-tagged Eps15 $\delta$ C indicating that the C-terminally truncated Eps15 protein can bind to Ese1 *in vivo*. The Ese1 and Eps15 proteins are therefore associated through interaction of their central coiled-coil regions and do not require the presence of SH3 and SH3-binding motifs in their respective C-termini.

In addition to the identification of Eps15 and Eps15R in the yeast two hybrid  
25   screen with the coiled-coil domain bait of Ese1, the following were also identified as Ese binding proteins: TSG101 (accession #U52945), meningioma expressed antigens 6/11 (accession #U94780 for mea6),  $\beta$ -tropomyosin, rabaptin5 (accession #D86066), Adora2a (accession #Y13345), L1 lipid binding protein (accession #K02109) and numerous cytokeratins and laminins. Novel genes identified in this screen are  
30   detailed below.

Also performed was a yeast two hybrid screen using amino acids 665-1213 of Ese1 as bait. This screen led to the isolation of the following clones which produced GAL4 Activation domain fusions which bound to this SH3 domain bait of Ese1. The Ese-binding proteins identified in our SH3 screen were the cbl-b oncoprotein  
35   (accession #U26712), Dynamin II (accession #L31398), KIAA0268 (accession #D87742), Jerky (accession #U35730), hnRNP-K (accession #L29769), SAP49

-20-

(accession #L35013) and SOS-1 (accession #Z11574). Novel genes identified in this screen are detailed below and several novel clones as outlined below.

These results demonstrate that the novel Ese genes and the proteins that they encode function in a complex with Eps15 proteins to regulate endocytosis together. In addition, this complex contains binding sites for numerous other proteins.

Furthermore, with the identification of several potential phosphorylation sites on the Ese proteins, these results also suggest that whether or not complexed with Eps15, Ese proteins are involved in intracellular signalling processes which are likely to lead to altered cellular activity. Many Ese partners have been identified in these studies. Also revealed is a novel method to identify more Ese partners. Yeast cells have a complex formed by two EH domain proteins (Pan1p and End3p) which regulates both endocytosis as well as the actin cytoskeleton. Indeed, the Eps15 protein has been reported to regulate both endocytosis and the actin cytoskeleton (1). As Eps15 and Ese function together, and Ese contain many protein-protein interaction surfaces on this complex, strongly suggesting that the Ese proteins and their binding proteins are critical regulators of Eps15:Ese functions *in vivo*.

#### Ese and Dynamin

Yeast two-hybrid screens using baits composed of the GAL4 DNA-binding domain fused to individual SH3 domains of Ese1 were performed to identify Ese partners which bind the SH3s of this multi-domain protein. Initial screens with SH3B and SH3C domain fusions resulted in the artifactual isolation of many proline-rich fragments which did not represent real Ese partners. Screens were then done with GAL4 fusions containing all five SH3 domains from amino acid 665 to 1213. Forty one His3+/LacZ+ colonies from such screens were selected for further analysis. Six colonies were found to encode fragments of the Dynamin II gene and two encoded fragments of Dynamin I (Figure 5A). All Dynamin II clones had 5' start sites between amino acid 252 and 278 and terminated within the 3' UTR. The two Dynamin I clones were identical and contained a small coding region from amino acid 673 to the C-terminus. Dynamin sequences contained within each Ese1-interacting clone therefore minimally code for the proline-rich motifs (Figure 5A) which are known to bind SH3 domains *in vitro* (44). This result is consistent with the interaction between Dap160 and Dynamin that has been recently described in *Drosophila* (59). To determine the significance of Ese1:Dynamin binding, functional interactions between these proteins were tested for. MycEse1 was transfected into Cos cells. The subcellular localization of Dynamin in Ese1 overexpressing cells was analyzed by staining for endogenous Dynamin and the myc tag on Ese1. In many

-21-

Ese1 transfectants, endogenous Dynamin was recruited to the Ese1 staining vesicles and both proteins were co-localized (Figure 5B, panel a, b and c). These results demonstrate that Ese proteins bind Dynamin and can regulate its subcellular localization. Given that Ese1 functions in a complex with Eps15 and Ese can regulate the subcellular distribution of Dynamin, it was investigated whether Eps15 also co-localized with Dynamin. Eps15 transfected into Cos cells was diffusely localized (Figure 4). Endogenous Dynamin was not concentrated and was therefore not visible in Eps15 transfected cells (data not shown). When Ese1 and Eps15 were co-transfected however, Eps15 and endogenous Dynamin are colocalized on the Ese1 induced circles (Figure 5, panels d, e and f) indicating that all three proteins co-localize at these structures.

#### Ese and Epsin Family Proteins

In order to identify additional Ese partners, a fusion between GAL4-DBD and the N-terminal EH domain region of Ese1 (amino acids 1-393) was generated. This fusion protein was also used in yeast two hybrid screens with several GAL4 activation domain cDNA libraries. A total of 11 His3+/LacZ+ colonies were identified as containing library encoded fusion proteins which interact with the Ese1 EH-domain bait. Two of these clones coded for mouse homologues of the Epsin protein which was recently identified on the basis of its affinity for Eps15, and  $\alpha$ -adaptin and is required for clathrin-mediated endocytosis (63). The two Epsin clones code for C-terminal fragments from amino acids 403 and 470 respectively. One of the Ese1 EH-domain interacting clones which was obtained coded for a C-terminal fragment of a novel Epsin-family protein (63, 64). This cDNA has been independently isolated and named Ibp-2 in accession #AF057286. The Ibp2 clone which has been identified includes amino acids 326 to 509 of the partial coding sequence in Genbank. Each Epsin family protein which has been isolated contains a C-terminal region which codes for three copies of an NPF motif. This is also the region of Epsin which binds to Eps15. It has previously been shown that AP-2 can independently bind both Epsin and Eps 15. It is now demonstrated that the C-terminus of Epsin family proteins can bind not only to the EH domains of Eps15 but also to the EH domains of Ese1. These data suggest that either multiple Epsin proteins exist in the Ese:Eps15 complex or the interaction between individual proteins in various AP-2:Epsin:Eps15:Ese: Dynamin complexes may be subject to dynamic rearrangement during clathrin coated pit formation, invagination and scission. Also identified was a mammalian homologue of *drosophila*, SINA, seven in absentia.



-22-

Ese1 Overexpression Blocks Endocytosis

Overexpression of Pan1p in yeast induces phenotypes which are identical to those observed in pan1 loss-of-function mutants (65) suggesting that by altering the relative ratios of Pan1p to its numerous partners, the function of higher order Pan1p complexes may be blocked. As the Ese:Eps15 complex contains many protein-protein interaction domains which bind partners including Dynamin, Epsin and AP-2, it was thought that overexpressed Ese1 may disrupt the formation of higher order complexes between Ese proteins and partners. It was therefore tested whether clathrin-mediated endocytosis was functional in myc Ese1 overexpressing cells. Cos-1 cells were transfected with myc-tagged Ese1, and 48 hrs post transfection, FITC-labelled Transferrin was added to cultures for 30 minutes. Cells were then fixed and analyzed for expression of mycEse1 and for internalization of Transferrin. As shown in Figure 6, transfected cells do not internalize transferrin in contrast to their untransfected neighbors. Cell counts in a representative experiment indicate that 96% of Ese1 overexpressing cells do not internalize labeled transferrin (N=46) whereas 100% of untransfected cells were capable of clathrin-mediated endocytosis (N=100). It appears that overexpression of Dynamin II may override the Ese1 induced endocytic block. These data indicate that overexpression of Ese1 blocks endocytosis and this may be through sequestration of Dynamin or other Ese1 partners into non-productive binary complexes during endocytosis or recycling of the transferrin receptor. Overexpressed Ese1 would therefore be functioning as a dominant inhibitory protein through recruitment of partners into non-productive complexes which do not contain all of the necessary components for endocytosis to proceed.

Taken together, these studies demonstrate the identification and isolation of novel mammalian Ese proteins encoded by novel Ese genes which are involved in the regulation of endocytosis via clathrin-coated pits, vesicular trafficking and actin dynamics. These studies also demonstrate the identification and isolation of two alternative transcripts of the genes, named Ese1L and Ese2L. The process of endocytosis including receptor-mediated endocytosis as well as pinocytosis or non-receptor mediated endocytosis. The novel Ese proteins of the present invention appear to function to regulate endocytosis involving the formation of clathrin-coated pits by the polymerization of clathrin into a lattice along the cytosolic face of a region of membrane causing the region to expand inward. Ultimately, the pit pinches off from the membrane, and the clathrin cage is completed thus producing a coated vesicle. Through the binding of Eps15 to form an Ese-Eps15 complex via a central binding

-23-

region, the complex can recruit other proteins such as, Epsin, AP-2 and dynamin and promote coated vesicle formation and perhaps their transport to appropriate locations within the cell and release of internalized proteins and/or molecules (Figure 7). The SH3 C-terminal domains of the Ese proteins can bind and interact with several other proteins leading to a host of protein-protein interactions involved in subcellular trafficking and signalling. The Ese proteins may be activated or inactivated via phosphorylation of the proteins at numerous phosphorylation sites by the action of activated receptors on cell surfaces.

Due to the fact that the Ese proteins appear to be a key central player in the complex process of endocytosis involving protein-protein interactions and intracellular signalling, these proteins are most likely involved in a myriad of clinical conditions and processes which are very likely to include but not be limited to regulation of endocytosis (as described above), cell division and cancer (Eps15 and cbl are oncoproteins), cell migration (regulation of the actin cytoskeleton is required for many forms of cell migration), cell polarity, plane of cell division and cell fate specification (Eps15 binds to Numb *in vivo* which is required for these processes (43), RNA localization (several RNA binding proteins have been identified in the present screens) and viral infection and life cycle (Eps15 binds to RAB a cellular cofactor for HIV Rev (43)).

With respect to viral infection Ese proteins may play an important role and thus may be a target for developing therapeutic strategies against viral infection and virally-induced disease states. HIV is known to alter endocytosis of several important cell surface molecules including CD4 and MHC antigens. HIV-NEF has been demonstrated to bind to SH3 domains. NEF induces clathrin coated pit formation. As NEF binds SH3 domains and induces endocytosis, it is possible that Ese proteins may bind to NEF and are involved in NEF function. Therapeutic strategies to provide treatment for viral infection and virally induced disease states may therefore include the inhibition of Ese-NEF interactions, antibodies or other agents directed against Ese complexes to inhibit endocytosis and in this manner inhibit viral infection and virally induced disease states. It is also expected that many types of viruses will interact with the multi-component Eps15-Ese complex.

Synaptic transmission and abnormal or altered synaptic transmission as seen in various nervous disorders may also be a target for the therapeutic use of Ese proteins and/or antagonists. The Eps15:Ese complex has been demonstrated to regulate endocytosis, is highly expressed in the brain and Ese binds to Jerky; a protein required to prevent epilepsy in mice (57). Furthermore, Ese proteins are highly expressed not only in the brain but also in the heart and in skeletal muscle which are tissues

involving high levels of synaptic transmission. This suggests that Ese protein may be used in the treatment of nervous system disorders involving altered synaptic transmission.

Receptor-mediated cell signaling such as seen with several different types of growth factors also involves endocytosis. Over-expression, mutation or over-stimulation of growth factor receptors has been demonstrated to lead to abnormal cell division and growth as seen in cancer. For example, EGF is a potent mitogen for many epithelial cells and EGF receptor activation is known to stimulate intracellular kinase pathways leading to cell proliferation. Such activity may play a role in cancer progression. By altering the rate of endocytosis by targeting Ese proteins, the cell proliferative effect of growth factor receptor stimulation may be counteracted.

Abnormal cell division and cell migration is seen in several diseases and involves the cell cytoskeleton. The intracellular cytoskeleton is highly organized and consists of microtubules, microfilaments and intermediate filaments acting as an internal reinforcement in the cytoplasm of a cell. Together these structures associate in a regular and defined manner which is regulated by extracellular signals and may transduce plasma membrane signals by association with other proteins or by second messengers. The Ese-Eps15 complex is very likely to regulate the cytoskeleton by analogy to the role of Pan1p:End3p in regulation of yeast cytoskeleton. Furthermore, endocytosis is known to involve a rearrangement of the intracellular cytoskeleton. Cell division and migration require the continual rearrangement of the intracellular cytoskeleton. Therefore, abnormal patterns of cell division and migration may involve altered Ese function and altered endocytosis. The Ese proteins or the genes may therefore be used to alter regulation of endocytosis or the association of the Ese proteins with the cytoskeleton and may restore cell division and migration to normal levels and patterns.

Tissue development also involves the continual remodeling of the cytoskeletal network along with its associated proteins. Developmental diseases can occur as a result of abnormal remodeling of the cytoskeleton leading to altered intracellular signaling. As Ese proteins are likely to be involved with both the cytoskeleton and intracellular signaling they may also be directly involved in the development of certain developmental diseases and therefore may be a target for therapeutic treatment of such diseases. Ese proteins may also be involved in normal development including that of stem cells which are self-renewing cells that divide to produce differentiated daughter cells in various tissues. As Ese proteins are associated with the cytoskeleton they may play a part in the formation of certain types of differentiated cells through the partitioning of RNA and proteins such as nuMb during cell division.

### Transgenic Animal Models

The creation of transgenic animal models for abnormal endocytotic function characterized by altered Ese1 or Ese2 activity is important to the understanding of the function of these proteins in intracellular signaling and for the testing of possible therapies for abnormal endocytosis involving protein-protein interactions and intracellular signalling and leading to various clinical conditions. In general, techniques of generating transgenic animals are widely accepted and practiced

There are several ways in which to create an animal model in which the Ese1 or Ese2 gene expression or function is altered. One could simply generate a specific mutation in the mouse Ese1 or Ese2 gene as one strategy. Secondly a wild type human Ese1 or Ese2 gene and/or a humanized murine gene could be inserted into the animals genome by homologous recombination. It is also possible to insert a mutant (single or multiple) human gene as genomic or minigene construct using wild type or mutant or artificial promoter elements. More commonly, and most preferred in the present invention, knock-out of the endogenous murine genes may be accomplished by the insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase. Gene knockout produces homozygous mutant mice, which show symptoms or phenotype similar to those exhibited by a human.

In general, for gene knock-out, embryonic stem cells heterozygous for a knockout mutation in a gene of interest (ie. Ese1 or Ese2 gene) and homozygous for a marker gene (eg. coat colour) are transplanted into the blastocoel cavity of 4.5 day embryos homozygous for an alternate marker. The early embryos then are implanted into a pseudopregnant female. Some of the resulting progeny are chimeras. Chimeric mice then are backcrossed. Intercrossing will eventually produce individuals homozygous for the disrupted allele that is, knockout mice. (Capecchi, MR. 1989. Science. 244:1299-1291).

To inactivate the Ese1 or Ese2 mouse gene chemical or x-ray mutagenesis of mouse gametes, followed by fertilization, can be applied. Heterozygous offspring can then be identified by Southern blotting to demonstrate loss of one allele by dosage, or failure to inherit one parental allele using RFLP markers.

To create a transgenic mouse, a mutant or normal version of the human Ese1 or Ese2 gene can be inserted into a mouse germ line using standard techniques of oocyte microinjection or transfection or microinjection into stem cells. Alternatively,

-26-

if it is desired to inactivate or replace the endogenous Ese1 or Ese2 gene, homologous recombination using embryonic stem cells may be applied.

For oocyte injection, one or more copies of a mutant or normal Ese1 or Ese2 gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of transgenic Ese1 or Ese2 gene sequences. The transgene can be either a complete genomic sequence injected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.

Retroviral infection of early embryos can also be done to insert the human or mouse Ese1 or Ese2 gene. In this method, the Ese1 or Ese2 gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.

Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of the Ese1 or Ese2 gene is desired. For example, inactivation of the Ese1 or Ese1 gene can be done by designing a DNA fragment which contains sequences from a Ese1 or Ese2 exon flanking a selectable marker. Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the Ese1 or Ese2 gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.

This embodiment of the invention has the most significant commercial value as a mouse model for abnormal endocytotic activity and this may include disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic transmission disorders.

### Therapy

Gene therapy is another potential therapeutic approach for treating disorders involving abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton. Such disorders may include for example but not be limited to disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic

-27-

transmission disorders.

In such therapy, normal copies of a mammalian Ese gene are introduced into patients to code successfully for normal protein in several different affected cell types. The gene must be delivered to those cells in a form in which it can be taken up and  
5 code for sufficient protein to provide effective function

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. The targeted cells however must be able to divide and the expression of the levels or normal protein should be high. The full length Ese gene can be cloned into a  
10 retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest.

Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpesvirus such as Epstein-Barr virus.

Gene transfer could also be achieved using non-viral means requiring infection  
15 *in vitro*. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA into a cell. Although these methods are available, many of these are lower efficiency.

Antisense based strategies can employed to explore mammalian Ese gene function and as a basis for therapeutic drug design. The principle is based on the  
20 hypothesis that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary antisense species. The formation of a hybrid RNA duplex may then interfere with the processing/transport/translation and/or stability of the target Ese mRNA. Hybridization is required for the antisense effect to occur, however the efficiency of  
25 intracellular hybridization is low and therefore the consequences of such an event may not be very successful. Antisense strategies may use a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA and transfection of antisense RNA expression vectors. Antisense effects can be induced by control (sense) sequences, however, the extend of phenotypic changes are highly  
30 variable. Phenotypic effects induced by antisense effects are based on changes in criteria such as protein levels. Protein activity measurement, and target mRNA levels. Multidrug resistance is a useful model to study molecular events associated with phenotypic changes due to antisense effects, since the multidrug resistance phenotype can be established by expression of a single gene *mdr1* (MDR gene) encoding for P-  
35 glycoprotein.

Transplantation of normal genes into the affected area of the patient can also be useful therapy for any disease condition which includes abnormal endocytosis,

-28-

vesicular trafficking and abnormal regulation of the actin cytoskeleton. In this procedure, a normal human Ese gene is transferred into a cultivatable cell type, either exogenously or endogenously to the patient. These cells are then injected serotologically into the disease-affected tissue or tissues.

5 Immunotherapy is also possible for treating disorders which includes abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton. Antibodies are raised to a mutant Ese protein (or a portion thereof) and are administered to the patient to bind or block the mutant protein and prevent its deleterious effects. Simultaneously, expression of the normal protein product could  
10 be encouraged. Alternatively, antibodies are raised to specific complexes between mutant or normal Ese proteins and their binding partners.

A further approach is to stimulate endogenous antibody production to the desired antigen. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. An immunogenic composition may be prepared  
15 as injectables, as liquid solutions or emulsions. The Ese protein or other antigen may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance  
20 effectiveness. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.

The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.

25

#### Screening for Disease

In another embodiment of the invention the knowledge of mammalian Ese1 and Ese2 cDNA sequences provides for screening by conventional methods to obtain the corresponding human sequences and thus screening for various diseases involving  
30 abnormal Ese1 or Ese2 (or alternative transcripts thereof) in which the defect is due to a mutant Ese1 or Ese2 gene and thus an altered and abnormal endocytosis process involved in various disorders. Mutant forms of the protein may not be able to bind with their normal binding partners and thus endocytosis, vesicular trafficking and/or actin dynamics are negatively affected. Such defects may include, for example,  
35 cancer. Other defects may include abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders. People at a risk for such an abnormality or,

individuals not previously known to be at risk, or people in general may be screened routinely using probes to detect the presence of a mutant Ese1 or Ese2 gene by a variety of techniques. Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be PCR amplified prior to analysis. RNA or cDNA may also be used. To detect a specific DNA sequence hybridization using specific oligonucleotides, direct DNA sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are all methods which can be utilized. Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non-radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences are then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions of the subject sequence containing identified mutations.

Direct DNA sequencing reveals sequence differences between normal and mutant Ese1 or Ese2 DNA. Cloned DNA segments may be used as probes to detect specific DNA segments. PCR can be used to enhance the sensitivity of this method. PCR is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension of the annealed primer with a DNA polymerase. This results in an exponential increase of the target DNA.

Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.

Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis. Alternatively fluorography may be employed.

Genetic testing based on DNA sequence differences may be achieved by



-30-

detection of alteration in electrophoretic mobility of DNA fragments in gels. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. Small deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.

Nuclease protection assays (S1 or ligase-mediated) also reveal sequence changes at specific locations. Alternatively, to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used. Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.

DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes. The probe and target sequences may be in solution or the probe sequence may be immobilized. Autoradiography, radioactive decay, spectrophotometry, and fluorometry may also be used to identify specific individual genotypes.

According to an embodiment of the invention, the portion of the DNA segment that is informative for a mutation, can be amplified using PCR. The DNA segment immediately surrounding a specific mutation acquired from peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplified by PCR, the products separated by electrophoresis, and transferred to membrane. Labeled probes are then hybridized to the DNA fragments and autoradiography performed.

In a further embodiment, the invention provides pharmaceutical compositions comprising Ese1 or Ese2 proteins or a functional analogue or mimetic of these proteins or their alternative transcripts for the treatment of certain disorders characterized by abnormal endocytosis and thus cell-signalling due to lack or absence of the proteins. Such disorders may include but are not limited to abnormal cell division, cancer, viral infection, abnormal synaptic transmission as seen in central nervous disorders and abnormal cell differentiation. Such compositions as provided herein can be appropriately packaged and targeted to specific cells and/or tissues.

Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result. This may also vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the Ese1 or Ese2 proteins, peptides or alternative transcripts ( for example Ese1L

-31-

and Ese2L) to elicit a desired response in the subject. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

5 By pharmaceutically acceptable carrier as used herein is meant one or more compatible solid or liquid delivery systems. Some examples of pharmaceutically acceptable carriers are sugars, starches, cellulose and its derivatives, powdered tragacanth, malt, gelatin, collagen, talc, stearic acids, magnesium stearate, calcium sulfate, vegetable oils, polyols, agar, alginic acids, pyrogen-free water, isotonic saline, 10 phosphate buffer, and other suitable non-toxic substances used in pharmaceutical formulations. Other excipients such as wetting agents and lubricants, tableting agents, stabilizers, anti-oxidants and preservatives are also contemplated.

The compositions described herein can be prepared by known methods for the preparation of pharmaceutically acceptable compositions which can be administered 15 to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable carrier. Suitable carriers and formulations adapted for particular modes of administration are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis the compositions 20 include, albeit not exclusively, solutions of the substance in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The pharmaceutical compositions of the invention may be administered therapeutically by various routes such as by injection or by oral, nasal, buccal, rectal, 25 vaginal, transdermal or ocular routes in a variety of formulations, as is known to those skilled in the art.

The present invention also enables the analysis of factors affecting the expression of the Ese1 or Ese2 gene in humans or in animal models. The invention further provides a system for screening candidate compounds for their ability to turn 30 on or turn off expression of the Ese1 or Ese2 gene or to screen compounds which are binding partners of these proteins.

For example, a cell culture system can be used to identify compounds which activate production of Ese1 or Ese2 proteins or, once Ese1 or Ese2 production has been activated in the cells, they can be used to identify compounds which lead to 35 suppression or switching off of Ese1 or Ese2 protein production. Compounds thus identified are useful as therapeutics in conditions where Ese1 or Ese2 production is deficient or excessive.

-32-

Compounds can also be screened in culture for their ability to overcome the effect of Ese protein expression in cell culture, tissue culture or in an animal model.

The present invention enables also a screening method for compounds of therapeutic utility as antagonists of the biological activity, binding activity, of Ese1 or  
5 Ese2 proteins and their binding partners. Those skilled in the art will be able to devise a number of possible screening methods for screening candidate compounds for Ese1 or Ese2 protein antagonism.

A screening method may also be based on binding to the Ese1 or Ese2 protein. Such competitive binding assays are well known to those skilled in the art. Once  
10 binding has been established for a particular compound, a biological activity assay is employed to determine agonist or antagonist potential.

Cell-free assays can also be readily designed by those skilled in the art to monitor and measure endocytosis, vesicular trafficking and actin dynamics.

To summarize, Ese proteins, Ese complexes including Eps15, Eps15R and  
15 many of the proteins identified in the screens as well as others identified through similar screens can be targeted for use in therapies to treat diseases including cancer, viral infection based diseases, developmental diseases due to altered cell fate specification and/or division as well as neurological diseases and diseases of altered cell migration and other diseases due to defects in the actin cytoskeleton.

20

### **EXAMPLES**

The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.

Methods of molecular genetics, protein and peptide biochemistry and  
25 immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

### **Material and Methods**

#### **Ese cloning and plasmids**

30 High Stringency screening was used to isolate the two mouse Ese cDNAs by previously described methodology (58). Ese1 was cloned from an adult mouse brain cDNA library using a PCR product from nt 1707-2197 of the coding sequence as probe. Ese2 was cloned from a mixed tissue adult mouse cDNA library using a mixture of three probes EST#583881 (Research Genetics Inc.), EST#652549  
35 (Research Genetics Inc.) and a PCR product from nt 2712 to nt 3456 of the Ese2 coding sequence.

-33-

The Ese1 sequence was obtained from a single clone, whereas the Ese2 reading frame was predicted from the overlap of two cDNA clones. The DBL/PH/C2 region of Ese1L was obtained using PCR with an upstream primer designed from sequences within the DBL/PH domain region:

- 5 GAAGGAGAACTCAGACCGGCTGGAGTGGAT (this sequence was obtained from one partial Ese1L clone which we had isolated from a mouse brain cDNA library). This upstream primer was paired with downstream primers for the vector. The DBL/PH/C2 region of Ese2L was obtained using PCR with upstream and downstream primers flanking the site in Ese2 where sequence divergence had been noted within an
- 10 EST clone (upstream Ese2 sequence: GACAGAGGAGCGGTACATGGA and downstream Ese2 sequence: AGCTCCCCTGGTTCTGGCTTC). The mouse Eps15 cDNA was generated through a combination of high stringency library screening with Est sequences from the Eps15 gene and rt PCT according to established methods.

15 pcDNA3Ese1:

Full length Ese1 was cloned into the NotI site of pcDNA3 (Invitrogen Inc.). The Ese1 cDNA includes 53 nucleotides of 5' UTR plus a natural NotI site and 288 nucleotides of 3'UTR plus a small region of polylinker including a NotI site.

20 pcDNA3mycEse1:

The 5' end of pcDNA3Ese1 from the EcoRI site in the pcDNA3 polylinker to the start codon was replaced with the DNA sequence

GAATTCAGAACCATGGAACAAAAGCTTATTTCTGAAGAAGACTTGGGGCCC

- 25 ATG: where the first underline corresponds to an EcoRI site which was fused into the pcDNA3 EcoRI site and the extended underlined sequence codes for a myc-epitope tag. This is followed by nine nucleotides which code for glycine, proline and the natural Ese1 start codon. This sequence was joined to the sequences coding for amino acids 2-1213 (the remainder of Ese1). The new start codon in this tagged Ese1 construct is bolded. The 3' end of Ese1 in this vector is the same as in pcDNA3Ese1 above.

30

pcDNA3Ese1δC:

The C-terminus of Ese1 was removed by replacing all sequences from nt 2209 of the coding sequence to the XhoI site in pcDNA3Ese1 with TGACTCGAG where the stop codon is in bold and the XhoI site is underlined. This construct codes for

35 amino acids 1-736 of Ese1.

pcDNA3Eps15:

-34-

This plasmid was constructed from four pieces. It contains the full length Eps15. The 5'UTR of this construct has been constructed to be GGATCC**ACCATG** where a BamHI site is underlined and the start codon is bolded. This BamHI site was fused to the BamHI site in pcDNA3. The 3'UTR in this vector is 204 nt of the mouse natural 3'UTR fused to a short cloning linker ending in the sequence AAGCTTGGGCCC where an ApaI site is underlined; this ApaI site was fused to the ApaI site in pcDNA3.

#### pcDNA3Eps15δC:

This vector is the same as pcDNA3Eps15 except that sequences downstream from and including mouse Eps15 coding nucleotide 1500 have been replaced with CCTGGATTACAAGGATGATGATGACAAATGACTCGAG where the first underlined sequence codes for the Flag-epitope, an inframe stop codon is bolded and an XhoI site is underlined. This XhoI site was fused to the polylinker in pcDNA3. The resulting plasmid encodes amino acids 1-501 of mouse Eps15 fused to a C-terminal Flag epitope. The 5' end of Eps15 in this construct is as indicated above for pcDNA3Eps15.

#### pGBT9Ese1cc:

The Ese1 sequence coding for amino acids 330 to 732 were fused directly to GAATTC (EcoRI site) on the 5' end and to **TAGGATCC** (stop codon followed by a BamHI site) on the 3' end. This fragment was cloned into EcoRI/BamHI digested pGBT9 in frame with the GAL4 DBD.

#### pGBT9Ese1A3.3:

This plasmid encodes the bait for our SH3 screen. It encodes all five SH3 domains from amino acid 665-1213 and was subcloned into pGBT9 on an EcoRI fragment which fuses the Ese1 SH3 region in frame with the DBD of GAL4.

#### pGBT9Ese1Nterm:

This plasmid codes for the N-terminal 393 amino acids of Ese1, including both EH domains. It was subcloned into pGBT9 on an EcoRI/Sall fragment.

#### Yeast 2-Hybrid Screening

pGBT9Ese1cc was transformed into *S. cerevisiae* strain Y190 using 45% PEG4000, 100 mM LiAc, 10 mM Tris-HCl (pH 7.5) as per standard protocols. Cells were plated onto Sc-Trp drop-out media. Single colonies were isolated and expression

-35-

of bait was analyzed by Western Blot using antibodies against the GAL4 DBD. A clone expressing the bait fusion was used to inoculate a 100 mL Sc-Trp liquid culture grown overnight at 30°C. Cells were then re-inoculated into YPD at a density of  $5 \times 10^6$  cells/mL and grown at 30°C until the titer reached  $2 \times 10^7$  cells/mL. Cells were pelleted, resuspended in 50 mL 100 mM LiAc and incubated for 10 min at 30°C. Once again the cells were pelleted, resuspended in 20 mL PLA [35% PEG, 100 mM LiAc, 2 mg/mL salmon sperm DNA] containing 30 µg plasmid library (cloned in pAD-GAL4) incubated at 30°C for 30 min.; then heat shocked at 42°C for 40 min., pelleted, resuspended in water and plated onto [Sc-Trp-Leu-His+40 mM 3-AT]. Plates were incubated at 30°C until colonies were formed. Colonies were picked, patched and grown at 30°C overnight on Whatman filter paper laid on top of Sc-Trp-Leu-His plates. Filters were submerged in liquid nitrogen for 15 seconds then placed on top of blotting paper soaked in Z-buffer + X-gal. β-galactosidase activity was measured by the appearance of blue colour. Plasmids from β-galactosidase positive colonies were shuttled to bacteria by electroporation and isolated for sequencing.

#### Northern Blot analysis

A multiple tissue northern blot (Clontech) was prehybridized in 5 mL of ExpressHyb Solution (Clontech) at 68°C for 30 min. Probe was added at  $1 \times 10^6$  cpm/mL for 1 hr. The Blot was washed twice (2X SSC, 0.05% SDS) at room temperature, twice (0.1X SSC, 0.1% SDS) at 50°C and then exposed to film overnight.

#### Antibodies and Western Blot analysis

Western blot analysis was performed according to standard protocols. Briefly, cultured cell lines or 48 hours post transfection Cos-1 cells were washed with PBS and lysed in one ml of cold lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 10% glycerol, 1% Triton X100, 1 mM EGTA, 1.5 mM  $MgCl_2$ , 10 mM NaF,  $10 \text{ mg ml}^{-1}$  aprotinin, 1 mM PMSF,  $10 \text{ mg ml}^{-1}$  leupeptin, 1 mM  $Na_3VO_4$ ). Supernatants were clarified by centrifugation and immunoprecipitated with specific antiserum as indicated. Antigen-Antibody complexes were purified on anti-rabbit agarose or anti-mouse agarose (Sigma Chemical Co.) Samples were run on 7.5% PAGE gels and transferred to nitrocellulose membranes. Filters were blocked in 5% dry milk powder/0.05% Tween 20/PBS, washed in 1% dry milk powder/0.05% Tween 20/PBS, and probed with the appropriate antisera at 1mg/ml in wash buffer (In the case of chicken anti-Ese1 we used 10µg/ml to probe western blots). Probed filters were

-36-

further washed, probed again with 1/5000 dilution of horseradish peroxidase conjugated anti-rabbit IgG, anti-mouse IgG antibodies (Amersham), or anti-chicken-IgY (Zymed); washed and signal detected using the Enhanced Chemiluminescence detection system as per manufacturers instructions (Amersham).

5 Rabbit anti-Ese1 antisera was raised against a peptide of the following sequence: MAQFPTPFGGSLDVWAITVEE. The antisera was affinity purified over the same peptide (Research Genetics). This peptide was also used at 5µg to compete for the 5µg of antibody per immunoprecipitation reaction. Chicken anti-Ese1 antisera was raised against a fusion protein between GST and amino acids 665-1213 of mouse  
10 Ese1. This sera was cleared of antibodies reacting against GST by incubation with glutathione s-transferase on glutathione agarose beads.

Rabbit antibodies have also been raised against a peptide encoding the first twenty one amino acids of mouse Ese2. These antibodies were affinity purified and used to immunoprecipitate endogenous Ese1 containing protein complexes from  
15 cultured PC12 cells. A protein of approximately 130 kDa was co-immunoprecipitated in complex with Ese2. This protein was isolated from a silver stained gel slice, digested with trypsin and the resulting peptide fragments were analyzed using both MALDI-TOF and Q-TOF Mass Spectrometers. Taken together, these mass spec analyses revealed that the Ese-2 binding protein in question is a Rho-Family exchange  
20 protein variably known as KIAA0362, Dbs and Ost. The gene encoding KIAA0362, Dbs and Ost proteins is subject to complex alternative splicing but each protein is predicted to contain the DBL/PH exchange domain. Thus Ese proteins are found in complex with exchange proteins for the Rho-family of small GTP-binding proteins.

25 Monoclonal antibodies against Ese proteins were produced by immunizing mice with a GST fusion protein encoding the Ese1 C-terminus (from amino acid 665 to the stop codon) according to standard protocols. After multiple injections, the mouse spleens were removed and resuspended in phosphate buffered saline (PBS).  
30 The spleen cells served as a source of lymphocytes. These lymphocytes were fused with a permanently growing myeloma partner cell, and the products of the fusion were plated into 96well plates in the presence of selective media. The culture supernatants were then screened by ELISA to identify those containing cells which were secreting anti-Ese antibodies. A histidine tagged version of the Ese1C-terminus was used in  
35 these ELISA screens to ensure that anti-Ese antibodies were detected rather than antibodies directed against the GST

-37-

portion of our original immunogen. From this procedure we isolated several independent stable hybridoma cloned lines which secrete anti-Ese antibodies. The monoclonal antibodies have then been purified on protein A/G columns as per standard protocols and demonstrated to bind Ese protein.

5

#### Immunofluorescence

For Immunofluorescent staining, Cos-1 cells were typically plated at a density of  $2 \times 10^5$  per 22x50mm coverglass and transfected with 2.5 $\mu$ g of plasmid using Superfect (Qiagen Inc.). After 2 hours, the cells were washed with 10%FBS in Iscove's Media and fed with fresh 10%FBS in Iscove's Media. Two days later, these cultures were fixed with cold methanol for 30 minutes at room temperature. Cultures were washed three times 10 minutes with Phosphate buffered saline (PBS), blocked for one hour at room temperature with 1%BSA in PBS and then incubated with primary antibody in blocking solution for one hour, also at room temperature. Slides were then washed three times 10 minutes with PBS, incubated with secondary antibody/1% BSA/PBS in the dark for one hour at room temperature. Finally, slides were washed three times 10 minutes in the dark at room temperature and mounted using Dabco anti-fade solution (Sigma Chemical Co.). Slides were analyzed on the confocal microscope using the 63x objective and optical filters to separate signals on each channel.

For primary antibodies Mouse anti-myc monoclonal 9E10 (10 $\mu$ g/ml: Santa Cruz Biotech.), Rabbit anti-myc (5 $\mu$ g/ml: Upstate Biotechnology Inc.), Rabbit anti-Eps15 antisera #C20 (1 $\mu$ g/ml: Santa Cruz Biotech), Rabbit anti-Flag epitope antisera (5 $\mu$ g/ml: Zymed) and mouse anti-Dynamin I #D25520, which recognizes Dynamin in Cos-1 cells by both immunoprecipitation and western blotting (data not shown) (20 $\mu$ g/ml: Transduction labs, Inc.) were used. As secondary antibodies we used FITC-labelled goat anti-mouse (1:80 dilution) and Texas Red-labelled goat anti-rabbit antibodies (1:100 dilution) (Jackson Immuno Research Laboratories Inc.). Endogenous Eps15 staining above background in non-transfected cells was undetected. Prominent cytoplasmic Eps15 staining in transfected cells obscured the detection of clathrin-coated pit associated Eps15 at the membrane (Figure 4B). In Figure 5B panel a and b, Dynamin staining with both primary and secondary antibodies was performed first. MycEse1 was then stained for using biotinylated 9E10 followed by streptavidin conjugated to Texas Red. Following application of the secondary antibody to stain for Dynamin, all further incubations and washes were



-38-

performed under dark condition. Endocytosis assays were performed as previously described (6, 9).

Mouse Esi1 cDNA - Sequence ID NO:1

5 CGGCACGAGGAGGAGTGGAGCGGCGGGAGGGCGCGCAGCTTGGTTGC  
TCCGTAGTACGGCGGCTCGCAAGGGAGCATCCCGAGCGGGCTCCGGGACG  
GCCGGGAGGCAGGCAGGCGGGCGGGCGGGGATGGTGTGCGCGGCTGCGG  
ACTCGGCGTTCTCTCGCGCGGCGTGCGGGCTGCACTGATTTGTGTGAGGGG  
CGGCCGCGCGCACCCGCCCGGAGATGAGGCGTCGATCAGCAAGGTGAAC  
10 GTAATAGAACCATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGATG  
TCTGGGCCATAACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTT  
AGCCTGAAGCCGATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACTT  
TTTTTTCCAATCTGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCT  
AGCGGACATGAATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATAG  
15 CCATGAAGCTTATCAAACCTGAAGCTACAAGGATATCAGCTCCCCTCCACA  
CTTCCCCCTGTCATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGCA  
TTTGGTATAGGAGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCT  
GTGCCAATGGGCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCT  
TCTGTCCCTCCAGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTC  
20 ATACAGCCTCTGCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGAG  
TTCTTCCTTCAGCAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTACA  
GAAGGCACAATCATTCGATGTCGCCAGCGCCCCTCCAGCAGCAGAATGGG  
CTGTGCCTCAGTCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCAC  
GACAAAACCTATGAGTGGACACTTAACAGGTCCCCAGGCAAGAAGTATTCT  
25 CATGCAATCAAGTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTTC  
TGACATTGATCAAGATGGAAAACCTCACTGCAGAAGAATTTATCCTAGCTA  
TGCACCTAATTGATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCTGC  
CTCCAGAATACATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGGA  
TGTCGGTCATAAGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGT  
30 CGTCAGAGGATGAGCAGCAGCCAGAGAAGAACTGCCTGTGACATTTGAA  
GATAAGAAGCGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGC  
GCCGCCAAGCGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGC  
TCAGCTGGAGCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAG  
CAGGAGGCCAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGC  
35 GGGAGCTGGAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGA  
GGCGCGAGGCCGCAAAACGGGAAGTGGAAAGGCAGCGACAAGTGAATG  
GGAACGGAACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCAG

-39-

GAGGGCACCGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTT  
AGAAGCTCTGAATGACAAAAAGCATCAGCTAGAAGGAAAAC TTCAGGAT  
ATCAGGTGTCGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACA  
AGTCTAGAGAGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTG  
5 CAGGAATCTCAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACT  
CAGTGACCAGTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGC  
TTCTTACCCTCAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCCGGCAGCAG  
CTCCGGGAGCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGC  
AGGAGATTGATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACAT  
10 AGCAAACAGCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGA  
AGCAGAAAGAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGG  
AAGACGCTCAGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCA  
TGTGCAGCAGGAGGAGCAGCCACGCCCCGGAAACCCACGAGGAGGAC  
AGACTGAAGAGGGAAGACAGTGTGAGGAAGAAGGAGGCGGAAGAGAGA  
15 GCCAAGCCGGAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCA  
GGAGCCAGCTAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAG  
GCCCCGTTACCATTTCTGCACAGGAGAGTGTAAGAGTGGTATATTACCGA  
GCGCTGTACCCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCC  
AGGAGATATAGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGG  
20 CTTGGAGGAGAGCTGAAAGGGAAGACGGGATGGTTCCTGCAAACATATGC  
AGAAAAGATTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCG  
ATCTGACATCTGCCCCTGCCCCCAAACCTGGCTCTGCGTGAGACCCCTGCTC  
CTTTGCCAGTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAG  
ACTTCAGTTCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGAC  
25 AACTGGGATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGG  
CCAGTTACGGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCT  
CCCCATCTCCCGTCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCG  
CAAGCCCTGTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAA  
CAAAAGTGACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTG  
30 GAGAAGTTCAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTC  
ATTCAGGGCCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGA  
AAGTCCTGCTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCAAGCCAGCCA  
TTCCCGGAGAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAA  
GGAGATTTAACCTTTCAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGA  
35 TGGTGACTGGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTT  
CTAACTATGTGAGGCTTAAAGATTAGAGGGCTCTGGAAGTCTGGGAAA  
ACAGGGAGTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTA

-40-

CGCTGCTACTGGTCCCGAACAACCTCACCCTGGCTCCTGGGCAGCTGATTCT  
 GATCCGGAAAAAGAACCAGGTGGATGGTGGGAAGGAGAACTGCAAGCT  
 CGAGGGAAAAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACCT  
 TCTAAGCCCCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCG  
 5 CAGTGCAGCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCC  
 CAGAACGATGACGAACCTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCT  
 CAACAAGGAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTT  
 GGGCTCTTCCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCAG  
 CCAGCAATGAATCATATGTTGTCCATCCCCCCTCAGGCTTGAAAGTCCTC  
 10 AAAGAGACCCACTATCCCATATCACTGCCCAGAGGGATGATGGGAGATGC  
 AGCCTTGATCATGTGACTTGCAGCATGATCACCTACTGCCTTCTGAGTAGA  
 AGAACTCACTGCAGAGCAGTTTACCTCATTTGACCTTAGTTGCATGTGATC  
 GAAATGTCTGAGTCACTGCGTGCAGAGGCAGAAGCAAATTGCAGAACTGC  
 ACAGGGTGGTGGGTCCTTTTGGGGCTTTCCTAGTCACTCAGACTGACCGGC  
 15 CCCGCCTTCACACGGGCGCTTTCAATAGTTTTAAGATTATTTTTAAATGTG  
 TATTTTAGCCTTTTAATAAAAATCTCAATCAATTACTTCTTTGCCTATTTTG  
 GTTTTACAAAAACACCCACTATCAAGGAGTGCCTGTCTGCGGACGATTAA  
 AATGCTGTTCCGGGCGTACCGTAAACTGAGAGCTTGCTGTACCTTTGCCGT  
 TTGTCCAGTGTTCCCAACCACATTGTGTAGTTTGGGGCTGTTCCCTGCCGT  
 20 AGAGCACAGAGGAGATGGGTGTACCTGTTTTGAAAATGTGTATGTAGACT  
 GAGCCTGACTATGGAAGGGGTATGCTTGTCTGTGACCATCACGTGTACCT  
 GTCGCGCATGTACCATCTGTACCGAAGAAGTAGCTCTTCCTCCATGGCTAA  
 ACCCACCACCGTGTACAGTGCTCTCATCTACTGCATTCATTTTACTTTGCA  
 CAGTGACCTTGTAGCCACCTGAGGAAGCACCCATGTTCCGTTTGGTCTCA  
 25 GATGTACCTAGTTGTGCCCCGTGTTTTGTTTTTATTTTTCAATCTGGCATGTC  
 TTCACACCATAAACTAGTAAGACGCCAACTGCCAGGCGGTTACGATCAT  
 CAGTACCCACCGTCTTAGTCTCTGTTACGTGAAGTTTATTCCAGTTGCTTTT  
 TATGGAATATCTTGAACAAGTAATCTTCTTGACAAGAAAGAAATGTATAGA  
 AGTCTCCCTGCAATTAATTTCCAGTGTTTACATTTTTTAAGTAGACTGTGG  
 30 GGGTTGCTACAGATTAATATGAAATGGCGCTCCTGGTCCGTGTGTGTGTTA  
 ACTTGTGCTGTAGCTGAAGCCGTGTGTCCTTAGATATTAGTTGGAAGTCGG  
 GAAGAGAATTCGATATCAAGCTT

Mouse Esel coding sequence - Sequence ID NO:2

35 ATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGATGTCTGGGCCATA  
 ACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTTAGCCTGAAGCC  
 GATAGCGGGATTATTACTGGTGATCAAGCGAGGAACTTTTTTTTCCAATC

-41-

TGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCTAGCGGACATGA  
ATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATAGCCATGAAGCTT  
ATCAAAGTGAAGCTACAAGGATATCAGCTCCCCTCCACACTTCCCCCTGTC  
ATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGCATTGTTGATAGG  
5 AGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCTGTGCCAATGG  
GCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCTTCTGTCCCTCC  
AGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTCATACAGCCTCT  
GCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGAGTTCTTCCTTCAG  
CAGATCTGGTCCAGGGTCACAATTAACACTAAGTTACAGAAGGCACAAT  
10 CATTGATGTGCGCCAGCGCCCCTCCAGCAGCAGAATGGGCTGTGCCTCAG  
TCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCACGACAAAACCTAT  
GAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTCTCATGCAATCAA  
GTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTTCTGACATTGATC  
AAGATGGAAAACCTACTGCAGAAGAATTTATCCTAGCTATGCACCTAATT  
15 GATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCCTGCCTCCAGAATAC  
ATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGGATGTCCGTCATA  
AGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGTCGTCAGAGGA  
TGAGCAGCAGCCAGAGAAGAACTGCCTGTGACATTTGAAGATAAGAAG  
CGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGCGCCGCCAAG  
20 CGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGCTCAGCTGGA  
GCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAGCAGGAGGC  
CAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGCGGGAGCTG  
GAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGAGGCGCGAG  
GCCGCAAAACGGGAACCTGGAAGGCAGCGACAACCTTGAATGGGAACGGA  
25 ACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCAGGAGGGCAC  
CGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTTAGAAGCTC  
TGAATGACAAAAAGCATCAGCTAGAAGGAAAACCTCAGGATATCAGGTGT  
CGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACAAGTCTAGAG  
AGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTGCAGGAATCT  
30 CAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACTCAGTGACCA  
GTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGCTTCTTACCC  
TCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCGGCAGCAGCTCCGGGA  
GCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGCAGGAGATT  
GATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACATAGCAAACA  
35 GCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGAAGCAGAAA  
GAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGGAAGACGCTC  
AGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCATGTGCAGCA

-42-

GGAGGAGCAGCCACGCCCCCGGAAACCCACGAGGAGGACAGACTGAAG  
 AGGGAAGACAGTGTCTCAGGAAGAAGGAGGCGGAAGAGAGAGCCAAGCCG  
 GAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCAGGAGCCAGC  
 TAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAGGCCCGCTTA  
 5 CCATTTCTGCACAGGAGAGTGTAAAAGTGGTATATTACCGAGCGCTGTAC  
 CCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCCAGGAGATAT  
 AGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGGCTTGGAGGA  
 GAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACCTATGCAGAAAAGA  
 TTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCGATCTGACA  
 10 TCTGCCCCCTGCCCCCAAACCTGGCTCTGCGTGAGACCCCTGCTCCTTTGCCA  
 GTGACCTCTTCTGAGCCCTCCACAACCCCAACAACCTGGGCAGACTTCAGT  
 TCCACGTGGCCAGCAGCTCAAACGAGAAGCCAGAAACGGACAACCTGGG  
 ATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGGCCAGTTAC  
 GGCAGAGATCAGCCTTTACCCCAAGCCACAGCCACTGGCTCCTCCCCATCTC  
 15 CCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCGCAAGCCCT  
 GTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAACAAAAGTG  
 ACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTGGAGAAGTT  
 CAAGGTCAGAAGGGTTGGTTCCCAAGTCTTACGTGAAACTCATTTCAGG  
 GCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGAAAGTCCTG  
 20 CTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCAAGCCAGCCATTCCCGGA  
 GAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAAGGAGATTT  
 AACCTTTCAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGATGGTGACT  
 GGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTTCTAACTAT  
 GTGAGGCTTAAAGATTCAGAGGGCTCTGGAACCTGCTGGGAAAACAGGGA  
 25 GTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCTACGCTGCTA  
 CTGGTCCCGAACAACCTCACCTGGCTCCTGGGCAGCTGATTCTGATCCGGA  
 AAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCTCGAGGGAA  
 AAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACCTTCTAAGCC  
 CCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCGCAGTGCA  
 30 GCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCCCAGAACG  
 ATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCTCAACAAG  
 GAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTTGGGCTCTT  
 CCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAAGCCAGCAAT  
 GAATCATATGTTGTCCATCCCCCCTCAGGCTTGAAAGTCCTCAAAGAGAC  
 35 CCACTATCCCATATCACTGCCCAGAGGGATGA

Mouse Ese1 protein - Sequence ID NO:3

-43-

MAQFPTPFGGSLDVWAITVEERAKHDQQFLSLKPIAGFITGDQARNFFFQSGL  
 PQPVLAQIWALADMNNDGRMDQVEFSIAMKLIKLLQGYQLPSTLPPVMKQ  
 QPVAISSAPAFGIGGIASMPPLTAVAPVPMGSIPVVGMSPPLVSSVPPAAVPPL  
 5 ANGAPPVIQPLPAFAHPAATWPKSSSFSGPGSQLNTKLQKAQSFDFASAPP  
 AAEWAVPQSSRLKYRQLFNHDKTMSGHLTGPQARTILMQSSLPQAQLASIW  
 NLSDIDQDGKLTAEFILAMHLIDVAMSGQPLPPVLPPEYIPPSFRRVRSRSGSM  
 SVISSSSVDQRLPEEPSSSEDEQQPEKKLPVTFEDKKRENFERGSVELEKRRQAL  
 LEQQRKEQERLAQLERAERKERERQEQAQRQLELEKQLEKQRELERQRE  
 10 EERRKEIERREAAKRELERQRQLEWERNRRQELLNQRNKEQEGTVVLKARR  
 KTLEFELEALNDKKHQLEGKLDIRCLATQRQEIESTNKSRELRIAEITHLQQ  
 QLQESQQMLGRLIPEKQILSDQLKQVQQNSLHRDSSLTLKRALEAKELARQQ  
 LREQLDEVERETRSLQLEIDVFNNQLKELREIHSKQQLQKQRSLEAARLKQKE  
 QERKSLELEKQKEDAQRRVQERDKQWLEHVQQEEQPRPRKPHEEDRLKRED  
 15 SVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQAPWSTTEKGPLTISAQE  
 SVKVYYRALYPFESRSHDEITIQPGDIVMVDESQTGEPGWLGGELKGKTGW  
 FPANYAEKIPENEVPTPAKPVTDLTSAAPKLALRETPAPLPVTSSEPSTTPNN  
 WADFSSTWPSSSNEKPETDNWDTWAAQPSLTVPSAGQLRQRSAFTPATATGS  
 SPSVLGQGEKVEGLQAQALYPWRAKKDNHLNFNKSDVITVLEQQDMWWF  
 20 GEVQGQKGWFPKSYVKLISGPVRKSTSIDTGPTESPASLKRVASPAKPAIPGE  
 EFIAMTYESSEQGDLTQQGDVIVVTKKDGDWWTGTGVDKSGVFPSNYVR  
 LKDSESGTAGKTGSLGKKPEIAQVIASYAATGPEQLTLAPGQLILIRKKNPGG  
 WWEGELQARGKKRQIGWFPANYVKLLSPGTSKITPTELPKTAVQPAVCQVIG  
 MYDYTAQNDELAFSGQIINVLNKEDPDWWKGEVSGQVGLFPSNYVKLTT  
 25 DMDPSQQ

Mouse Ese2 cDNA - Sequence ID NO:4

CCTTCCTTTCTTTTTTGTGTTCGCCTTCGGCCGTGCCGGCTGAGAGCCC  
 AGCAGCCGTGACAGGCTGCGCAACAGGTTCGCTGCGGCCGGCCTGACGAC  
 30 TGACCCGGCGGCGGCGGCCGCGGCACGGCAGGGTCTTCCCGGAGCTTGGC  
 CGCGCCACGCGCCGGTGTCTGAGGAGCGCGCGGGGTCTGCGCCGGGACGT  
 GCGCGAGGCGCCAGATGGCTGAGAGCTGCAAGAAGAAGTCAGGATCATG  
 ATGGCTCAGTTTCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT  
 TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC  
 35 CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCTACAGT  
 CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA  
 ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC

-44-

ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC  
ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG  
GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT  
ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA  
5 ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT  
GGAAGTGCAGTCTCATTACGCCTTTATCCATTCCCTTATTCTTCTTCAACAT  
TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA  
GTATCCAGAAGGCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT  
CCTCAACTGCTTCCCTCTCAGGGAACCTCACCTAAGACAGGGACCTCAGAG  
10 TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT  
CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC  
CCTTCTTCAGTCAAATCTCTCTCAAACCTCAGCTAGCTACTATTTGGACTCT  
GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG  
CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG  
15 TTGCCTCCCGAGCTTGTCCCTCCATCTTTTCAGAGGGGGAAAGCAAGTTGAT  
TCTGTTAATGAACTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC  
TCAGAAGAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACCTATG  
AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA  
GCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGAGTG  
20 GGAGCGGAAACAGAGAGAAGCTGCAAGAGCAAGAATGGAAGAAGCAGCTG  
GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG  
AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG  
AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG  
CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC  
25 CAGAAAGAAAAGTCTCCACCTGGAAGTGAAGCAGTGAATGGAAAACAT  
CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC  
AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG  
GAAATCAAACAACCTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT  
CTATCTGGTCCCTGAGAAGCAGCTATTAACGAAAGAATTAATAAACATGC  
30 AGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAAAGTCA  
TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT  
TGAAAAAGAACTGCATCTAAGCTCTCAGAAATGGATTCAATTAACAATC  
AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA  
CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA  
35 GATTAGAGCAAATTCAAAAAAAGAACTAGAAGATGAGGCTGCAAGGAA  
AGCAAAGCAAGGAAAAGAAAACCTTGTGGAGAGAAAGTATTAGAAAGGAA  
GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA

-45-

ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA  
GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT  
GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAC  
TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTTCAGGGAAAGTTTGGCTG  
5 GTTCCCCTGCAACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGT  
CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA  
CTTCTTCCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT  
CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC  
ACTGTGTCCCCTGGATCTGTGTCCCCCATTACGGACAGGGGCAGGCTGTA  
10 GAAAACCTGAAAGCCCAGGCCCTTTGTTCCCTGGACGGCAAAGAAGGAGA  
ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCTGAGCAGCAG  
GAAAACCTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCCA  
AGTCTTATGTCAAGCTCATTCTGGGAATGAAGTACAGCGAGGAGAGCCA  
GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC  
15 AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC  
ATACTCAAGTGTAGAGCCCCGGGGATTTGACTTTTCACTGAAGGTGAAGAAA  
TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA  
GAGAACTGGAATCTTCCCGTCCAACCTACGTCAGACCAAAGGATCAAGAGA  
ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC  
20 GCTCAAGTAACTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT  
GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG  
GCAAGGAGAGCTACAGGCCAGAGGGAAGAAACGACAGAAGGGGATGGTTT  
CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC  
TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA  
25 TAACGAAGATGAGCTCAATTTCTCAAAGGACAGCTGATTAATGTTATGA  
ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT  
CTCTTTCCTTCAAACCTATGTAAAGATGACAACAGACTCAGATCCAAGTCAA  
CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG  
GAAGCGACAGGGCTACATTCACGAGCTCATTACAGACAGAGGAGCGGTAC  
30 ATGGACGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGAGGGCCTGG  
GGAAGCCAGAACCAGGGGAGCTGCCACAAGGCTGGGTCTAAAGACAGA  
TTTTGCTCTCCAGGACAGAGGAGCATCACATCGGCTTCATCCATCCAAAC  
AAGCCACACTCGCTGGGCCTGGTATTTTATTGCACCACTAAAATTGCTAGC  
AATCTATGCAAACATGATCTTTTTTAAACAAACGCCACAGCACAGTGCCTT  
35 GTACTAGTGTTAACCTGTTTCACTGTGTTAGATGCCAGGGTTTCCATTTTC  
AGGGCTATAAAAGTATTATGTGGGAAATGAGACATCAGACCACCGGACGT  
TACCACTTGGCAAATCTGTCCACTGTGGAGTTGGTGATGTTGGAACCATTC



-46-

CACACTATGTGACCTCTGCTGGGTCACACACTCAGGAGGTGAAGGGCTGA  
GATGAAATGCTGCAGCCTTGGGGCTTGTGCAGCCTGATACTGAAATAGCA  
TCCACTTGTGCACTGAATAAATAGAACTTGATCGTTTTATTCTGACTAGA  
TATTATCATTCTCTGCTAAGACAATATAGTTTGAAATATTATAGTTTGAAT  
5 ATAAGGAGGAAAGCTTGATGTACTTTAAATATACTGTGAACTCTAATAAT  
GTGGGGATATTTTTCAACTTTAATTTCTTAAGTATAAATTATTTATGTAAA  
TTCTTTGTTTTGCATATTTCATAGAACATGCATCTTTAAGCTTTATCATTGC  
CAACAATGTACAGAAAGAGAATAAAAGTATAAGTTTATGAATGTAAAAA  
AAAAAAAAAAAAAAAAA

10

Mouse Ese2 coding sequence - Sequence ID NO:5

ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT  
TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC  
CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCCTACAGT  
15 CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA  
ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC  
ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC  
ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG  
GGAAGCATGCCCAATCTGTCCATTTCATCAGCCATTGCCTCCAGTTGCACCT  
20 ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA  
ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT  
GGAAGTCCAGTCTCATTTCAGCCTTTATCCATTCTTATTCTTCTTCAACAT  
TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA  
GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT  
25 CCTCAACTGCTTCCCTCTCAGGGAACTCACCTAAGACAGGGACCTCAGAG  
TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT  
CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC  
CCTTCTTCAGTCAAATCTCTCTCAAACCTCAGCTAGCTACTATTTGGACTCT  
GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG  
30 CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG  
TTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTTGAT  
TCTGTTAATGGAAGTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC  
TCAGAAGAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACCTATG  
AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA  
35 GCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGAGTG  
GGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCAGCTG  
GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG

-47-

AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG  
AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG  
CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC  
CAGAAAGAAAAGTCTCCACCTGGAAGTGAAGCAGTGAATGGAAAACAT  
5 CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC  
AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG  
GAAATCAAACAACCTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT  
CTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTA AAAACATGC  
AGCTCAGTAACACACCTGATT CAGGGATCAGTTTACTTCATAAAAAGTCA  
10 TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT  
TGAAAAAGAACTGCATCTAAGCTCTCAGAAATGGATT CATTTAACAATC  
AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA  
CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA  
GATTAGAGCAAATTCAAAAAAAGAACTAGAAGATGAGGCTGCAAGGAA  
15 AGCAAAGCAAGGAAAAGAAAACCTTGTGGAGAGAAAAGTATTAGAAAGGAA  
GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA  
ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA  
GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT  
GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAAC  
20 TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTTCAGGGAAAGTTTGGCTG  
GTTCCCTGCAACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGT  
CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA  
CTTCTTCCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT  
CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC  
25 ACTGTGTCCCCTGGATCTGTGTCCCCCATTACGGACAGGGGCAGGCTGTA  
GAAAACCTGAAAGCCCAGGCCCTTTGTTCCCTGGACGGCAAAGAAGGAGA  
ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCCTGGAGCAGCAG  
GAAAACCTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCA  
AGTCTTATGTCAAGCTCATTCCCTGGGAATGAAGTACAGCGAGGAGAGCCA  
30 GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC  
AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC  
ATACTCAAGTGTAGAGCCCGGGGATTTGACTTTCACTGAAGGTGAAGAAA  
TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA  
GAGAACTGGAATCTTCCCGTCCAACCTACGTCAGACCAAAGGATCAAGAGA  
35 ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC  
GCTCAAGTAACTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT  
GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG

-48-

GCAAGGAGAGCTACAGGCCAGAGGGAAGAAACGACAGAAGGGATGGTTT  
CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC  
TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA  
TAACGAAGATGAGCTCAATTTCTCCAAAGGACAGCTGATTAATGTTATGA  
5 ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT  
CTCTTTCCTTCAAACCTATGTAAAGATGACAACAGACTCAGATCCAAGTCAA  
CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG  
GAAGCGACAGGGCTACATTCACGAGCTCATTGACAGAGGAGCGGTAC  
ATGGACGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGA

10

mouse Ese2 - Sequence ID NO:6

MAQFPTAMNGGPNMWAITSEERTKHDKQFDNLKPSGGYITGDQARTFFLQS  
GLPAPVLAEIWALSDLNKDGKMDQQEFSIAMKLIKLLKQGGQLPVVLPPIMK  
QPPMFSPLISARFGMGSMPLNSIHQPLPPVAPIATPLSSATSGTSIPPLMMPAPL  
15 VPSVSTSSLPNGTASLIQPLSIPYSSSTLPHASSYSLMMGGFGGASIQKAQSLID  
LGSSSSTSTASLSGNSPKTGTSEWAVPQPSRLKYRQKFNSLDKGMMSGYLSGF  
QARNALLQSNLSQTQLATIWTADIDGDGQLKAEFILAMHLTDMAGQPL  
PLTLPPPELVPPSFRGGKQVDSVNGTLPSYQKTQEEEPQKKLPVTFEDKRKANY  
ERGNMELEKRRQVLMEQQQREAEKKAQKEKEEWERKQRELQEQEWKKQLE  
20 LEKRLEKQRELERQREEERRKEIERREAAKQELERQRRLEWERLRRQELLSQK  
TREQEDIVRLSSRKKSLHLELEAVNGKHQQISGRLQDVQIRKQTQKTELEVLD  
KQCDLEIMEIKQLQQELKEYQNKLIYLVPEKQLLNERIKNMQLSNTPDGSGISLL  
HKKSSEKEELCQRLKEQLDALEKETASKLSEMDSFNNQLKELRESYNTQQLA  
LEQLHKIKRDKLKEIERKRLEQIQKKLEDEAARKAKQGKENLWRESIRKEEE  
25 EKQKRLQEEKSQDKTQEEERKAEAKQSETASALVNYRALYPFEARNHDEMS  
FSSGDIIQVDEKTVGEPGWLYGSFQGGKFGWFCNYVEKVLSSSEKALSPKKALL  
PPTVSLSATSTSSQPPASVTDYHNVFSNLTVNTTWQQKSAFTRTVSPGVSPI  
HGQGQAVENLKAQALCSWTAKKENHLNFSKHDVITVLEQQENWWFGEVHG  
GRGWFPKSYVKLIPGNEVQRGEPEALYAAVTKKPTSTAYPVTSTAYPVGEDY  
30 IALYSYSSVEPGDLTFTEGEEILVTQKDGEWWTGSIGERTGIFPSNYVRPKDQE  
NFGNASKSGASNKKPEIAQVTSAYAASGTEQLSLAPGQLILILKNTSGWWQ  
GELQARGKKRQKGWFPASHVKLLGPSSERTMPTFHAVCQVIAMDYDMANN  
EDELNFSKGQLINVMNKDDPDWWQGETNGLTGLFPSNYVKMTTDS DPSQQ  
WCADLQALDTMQPTERKRQGYIHELITQTEERYMDDLQLFEQKTLL

35

Mouse Ese2 alternative transcript partial cDNA sequence - Sequence ID NO:7

-49-

CCGTCTTCCACATTTCCCACATTGATCGTGTGTACACACTCCGAACAGACA  
ACATCAACGAGAGGACGGCCTGGGTCCAGAAGATCAAGGGTGCCTCAGA  
GCAGTACATCGACACTGAGAAGAAGAAACGGGAAAAGGCTTACCAAGCC  
CGTTCTCAAAAGACTTCAGGTATTGGGCGTCTGATGGTGCATGTCATTGAA  
5 GCTACAGAATTAAGCCTGCAAACCAAACGGGAAAAGTAATCCATACTG  
TGAAGTCAGCATGGGCTCCCAAAGCTATACCACCAGGACCCTGCAGGACA  
CACTAAACCCCAAGTGGAAGTTCAACTGCCAGTTCTTCATCAAGGATCTTT  
ACCAGGACGTTCTGTGTCTCACTATGTTTGACAGAGACCAGTTTTCTCCAG  
ATGACTTCTTGGGTCTGACTGAAGTTCCAGTGGCAAAAATCCGAACAGAA  
10 CAGGAAAGCAAAGGCCCCACCACCCGCCGACTACTACTGCACGAAGTCCC  
CACTGGAGAAGTCTGGGTCCGCTTTGACCTGCAACTTTTTGAACAAAAAA  
CTCTCCTTTGAGGGCCTGGGGAAGCCAGAACCAGGGGAGCTGCCCACAAG  
GCTGGGTCTAAAGACAGATTTTGCTCTCCCAGGACAGAGGAGCATCACAT  
GGCTTCATCCATCAAACAGCCACACTCGCTGGGCCTGTATTTTATTGCACA  
15 CTAAATTGCTAGCAATCTATGCAAACATGATCTTT

Mouse Ese2 alternative partial protein containing C2 membrane-binding domains -

Sequence ID NO:8

VFHISHIDRVYTLRTDNINERTAWVQKIKGASEQYIDTEKKKREKAYQARSQK  
20 TSGIGRLMVHVIEATELKACKPNGKSNPYCEVSMGSQSYTTRTLQDTLNPKW  
NFNCQFFIKDLYQDVLCLTMFDRDQFSPDDFLGRTEVPVAKIRTEQESKGPTT  
RRLLLHEVPTGEVWVRFDLQLFEQKTLL

**Novel Ese-coiled-coil interacting clones:**

25 Mouse homologue of C07E3.1 protein (clone 65): - Sequence ID NO:9

GAATTCCGGCACGAGGGCTGAGAGAAGCGGACTCCGAGGACTCTGATGCTG  
AAGAGAAGCCTGTTAAGCAGGAGGACTTCCCGAAGATTTAGGACCAAAG  
AAGTTAAAGACGGGTGGCAATTTTAAGCCCAGCCAGAAAGGCTTTTCAGG  
AGGAACCAAGTCCTTCATGGACTTTGGCAGCTGGGAGAGACACACGAAAG  
30 GGATCGGGCAGAAGCTGCTGCAGAAGATGGGCTACGTCCCTGGGCGTGGC  
CTGGGGAAGAACGCACAGGGGATCATCAACCCCATCGAAGCCAAACAGA  
GAAAAGGCAAGGGAGCCGTGGGGGCCTATGGCTCGGAGAGGACCACTCA  
GTCTCTGCAGGACTTCCCCGTGGCCGACTCGGAAGAGGAGGCAGAAGAGG  
AGTTTCAGAAGGAGCTGAGCCAATGGAGGAAAGACCCCAGCGGGAGCAA  
35 GAAGAAGCCAAAGTACTCTTACAAGACTGTGGAGGAGCTGAAGGCCAAG  
GGCAGGGTCAGCAAGAAGCTCACAGCACCTCAGAAGGAACTGTCTCAGGT  
CAAGGTGATCGACATGACAGGCCGGGAGCAGAAGGTGTACTACAGCTAC

-50-

AGCCAAATCAGCCACAAGCACAGCGTGCCCGATGAAGGGGTGCCATTGCT  
GGCGCAGCTGCCCCCACAGCCGGCAAGGAAGCCAGGATGCCGGGCTTTG  
CACTGCCTGAGCTGGAGCACAACTGCAGCTGCTCATTGAGCGCACGGAG  
CAGGAGATCATCCAGAGCGACCGGCAGCTCCAGTATGAGCGGGACATGGT  
5 GGTGAGCCTGTCGCATGAGCTGGAGAAGACGGCCGAGGTTCTTGCACATG  
AGGAGCGTGTCATCTCTAACCTCAGCAAGGTGCTGGCCCTGGTGGAGGAA  
TGTGAGCGCCGCATGCAGCCCCATGGCACCGACCCCCTCACTCTGGATGA  
GTGTGCCCCGATCTTTGAGACACTACAGGACAAGTATTATGAGGAGTACC  
GCCTGGCGGACCGCGCAGACCTCGCTGTGGCCATTGTCTACCCGCTCGTG  
10 AAGGACTACTTTAAGGATTGGCACCCCTCGAGGG

Mouse partial C07E3.1 protein (clone 65): - Sequence ID NO:10  
GTKSFMDFGSWERHTKGIGQKLLQKMGYVPGRGLGKNAQGIINPIEAKQRKG  
KGAVGAYGSERTTQSLQDFPVADSEEEAEEEFQKELSQWRKDPSGSKKKPKY  
15 SYKTVEELKAKGRVSKKLTAPQKELSQVKVIDMTGREQKVYYSSYSQISHKHS  
VPDEGVPLLAQLPPTAGKEARMPGFALPELEHNLQLLIERTEQEIIQSDRQLQY  
ERDMVVSLSHELEKTAEVLAHEERVISNLSKVLALVEECERRMQPHGTDPLT  
LDECARIFETLQDKYYEYRLADRADLAVAIVYPLVKDYFKDWHPSR

20 Mouse Novel cDNA clone 42/ Est accession #W29719 and #AA915044: - Sequence  
ID NO:11  
CATGGCGGCGGCTGCGGAGGGCGTCCCGGCGACGCGACGGAGGACGAGC  
CACCTCGAGATGATGCTGCGGTGGAGACAGCCGAGGAAGCAAAGGAGC

25 Mouse Novel cDNA clone 70: - Sequence ID NO:12  
CTTGAGTCTACTGAAAATACCCTGCAGGAAGCTACATCATCCATGTCTTTG  
ATGACCCAATTTGAACAGGAAGTATCTGGCCTCAAAGACCATACGTGAT  
ATTGAGACTAGCGAAGAGATGC

30 Mouse Novel cDNA clone 83/Est accession #AA589041 and W98708: - Sequence ID  
NO:13  
GAATTCGGCACGAGGGAGTCTGGTTCTGGAAAGCCGACAGAAGCTGAGCT  
TGTCAACTTAGATTTCTTGGGAGATTTGGATGTTCCGGTATCTGCCCCACC  
CCTGTGTGTCTGAGCTCGAGTCTCTCTGCTGGACTATGG

35

**Novel Ese-SH3 interacting clones:**

Mouse YNK1 partial cDNA: - Sequence ID NO:14

-51-

CTTTACGAGCAGAGGGAGCCAAATTCAGAGCCGTTTTAGATAAAGCTGTG  
CAAGCGGATGGACAGGTGAAGGAGCGCTACCAGTCCCATCGAGACACCA  
TCGCACTTCTGTGTAAGCCGGAGCCAGAGCTGAATGCTGCCATCCCCTCTG  
CTAACCCAGCAAAGACCATGCAGGGCAGCGAGGTTGTAAGTGTCTTAAAG  
5 TCCTTATTATCAAATCTTGATGAAATCAAGAAGGAAAGAGAGAGTCTTGA  
GAATGACCTGAAGTCAGTGAATTTTGACATGACAAGCAAGTTTTTGACAG  
CTCTGGCCCAAGATGGCGTGATAAATGAGGAGGCTCTCTCTGTCACTGAG  
CTGGATCGGATCTATGGCGGTCTAACAAGTAAAGTTCAAGAGTCTCTGAA  
GAAACAAGAGGGACTTCTAAAAAATATACAGGTCTCACACCAAGAATTCT  
10 CCAAAATGAAGCAATCTAACAACGAGGCTAACTTGAGAGAAGAAGTTCTG  
AAGAACCTAGCAACTGCGTATGACAACTTTGTTGAGCTTGTAGCTAACTTG  
AAGGAGGGCACAAGTTTTACAATGAGCTGACTGAGATCCTGGTCAGGTT  
CCAGAACAAATGCAGTGACATAGTGTTTGCACGGAAGACAGAAAGAGAC  
GAGCTCTTGAAGGATCTGCAGCAGAGCATTGCCAGAGAGCCCAGCGCTCC  
15 TTCAATCCCTCCTCCAGCCTATCAGTCCTCCCCAGCAGCGGGGCATGCAGC  
AGCGCCTCCAACCTCCAGCCCCAAGAACCATGCCGCCTGCTAAGCCCCAGC  
CTCCAGCCCCGGCCTCCACCTCCTGTGCTTCCTGCAAACCGAGTTCCTCCTG  
CTTCTGCTGCTGCTGCCCTGCAGGCGTGGGGACGGCTTCAGCAGCGCCG  
CCACAGACCCCTGGCTCTGCTCCCCCGCCACAGGCTCAGGGACCACCATA  
20 CCCTACCTATCCAGGATATCCCGGGTATTGCCAAATGCCCATGCCCATGGG  
CTACAACCCCTACGCATATGGCCAGTACAATATGCCGTACCCACCGGTGT  
ATCACCAGAGCCCCGGACAGGCTCCATACCCAGGACCCCAGCAGCCTACC  
TACCCCTTCCCTCAGCCCCCGCAGCAGTCCTACTATCCACAGCAGTAACGC  
TGCCACGTGCTGCTGGTTCAGATCAGAGCGACAGGACAGCAGCTGCCACC  
25 AGCTCTAAGCCACGCTCTGGCCACTCGAGAGTATCTTGCTCTATTGATTGC  
TGTGGATGATTTCTGTCTGTGGCTAAAGCCGAAGGCTGGGCCCCACCTCCA  
CATTTGATCGCACTCGTGAGATTCTGCTGCTGTTGCAGTATAAACGCTAGC  
TATAATAGCATTTGAAAAAAATTACAGTTCCATAAAATGCTGAAAATGAG  
AAATTAAACCTGCAAGTGAAACATTTGAAATTAGCATACTTTATAAGATG  
30 CAGTTGGGACAAAGATGGCTTAAGTACTGATATTTAAGGAAAAAGTTTTTC  
TTTCTCTTTTGGTTTATTGATTTAGTTTAAATTTCTATTATGATATTTTGATA  
ATCAAGGCATTGTAAATCTTATAATTTAAAAATAAATTACTTACGAACAGT  
TGTCATTGTTATGTTTTGTCATTGATTCTCATTGCTGTCTAGTTCCTTTCTG  
GTATTAGCCTCTCCTTCTGTATGTTTACAGGCTCCATTACTGTGTTGAATTG  
35 CGTGACGTCAGGTGAGCAGTCAGGGAGGGCTGCTCTGCGGACGCCAAGCG  
CACACCAGCTTGTCTCAGGCTCAGCAGTCAGCTCATCTGGACATTTCTATT  
TAAAAGTCCTTTAATGTGGAAGATACACACAATTGTTACCAAAGGTTCTTC

-52-

CAATTAATTTTACAATTTAAAAAGTATGTATTAATGTTTTATTGTTAGATTT  
TCCAAAAAATGATGCAAATTTCTGGTAATATTCATTTCCCTCACCCATAAT  
TTGGTTAAAATGAGTAGTTTTAGCCATACAGTCTCATCTGCTGTGGAGGAA  
CCTGGAGAAAGTCCCCTGTGCCTTTCTAGCCCTTGGGTTCTATTCTTATCCT  
5 GCAATGTCTACTGCACAGTGTGTTTGAGCAGATCCTAACCCTCCTTTTACA  
GTTTCTTCTTCTTACTTCTTTATTCTTTTTGTGGCTCCTGAAATCTGAGGTTA  
TTTTGTAATTCAGGAGCATGCAGGACAATTGTTGGGACATGTGCCTAGTCC  
GGAATACAGCCCAGGACAGCAAGGAGATGCGTCCTGCACCAGGAAGCCG  
TGCAGGCAGGAGCTGTCCAAGGTCCCGGCGGCTCTGCCTGTGTGAGGCAG  
10 GAGAATGAGCAGATTCCCTAATCTATGTTCTCGAAGTTTAATGCTGATGTT  
GTCTTGCCTTATCCTCATTTAACTGATACTGTCACCCAGTCCACCTTTGCTC  
TCATTGCAAAGTGATAGTGTAATTTCAAATGTAAGACTGAAGATACGATT  
GTAAAAGGGAGTAACTGGTTTTAAACGTGTTATTCTAAAGCACCTTACTTT  
GTTGTTGTATGCAGAAAACACAGATGCGCTAATTCAGTATAAATGACTGA  
15 TTGCCTGGAATTTGGACGTTGGCTTAAAGTCCGATAGCTAAACCTTGGCAA  
AACATAACAAACATTTTATTGCTCAGCCTCAGTGCTCTGGAGTATTCAGTG  
TATGAGACAGGTTTATTTGAGTCCTCTGTAAATGGCATTGGAATTTTATAT  
TCTCCCCTCCCGAGTATCTTATAAGACATCCCCTGAGTTAGGGAGTTCCCA  
GACTGCTACTCTATTCTTATGAATGCAAAAACAACCACCAATAGAACAAA  
20 AAAAAAAAAAAAAAACTCGAG

Mouse YNK1 partial coding cDNA - Sequence ID NO:15

CTTTACGAGCAGAGGGAGCCAAATTCAGAGCCGTTTTAGATAAAGCTGTG  
CAAGCGGATGGACAGGTGAAGGAGCGCTACCAGTCCCATCGAGACACCA  
25 TCGCACTTCTGTGTAAGCCGGAGCCAGAGCTGAATGCTGCCATCCCCTCTG  
CTAACCCAGCAAAGACCATGCAGGGCAGCGAGGTTGTAAGTGTCTTAAAG  
TCCTTATTATCAAATCTTGATGAAATCAAGAAGGAAAGAGAGAGTCTTGA  
GAATGACCTGAAGTCAGTGAATTTTGACATGACAAGCAAGTTTTTGACAG  
CTCTGGCCCAAGATGGCGTGATAAATGAGGAGGCTCTCTCTGTCACTGAG  
30 CTGGATCGGATCTATGGCGGTCTAACAAGTAAAGTTCAAGAGTCTCTGAA  
GAAACAAGAGGGACTTCTAAAAAATATACAGGTCTCACACCAAGAATTCT  
CCAAAATGAAGCAATCTAACAACGAGGCTAACTTGAGAGAAGAAGTTCTG  
AAGAACCTAGCAACTGCGTATGACAACTTTGTTGAGCTTGTAGCTAACTTG  
AAGGAGGGCACAAAGTTTTACAATGAGCTGACTGAGATCCTGGTCAGGTT  
35 CCAGAACAAATGCAGTGACATAGTGTGTTGCACGGAAGACAGAAAGAGAC  
GAGCTCTTGAAGGATCTGCAGCAGAGCATTGCCAGAGAGCCCAGCGCTCC  
TTCAATCCCTCCTCCAGCCTATCAGTCCTCCCCAGCAGCGGGGCATGCAGC

-53-

AGCGCCTCCAACTCCAGCCCCAAGAACCATGCCGCCTGCTAAGCCCCAGC  
CTCCAGCCCCGGCCTCCACCTCCTGTGCTTCCTGCAAACCGAGTTCCTCCTG  
CTTCTGCTGCTGCTGCCCCCTGCAGGCGTGGGGACGGCTTCAGCAGCGCCG  
CCACAGACCCCTGGCTCTGCTCCCCCGCCACAGGCTCAGGGACCACCATA  
5 CCCTACCTATCCAGGATATCCCGGGTATTGCCAAATGCCCATGCCCATGGG  
CTACAACCCCTACGCATATGGCCAGTACAATATGCCGTACCCACCGGTGT  
ATCACCAGAGCCCCGGACAGGCTCCATAACCAGGACCCAGCAGCCTACC  
TACCCCTTCCCTCAGCCCCCGCAGCAGTCCTACTATCCACAGCAGTAA

10 Mouse YNK1 partial protein - Sequence ID NO:16

LRAEGAKFRAVLDAVQADGQVKERYQSHRDTIALLLCKPEPELNAAIPSANP  
AKTMQGSEVVSVLKSLLSNLDEIKKERESLENDLKSVNFDMTSKFLTALAQD  
GVINEEALSVTELDRIYGGTTSKVQESLKKQEGLLKNIQVSHQEFKMKQSN  
EANLREEVLKLNLAAYDNFVELVANLKEGTKFYNELTEILVRFQNKCSDIVFA  
15 RKTERDELLKDLQQSIAREPSAPSIPPPAYQSSPAAGHAAAPPTPAPRTMPPAK  
PQPPARPPPPVLPANRVPPASAAAAPAGVGTASAAPPQTPGSAPPPQAQGPPY  
PTYPGYPGYCQMPMPMGYNPYAYGQYNMPYPPVYHQSPGQAPYPGPQQPT  
YFPQPPQQSYYPQQ

20 Mouse novel cDNA clone 4: - Sequence ID NO:17

GGTCTTGGCTAGAATTTTAAATTTCTTCTCATTTGAGTAAAATGTTGCATTC  
TGAAGTCCCATGCTACCTGAAGTTGCATTTGGAGTCCCAAGCTACTGGAAT  
GTTTATATGTGACCGTTTCCCAGGAGGCTTACACTGCAGAAGGAAGAATG  
AATCTAGGTGAGGTGGGCAGCTGCTTGGCAGTCCTCTCTTGTGCCCCAACT  
25 GTAAACCAGATAGAAATGTTTCAGGGGAGGATACTTTCATTATTGTGGTTTG  
TAGTGTTAAGATGATTGCTTCTGCCTTGGAAATACCTCAAGCTGTTCTTAT  
TTAACAGGTAAAGTGACTGAGTATAATATTCCAGAAAAATTTGAAATCCTA  
ATTTCTTCCATATTTTATTAAATTTTTTGCATACAGGTCTAACAAATATGGA  
TATGTATACACATCCTCTTTAATGAAGGTATTATTTTGGTTACTTTTCCTAA  
30 GATATACCTTAAAAGATGTTCTATACATTTCTACTTAAATTCTGGGGGAT  
TTGGAGTATGTACATGATAAAAAAGATTATAATATATCGATTGAAGTTACT  
TTATTTTCTAATTAGAATTATTTTAATAGTCCTTTATTGAATAAGTGCTGTA  
ATTTGTTTGCTATGAGACTTATTCCTGATGTGAATGTAAATTATTTTCCAC  
ATGCATGAAAAAATGTATGTACTAATCAGAGTTGTCTCCATTGCATTGAAA  
35 TTACTTGTTTTGAACTAAAGTAACTCATATTTATGTAGTAGAATGCTTATG  
TTTTCAGACTTTGTAAATGATTTTCTTTGGATGTATTTTAAATCAATCGGTCT  
GGGTAACATATCAGTTTAGATTAATATGTGCTTAAAAGAAGAAAAAAATT



-54-

- CAATGGTTCATAGTAGAAATGTGCCACACTTAAATAAGCTCTGTATGACAT  
 GAAATTCTGTAAACATTGTAATTCATGGTGACTTTTAACTTATAAAAAT  
 ACTACTTGCACGGGTACTTGATTTATGGATATATGAAAACCTCTCAGGAC  
 GAAAGTTCTTCTTTCTCTAGAACTATTCTTCTGTCGGTCATGCAGAATGCT  
 5 GTTATTCTGAAAAGTGTCCTGTTGCATATGATGGTCACTTTATTTGGGGG  
 GATTCTTCATAAGATGTGAGATGTTGATGCCAGTCTTCCCAAGTAAGTGC  
 TCGTAAAAAAGGACTACTAACTAGCCTGCATCTGTCTCTAACTGGGACCA  
 AGGGGTCTGCTGAAGGAACTGAAGAGCTCTAACATTTTCACAGCTTGGA  
 GAAGATAGAATCTTTAAAAGTACAACCTGAAGCTTGATCTATTTTACAAGT  
 10 GCATTGATGGCCCCTGTCCTTCTCTGGTTCCTGTCATTTGAAACCAACTCCT  
 GTTGTAATAGGAAGAATATGGGACATTCATATTTAAGAAAATTTGATGT  
 CATTAGGTGACTAAGTAGAAGGCTTAGAAAAATGTATTCATTTGCAAGTA  
 TTTTGGCACAAGAAATTTCCAACCTGAATAGTAAGCAAAAGCTAAGTTGTT  
 TCATTGAAATCATAAGGCAGTTTAAGATAAACTGGAGAAGATAACTGTTC  
 15 TAATAGAGGATAATCGAATTGATTGTCAAGTGGATGTTATTTATTGGATAG  
 TGACAGAGTTTATTTGTAACCTTAATTATATTA AAAAGTTATTCTGTTAGGA  
 TGTTTTGTATTAATAAACGTGAACAAAATTAAAAAAAAAAAAAAAAAAAAAC  
 TCGAGGG
- 20 Mouse Novel cDNA clone 8/47/52: - Sequence ID NO:18  
 GAGAAGGCGGCCTGCCGCAGCGGGACAACCTAGAGCGCGACGTGGAGGC  
 GCGTAGCGGAGCTGGAGCAACTGCGCACCGAGGTGGATGTGCGCATTAGC  
 GCNNTGGACACCTGCGTCAAGGCCAAGTCGCTGCCAGCCGTCCCGCCGAG  
 AGTCTCAGGCCCACCCCGAACCCTCCACCCATTGATCCAGCTAGCCTGG  
 25 AGGAATTCAAGAAAAGGATCCTGGAGTCTCAGCGGCTCCCTGTAGTCAAC  
 CCTGCGWGCCCAACCCAGCGGTTGAGRACCCAGCTGCCGCAGGACGCTGG  
 GTGCCAGAATCGCCACCTGTGGATGGGGGCAGCCAGGTGCCACAGTGC  
 TGGACACCCGCCGTGCCTGCCGGCAGCCTCCACCCCCAGCGCCTTCTCTGG  
 CACCCCTTCACTGTCCCSTGCATCCCCRCCATTCSSCASWSASKGGATTTAA  
 30 GGCACACACAGCTGTGAGATGACTTCACATCGACCCCTTGTGCAGTGACC  
 CGGATGGTGCCCCACCCACACATGAAGCACCCACAGCTCAGCTGCCACCC  
 TAGGCAACTCCTCCGGTTTCCTATCACTCTGCTCCTGACCCGGGAGGTGAG  
 AACAGGAAGCCCAGCCTTCAGCTCCCTTGGGAGTTTCCAGCCTCCCTCTTA  
 AAGGCCACTAGGGTTTCCAGATCCTATTTGAGAGTCTCCAGGCCTCCCTGT  
 35 AAGGGTTCTAGCCACCACGCCACAGGATTCCCATTAGGTTTTAAAGTCTT  
 TTCCAGAGTCCGCTGGTTCCCCTCCTCCTCACAAGGAAGGGCCTCAATTGT  
 AGATGAGCGTTCCGGGTGGATCTTAGAGCCCTAGAGGGAGGCTTTTGCTT

-55-

GTARCCCCCTAAAGATATTACTGGCACATAATAAATATGAAAGTCCTTTG  
AAA  
GTTGGACACTGCGCAAATGGGGCTCTCCATGGACCGCAGCCCATACGCCC  
GCACGGGGGACCAGCAGCGCGGCTCTGGTTCTACCTGCGCTATTTCTTCCT  
5 CTTCTGTGTCGCTCATTTCAGTTCCTCATCATCCTGGGCCTGGTCCTCTTCATG  
ATCTATGGCAATGTGCACGCCACCACTGAGTCCAGCCTGCGCGCCACGGA  
GATCCGCGCCGACAGCCTGTACAGCCAGGTGGTTGGACTATCGGCCTCAC  
AGGCTAACCTGAGCAAACAGCTGAACATCAGCTTGCTTGTCAAGGAAACA  
GTCATGCAGCAACTGTTGACTACGCGACGTGAGATGGAGCGCATCAACGC  
10 CAGCTTCCGCCAGTGCCAAGGCGACCTGATCACCTACATAAACTATAATC  
GCTTCATCGCCGCTATCATCCTGAGCGAGAAGCAGTGCCAGGAACAGCTG  
AAGGAGGTCAACAAGACCTGCGAACTTTACTCTTCAAGCTGGGAGAAAAA  
GTTAAGACACTGGAGATGGAGGTGGCCAAGGAGAAGGCAGTGTGCTCCA  
AGGACAAGGAGAGCCTGCTGGCAGGAAAGCGGCAGACGGAAGAGCAGCT  
15 GGAGGCCTGTG

Mouse Novel cDNA clone 18/25 - Sequence ID NO:19

5'end of partial clone

TGTGCGCCGCCTCTAGAACTAGTGGATCCCCCGGGCCTGCAGGAATTCCG  
20 GCACGACGGCCGAGCGCCGCGGACCACCCGCGGCTGCCCCGCCGAGCCGTC  
GACATGTGGGGGGGACTGGGGTGGGAGCGGCCGGAGCAGCGCCAGGTACC  
CGGGCGCGCAGAACCATGGCTCTCGCTCGCCTGTCCTGACCTGGCTTGCTC  
GCCCCACCGAAGAATGTCAGCCAAGTCCAAGGGGAACCCCTCCTCGTCCTC  
CGCAGCCGAGGGACCGCCGGCAGCCTCCAAAACCAAGGTGAAGGAGCAG  
25 ATCAAGATCATAGTGGAGGATCTGGAATTAGTCCTGGGCGACCTGAAGGA  
CGTGGCCAAAGAACTTAAGGAGGTGGTTGACCAGATTGACACCCTGACCT  
CTGATCTACAGCTGGAAGATGAGATGACCGACAGCTCCAAAACAGACACT  
CTGAACAGCAGCTCCAGTGGGACAACAGCCTCCAGCATAGAGAAGATCA  
AAGAACAGGCCAATGCTCCCCTCATTAACCTCCAGCACACCCGTCTGCT  
30 ATCCTGACTGTCCTGAGAAAGCCAAACCCTCCACCGCCTCCTCCAAGGTTG  
ACACCCGTGAGGTGTGAAGAGCCTCAGAGAGTGGTGCCGACTGCCAACCC  
TGTAAGACCAATGGCACTCTTCTGCGGAATGGAGGCTTAGCGGGGAGGC  
CCAACAAAATTCCAAATGGAG

35 3' end - Sequence ID NO:20

CTCGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTTCATTATTTACTATTATTTATT  
GACATATTTCCAAAGCTCAAAATATTTTATTATACATATAGTTGAACATAT

5 GTTTCAAATTGTATAGTATAGAAAATAAACTTTTTTGTAGTGTCTCAGCA  
TTTCATGATGCAAAACTATTGACAAACATCTTTAGAAAAATAATAAAATA  
GTCCTTCGGTATTAATAATTCTTATTAATAAGCATTAGATCAAAGGGAGAA  
CTATGACATCATCAATGCATAGATGAGATAGGCATGAATGGAATGAGTTG  
CCCTGGCTTTATCAACAAATCAAAATATCTGACATCCCAGCTCTTATAATA  
GACCAAAATACTTGGAATCAGAAGGTCACAGTTTGTTTTAGGTCAATCAC  
AAAAAAATAAAATTCATTCATACTTTCTCAATTTTCCGCAGTTTCTGATGA  
TGGAACATAGAAAACAATGTACGTCCAGGACAGAGGGCGCTACTCTGCATA  
CTTACCACGTGATTTTTTATGCCACTTTGTTGAATGCAGATTAATATATTTG  
10 GGCTTTTTATTGCTTGAGTAGAAAGTGCTCATTACTTATTATTTTACGTTTA  
TCATATAGAAAATTAATAACAAACAGAACGTTTTCTTAAATGGCAGATAT  
CACACTGTGGTAGTGGTGGATTTCTCAGGATGGTCTTCTGTGGTTTTGGT  
GCAGCGGGAGGAGGCACGGTTGCAGGTGTGGGAGGGGGGAAACTGTTAC  
TGTGGCTTATTCCCAGTCCCCCATTTTCTAATGGGAAAT

15 Mouse Novel cDNA clone 95/ EST accession #AA119951: - Sequence ID NO:21  
GCACAGCCCCCTCCATCCTGAAGAAAACCTCAGCGTATGGGCCTCCAGC  
TTCGGGCGGTGTCTATCCTTCCTCTCCTGGGACATGGTGTCCCCGCTTGCC  
CCCCTGGCAGAAAACCG

20 Mouse Ese1L cDNA: Sequence ID NO:22  
CGGCACGAGGAGGAGTGGAGCGGCGCGGGGAGGGCGCGCAGCTTGGTTG  
CTCCGTAGTACGGCGGCTCGCAAGGGAGCATCCCGAGCGGGCTCCGGGAC  
25 GGCCGGGAGGCAGGCAGGCGGGCGGGCGGGGATGGTGTGCGCGGCTGCG  
GACTCGGCGTTCCTCGCGCGGCGTGCAGGCTGCACTGATTTGTGTGAGGG  
GCGGCGCGCGCACCCGCCCGGAGATGAGGCGTCGATCAGCAAGGTGAA  
CGTAATAGAACCATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGAT  
GTCTGGGCCATAACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCT  
30 TAGCCTGAAGCCGATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACT  
TTTTTTTCCAATCTGGGTACCTCAGCCTGTCTTAGCACAAATATGGGCGC  
TAGCGGACATGAATAACGATGGAAGGATGGATCAAGTGAATTTTCCATA  
GCCATGAAGCTTATCAAACTGAAGCTACAAGGATATCAGCTCCCCCTCCAC  
ACTTCCCCCTGTCAATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGC  
35 ATTTGGTATAGGAGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCC  
TGTGCCAATGGGCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATC  
TTCTGTCCCTCCAGCAGCAGTGCCTCCCCCTGGCTAACGGGGCTCCTCCCGT

-57-

CATACAGCCTCTGCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGA  
GTTCTTCCTTCAGCAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTAC  
AGAAGGCACAATCATTCGATGTCGCCAGCGCCCCCTCCAGCAGCAGAATGG  
GCTGTGCCTCAGTCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCA  
5 CGACAAAACCTATGAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTC  
TCATGCAATCAAGTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTT  
CTGACATTGATCAAGATGGAAAACCTCACTGCAGAAGAATTTATCCTAGCT  
ATGCACCTAATTGATGTTGCCATGTCTGGTCAGCCACTGCCGCCCCGTCCTG  
CCTCCAGAATACATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGG  
10 ATGTCCGTCATAAGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCG  
TCGTCAGAGGATGAGCAGCAGCCAGAGAAGAACTGCCTGTGACATTTGA  
AGATAAGAAGCGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAG  
CGCCGGCAAGCGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGG  
CTCAGCTGGAGCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGA  
15 GCAGGAGGCCAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAG  
CGGGAGCTGGAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAG  
AGGCGCGAGGCCGCAAAACGGGAACCTGGAAAGGCAGCGACAACCTGAAT  
GGGAACGGAACCGGAGACAGGAACCTCCTGAATCAGAGGAACAAGGAGCA  
GGAGGGCACCGTGGTCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGT  
20 TAGAAGCTCTGAATGACAAAAAGCATCAGCTAGAAGGAAAACCTCAGGAT  
ATCAGGTGTGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACA  
AGTCTAGAGAGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTG  
CAGGAATCTCAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACT  
CAGTGACCAGTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGC  
25 TTCTTACCCTCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCCGGCAGCAG  
CTCCGGGAGCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGC  
AGGAGATTGATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACAT  
AGCAAACAGCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGA  
AGCAGAAAGAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAGG  
30 AAGACGCTCAGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCA  
TGTGCAGCAGGAGGAGCAGCCACGCCCCGGAAACCCACGAGGAGGAC  
AGACTGAAGAGGGAAGACAGTGTGAGGAAGAAGGAGGCGGAAGAGAGA  
GCCAAGCCGGAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCA  
GGAGCCAGCTAAGCTGGCCACCCAGGCACCTGGTCTACCACAGAGAAAG  
35 GCCCCGCTTACCATTTCTGCACAGGAGAGTGTAAGTGGTATATTACCGA  
GCGCTGTACCCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCC  
AGGAGATATAGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGG

-58-

CTTGGAGGAGAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACCTATGC  
AGAAAAGATTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCG  
ATCTGACATCTGCCCCTGCCCCCAAACCTGGCTCTGCGTGAGACCCCTGCTC  
CTTTGCCAGTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAG  
5 ACTTCAGTTCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGAC  
AACTGGGATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGG  
CCAGTTACGGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCT  
CCCCATCTCCCGTCTCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCG  
CAAGCCCTGTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAA  
10 CAAAAGTGACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTG  
GAGAAGTTCAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTC  
ATTTCAAGGGCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGA  
AAGTCCTGCTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCCAAGCCAGCCA  
TTCCCGGAGAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAA  
15 GGAGATTTAACCTTTTCAAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGA  
TGGTGACTGGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTT  
CTAACTATGTGAGGCTTAAAGATTCAGAGGGCTCTGGAACCTGCTGGGAAA  
ACAGGGAGTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTA  
CGCTGCTACTGGTCCCGAACAACCTACCCTGGCTCCTGGGCAGCTGATTCT  
20 GATCCGGAAAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCT  
CGAGGGAAAAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACCT  
TCTAAGCCCCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCG  
CAGTGCAGCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCC  
CAGAACGATGACGAACCTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCT  
25 CAACAAGGAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTT  
GGGCTCTTCCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAAG  
CCAGCAATGGTGTCTCAGACCTGCATCTCTTAGATATGCTGACCCCGACTGA  
GAGGAAGCGGCAAGGCTACATCCATGAACTCATTGTACGGAGGAGAACT  
ACGTGAACGACTTGCAGCTGGTCACAGAGATCTTTCAGAAACCCCTGACG  
30 GAGTCTGAGCTGCTGACAGAAAAAGAGGTTGCTATGATTTTTGTAACTG  
GAAGGAGCTGATCATGTGTAATATCAAACCTGCTGAAAGCGCTGAGAGTCC  
GCAAGAAGATGTCTGGGGAGAAGATGCCGGTGAAGATGATTGGCGACAT  
CCTGAGCGCCCAGCTGCCGCACATGCAGCCTTACATCCGCTTCTGCAGCTG  
CCAGCTCAATGGGGCTGCCCTCATCCAGCAGAAGACGGACGAGGCTCCAG  
35 ACTTCAAGGAGTTCGTCAAAGACTGGCAATGGACCCCTCGGTGCAAAGGA  
ATGCCTCTGTCCAGCTTTATACTGAAGCCTATGCAGCGTGTACAAAGATAC  
CCGCTGATCATTAAAAACATCCTGGAAAACACTCCTGAGAACCATCCAGA

-59-

CCACAGCCACCTGAAGCATGCCCTGGAAAAGGCGGAGGAGCTGTGCTCCC  
 AGGTGAACGAGGGAGTTTCGAGAGAAGGAGAACTCAGACCGGCTGGAGTG  
 GATCCAAGCCCACGTGCAGTGTGAAGGCCTTTCTGAGCAACTGGTGTTC  
 ATTCAGTGACCAACTGCTTGGGACCACGCAAGTTTCTGCACAGCGGGAAG  
 5 CTCTACAAGGCCAAGAGCAATAAAGAACTGTATGGCTTCCTCTTCAACGA  
 CTTCTCCTGCTGACCCAAATCACAAGCCCTTAGGCTCTTCCGGCACCGA  
 CAAAGTCTTCAGCCCCAAATCTAACCTTCAGTATAAAATGTACAAAACGC  
 CCATTTTCTTAAATGAGGTTCTAGTAAAATTGCCACGGACCCTTCTGGAG  
 ATGAGCCTATCTTCCACATTTCCCACATCGACCGGGTCTACACCCTCCGAG  
 10 CAGAGAGCATAAATGAGAGGACTGCCTGGGTGCAGAAAATCAAGGCGGC  
 GTCTGAGCTCTACATAGAGACGGAGAAAAAGAAGCGAGAGAAGGCGTAC  
 CTGGTCCGTTCCCAGCGGGCGACCGGTATTGGAAGGTTGATGGTGAACGT  
 GGTAGAAGGCATTGAGCTGAAGCCCTGTCCGTCACATGGAAAGAGCAACC  
 CGTACTGTGAGGTGACCATGGGCTCTCAGTGCCACATCACCAAGACAATC  
 15 CAGGACACGCTAAACCCCAAGTGGAATTCTAACTGCCAGTTCTTCATCAG  
 AGACCTGGAGCAGGAGGTTCTCTGCATCACAGTGTTTGAGAGGGACCAGT  
 TCTCGCCTGATGATTTTTTGGGTCCGACAGAGATCCGAGTGGCCGACATCA  
 AGAAAGACCAGGGCTCCAAGGGGGCCGGTTACGAAGTGTCTCCTGCTGCAT  
 GAGGTCCCCACGGGAGAGATTGTGGTCCGCCTTGACCTGCAGTTGTTTGAT  
 20 GAGCCGTAGCAGCCCTGCGATGATCGTAGATGACTTCCTCCTCAAGGCCC  
 CGTGCGGGCGTGCTGTCTGGTGGTCAGCCTCAGAGCAACGGGGATGAAGC  
 AAAGACGAAGCCCCTCGAGGCTGCTAGGAGTCGTTCTCGACAATCCTGCC  
 CTTCAAACCATGTCTCATTTTTATGAATCCAAATTCTCTTTTCCTTTGCTCTC  
 CCTATGGTCTCATCATGGCTTCTAGAGTCTCTGAAATCTGTGACCTTTAAC  
 25 TAGGTTCCATTGGGAGCCTGGCTCCTTCCCTGGGCTGGAGGTGTGGGTCTG  
 GTTCTATAAAATAGATTATAAACTCGAGAATCACTAGT

Mouse Ese1L coding: Sequence ID NO:23

ATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGATGTCTGGGCCATA  
 30 ACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTTAGCCTGAAGCC  
 GATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACTTTTTTTTCCAATC  
 TGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCTAGCGGACATGA  
 ATAACGATGGAAGGATGGATCAAGTGGAATTTCCATAGCCATGAAGCTT  
 ATCAAACCTGAAGCTACAAGGATATCAGCTCCCCTCCACACTTCCCCCTGTC  
 35 ATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGCATTTGGTATAGG  
 AGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCTGTGCCAATGG  
 GCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCTTCTGTCCCTCC

-60-

AGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTCATACAGCCTCT  
GCCTGCGTTTGGCGATCCTGCAGCCACATGGCCAAAGAGTTCTTCCTTCAG  
CAGATCTGGTCCAGGGTCACAATTAACACTAAGTTACAGAAGGCACAAT  
CATTGATGTCGCCAGCGCCCCCTCCAGCAGCAGAATGGGCTGTGCCTCAG  
5 TCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCACGACAAAACATAT  
GAGTGGACACTTAACAGGTCCCCAGGCAAGAAGTATTCTCATGCAATCAA  
GTTTACCCAGGCTCAGCTGGCTTCAATATGGAATCTTTCTGACATTGATC  
AAGATGGAAAACACTGTCAGAAGAATTTATCCTAGCTATGCACCTAATT  
GATGTTGCCATGTCTGGTCAGCCACTGCCGCCCCGTCCTGCCTCCAGAATAC  
10 ATCCCTCCTTCCTTCAGAAGAGTTGCTCCGGCAGTGGGATGTCCGTCATA  
AGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGTCGTCAGAGGA  
TGAGCAGCAGCCAGAGAAGAACTGCCTGTGACATTTGAAGATAAGAAG  
CGGGAGAAGTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGCGCCGGCAAG  
CGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGCTCAGCTGGA  
15 GCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAGCAGGAGGC  
CAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGCGGGAGCTG  
GAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGAGGCGCGAG  
GCCGCAAACGGGAAGTGGAAAGGCAGCGACAAGTGAATGGGAACGGA  
ACCGGAGACAGGAAGTCTGAATCAGAGGAACAAGGAGCAGGAGGGGCAC  
20 CGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTTAGAAGCTC  
TGAATGACAAAAGCATCAGCTAGAAGGAAAAGTTCAGGATATCAGGTGT  
CGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACAAGTCTAGAG  
AGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTGCAGGAATCT  
CAGCAAATGCTTGGAAAGACTTATTCAGAGAAACAGATACTCAGTGACCA  
25 GTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGCTTCTTACCC  
TCAAAAGAGCCTTGGAAAGCAAAGGAGCTGGCCCCGGCAGCAGCTCCGGGA  
GCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGCAGGAGATT  
GATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACATAGCAAACA  
GCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGAAGCAGAAA  
30 GAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGGAAGACGCTC  
AGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCATGTGCAGCA  
GGAGGAGCAGCCACGCCCCCGGAAACCCACGAGGAGGACAGACTGAAG  
AGGGAAGACAGTGTGAGGAAGAAGGAGGCGGAAGAGAGAGCCAAGCCG  
GAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCAGGAGCCAGC  
35 TAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAGGCCCGCTTA  
CCATTTCTGCACAGGAGAGTGTAAGAGTGGTATATTACCGAGCGCTGTAC  
CCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCCAGGAGATAT

-61-

AGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGGCTTGGAGGA  
GAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACCTATGCAGAAAAGA  
TTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCGATCTGACA  
TCTGCCCCCTGCCCCCAAACCTGGCTCTGCGTGAGACCCCTGCTCCTTTGCCA  
5 GTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAGACTTCAGT  
TCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGACAACCTGGG  
ATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGGCCAGTTAC  
GGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCTCCCCATCTC  
CCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCGCAAGCCCT  
10 GTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAACAAAAGTG  
ACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTGGAGAAGTT  
CAAGGTCAGAAGGGTTGGTTCCCAAGTCTTACGTGAAACTCATTTCAGG  
GCCCCGTAAAGGAAATCCACAAGCATCGATACTGGCCCTACTGAAAGTCCTG  
CTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCAAGCCAGCCATTCCCGGA  
15 GAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAAGGAGATTT  
AACCTTTTACGCAAGGGGATGTGATTGTGGTTACCAAGAAAGATGGTGACT  
GGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTTCTAACTAT  
GTGAGGCTTAAAGATTCAGAGGGGCTCTGGAAGTCTGGGAAAACAGGGA  
GTTTAGGAAAAAAACCTGAAATTGCCAGGTTATTGCTTCCTACGCTGCTA  
20 CTGGTCCCGAACAACCTCACCTGGCTCCTGGGCAGCTGATTCTGATCCGGA  
AAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCTCGAGGGAA  
AAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACCTTCTAAGCC  
CCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCGCAGTGCA  
GCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCCCAGAACG  
25 ATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCTCAACAAG  
GAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTTGGGCTCTT  
CCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAGCCAGCAAT  
GGTGCTCAGACCTGCATCTCTTAGATATGCTGACCCCGACTGAGAGGAAG  
CGGCAAGGCTACATCCATGAACTCATTGTCACGGAGGAGAACTACGTGAA  
30 CGACTTGCAGCTGGTCACAGAGATCTTTCAGAAACCCCTGACGGAGTCTG  
AGCTGCTGACAGAAAAAGAGGTTGCTATGATTTTTGTAACTGGAAGGAG  
CTGATCATGTGTAATATCAAACCTGCTGAAAGCGCTGAGAGTCCGCAAGAA  
GATGTCTGGGGAGAAGATGCCGGTGAAGATGATTGGCGACATCCTGAGCG  
CCCAGCTGCCGCACATGCAGCCTTACATCCGCTTCTGCAGCTGCCAGCTCA  
35 ATGGGGCTGCCCTCATCCAGCAGAAGACGGACGAGGCTCCAGACTTCAAG  
GAGTTCGTCAAAAGACTGGCAATGGACCCTCGGTGCAAAGGAATGCCTCT  
GTCCAGCTTTATACTGAAGCCTATGCAGCGTGTCAAGATAACCGCTGAT



-62-

CATTAAAAACATCCTGGAAAACACTCCTGAGAACCATCCAGACCACAGCC  
 ACCTGAAGCATGCCCTGGAAAAGGCGGAGGAGCTGTGCTCCCAGGTGAAC  
 GAGGGAGTTCGAGAGAAGGAGAACTCAGACCGGCTGGAGTGGATCCAAG  
 CCCACGTGCAGTGTGAAGGCCTTTCTGAGCAACTGGTGTTCATTCAAGTGA  
 5 CCAACTGCTTGGGACCACGCAAGTTTCTGCACAGCGGGAAGCTCTACAAG  
 GCCAAGAGCAATAAAGAACTGTATGGCTTCCTCTTCAACGACTTCCTCCTG  
 CTGACCCAAATCACAAAGCCCTTAGGCTCTTCCGGCACCGACAAAGTCTT  
 CAGCCCCAAATCTAACCTTCAGTATAAAATGTACAAAACGCCCATTTTCTT  
 AAATGAGGTTCTAGTAAAAATTGCCACGGACCCTTCTGGAGATGAGCCTA  
 10 TCTTCCACATTTCCACATCGACCGGGTCTACACCCTCCGAGCAGAGAGCA  
 TAAATGAGAGGACTGCCTGGGTGCAGAAAATCAAGGCGGCGTCTGAGCTC  
 TACATAGAGACGGAGAAAAAGAAGCGAGAGAAGGCGTACCTGGTCCGTT  
 CCCAGCGGGCGACCGGTATTGGAAGGTTGATGGTGAACGTGGTAGAGGCA  
 TTGAGCTGAAGCCCTGTCGGTCACATGGAAAGAGCAACCCGTAAGTGTGAG  
 15 GTGACCATGGGCTCTCAGTGCCACATCACCAAGACAATCCAGGACACGCT  
 AAACCCCAAGTGAATTCTAACTGCCAGTTCTTCATCAGAGACCTGGAGC  
 AGGAGGTTCTCTGCATCACAGTGTTTGAGAGGGACCAGTTCTCGCCTGAT  
 GATTTTTTGGGTCGGACAGAGATCCGAGTGGCCGACATCAAGAAAGACCA  
 GGGCTCCAAGGGGCGGTTACGAAGTGTCTCCTGCTGCATGAGGTCCCCA  
 20 CGGGAGAGATTGTGGTCCGCCTTGACCTGCAGTTGTTTGATGAGCCGTAG

Murine Ese1L protein: Sequence ID NO: 24

MAQFPTPFGGSLDVWAITVEERAKHDQQFLSLKPIAGFITGDQARNFFFQSGL  
 PQPVLAQIWALADMNNDGRMDQVEFSIAMKLIKLLKQGYQLPSTLPPVMKQ  
 25 QPVAISSAPAFGIGGIASMPPLTAVAPVPMGSIPVVGMSPPLVSSVPPAAVPPL  
 ANGAPPVIQPLPAFAHPAATWPKSSSFSGPGSQLNTKLQKAQSFQVAVAPP  
 AAEWAVPQSSRLKYRQLFNHDKTMSGHLTGPQARTILMQSSLPQAQLASIW  
 NLSIDIDQDGKLTAEFILAMHLIDVAMSGQPLPPVLPPEYIPPSFRRVRSRSGM  
 SVISSSSVDQRLPEEPSEDEQPEKKLPVTFEDKKRENFERGSVELEKRRQAL  
 30 LEQQRKEQERLAQLERAERKERERQEQAQRQLELEKQLEKQRELERQRE  
 EERRKEIERREAAKRELERQRQLEWERNRRQELLNQRNKEQEGTVVLKARR  
 KTLFELEALNDKKHQLEGKLQDIRCRLATQRQEIESTNKSRELRIAEITHLQQ  
 QLQESQQMLGRLIPEKQILSDQLKQVQQNSLHRDSSLTLKRALEAKELARQQ  
 LREQLEVERETRSLQLEIDVFNNQLKELREIHSKQQQLQKQRSLEAARLKQKE  
 35 QERKSLELEKQKEDAQRRVQERDKQWLEHVQQEEQPRPRKPHEEDRLKRED  
 SVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQAPWSTTEKGPLTISAQE  
 SVKVYYRALYPFESRSHDEITIQPGDIVMVDESQTGEPGWLGGELKGKTGW

-63-

FPANYAEKIPENEVPTPAKPVTDLTSAPAPKLALRETPAPLPVTSSEPSTTPNN  
 WADFSSTWPSSSNEKPETDNWDTWAAQPSLTVPSAGQLRQRSAFTPATATGS  
 SPSVLGGQGEKVEGLQAQALYPWRAKKDNHLNFNKSDVITVLEQQDMWWF  
 GEVQGQKGWFPKSYVKLISGPVRKSTSIDTGPTESPASLKRVASPAKPAIPGE  
 5 EFIAMYTYESSEQGDLTFFQQGDVIVVTKKDGDWWTGTVDKSGVFPSNYVR  
 LKDSESGTAGKTGSLGKKPEIAQVIASAAATGPEQLTAPGQLILIRKKNPGG  
 WWEGELQARGKKRQIGWFPANYVKLLSPGTSKITPTLPAVQPAVCQVIG  
 MYDYTAQNDDLAFAFSKGQIINVLNKEDPDWWKGEVSGQVGLFPSNYVKLTT  
 DMDPSQQWCSDLHLLDMLTPTERKRQGYIHELIVTEENYVNDLQLVTEIFQK  
 10 PLTESELLTEKEVAMIFVNWKELIMCNILLKALRVRKKMSGKMPVKMIGD  
 ILSAQLPHMQPYIRFCSCQLNGAALIQKKTDEAPDFKEFVKRLAMDPRCKGM  
 PLSSFILKPMQVRVTRYPLIKNILENTPENHPDHSCLKHALEKAEELCSQVNEG  
 VREKENSRLLEWIAHVQCEGLSEQLVFNSTNCLGPRKFLHSGKLYKAKSN  
 KELYGFLFNDFLLLTQITKPLGSSGTDKVFSPKSNLQYKMYKTPIFLNEVLVKL  
 15 PTDPGDEPIFHISHIDRVYTLRAESINERTAVVQKIKAASELYIETEKKKREKA  
 YLVRQRATGIGRLMVNVVEGIELKPCRSHGKSNPYCEVTMGSGCHITKTIQD  
 TLNPKWNSNCQFFIRDLEQEVLCITVFERDQFSPDDFLGRTEIRVADIKKDQGS  
 KGPVTKCLLLHEVPTGEIVVRLDLQLFDEP

20 Mouse E2L cDNA: Sequence ID NO:25  
 CCCTTCCTTTCTTTTTTGTGTTTCGCTTCGGCCGTGCCGGCTGAGAGCCC  
 AGCAGCCGTGACAGGCTGCGCAACAGGTTGCTGCGGCCGGCCTGACGAC  
 TGACCCGGCGGCGGCGGCCGCGGCACGGCAGGGTCTTCCCGGAGCTTGGC  
 CGCGCCACACGCGCCGGTGTGAGGAGCGCGCGGGGTCGCGCCGGGACGT  
 25 GCGCGAGGCGCCAGATGGCTGAGAGCTGCAAGAAGAAGTCAGGATCATG  
 ATGGCTCAGTTTCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT  
 TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC  
 CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCTACAGT  
 CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA  
 30 ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAACTC  
 ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC  
 ATGAAACAACCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG  
 GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT  
 ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCTA  
 35 ATGATGCCTGCTCCCCTAGTGCCTTCTGTAGTACATCCTCATTACCAAAT  
 GGAAGTGCAGTCTCATTACGCCTTTATCCATTCTTATTCTTCTTCAACAT  
 TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA

-64-

GTATCCAGAAGGCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT  
CCTCAACTGCTTCCCTCTCAGGGAACCTACCTAAGACAGGGACCTCAGAG  
TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT  
CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC  
5 CCTTCTTCAGTCAAATCTCTCTCAAACCTCAGCTAGCTACTATTTGGACTCT  
GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG  
CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG  
TTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTTGAT  
TCTGTTAATGGAACCTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC  
10 TCAGAAGAAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACATG  
AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA  
GCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGAGTG  
GGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCAGCTG  
GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG  
15 AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG  
AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG  
CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC  
CAGAAAGAAAAGTCTCCACCTGGAACCTGGAAGCAGTGAATGGAAAACAT  
CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC  
20 AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG  
GAAATCAAACAACCTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT  
CTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTA AAAACATGC  
AGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAAAGTCA  
TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT  
25 TGAAAAAGAACTGCATCTAAGCTCTCAGAAATGGATTCATTTAACAATC  
AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA  
CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA  
GATTAGAGCAAATTCAAAAAAGAACTAGAAAGATGAGGCTGCAAGGAA  
AGCAAAGCAAGGAAAAGAAAACCTTGTGGAGAGAAAGTATTAGAAAGGAA  
30 GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA  
ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA  
GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT  
GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAAC  
TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTTCAGGGAAAGTTTGGCTG  
35 GTTCCCCTGCAACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGT  
CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA  
CTTCTTCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT

-65-

CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC  
ACTGTGTCCCCTGGATCTGTGTCCCCCATTACGGACAGGGGCAGGCTGTA  
GAAAACCTGAAAGCCCAGGCCCTTTGTTTCCTGGACGGCAAAGAAGGAGA  
ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCCTGGAGCAGCAG  
5 GAAAACCTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCCA  
AGTCTTATGTCAAGCTCATTCCTGGGAATGAAGTACAGCGAGGAGAGCCA  
GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC  
AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC  
ATACTCAAGTGTAGAGCCCGGGGATTTGACTTTCACTGAAGGTGAAGAAA  
10 TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA  
GAGAACTGGAATCTTCCCGTCCAACCTACGTCAGACCAAAGGATCAAGAGA  
ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC  
GCTCAAGTAACCTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT  
GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG  
15 GCAAGGAGAGCTACAGGCCAGAGGGAAGAAACGACAGAAGGGATGGTTT  
CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC  
TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA  
TAACGAAGATGAGCTCAATTTCTCCAAAGGACAGCTGATTAATGTTATGA  
ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT  
20 CTCTTTTCCTTCAAACCTATGTTAAGATGACAACAGACTCAGATCCAAGTCAA  
CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG  
GAAGCGACAGGGCTACATTCACGAGCTCATTTCAGACAGAGGAGCGGTAC  
ATGGACGACGACCTGCAGCTGGTCATCGAGGTCTTCCAGAAACGGATGGC  
TGAGGAAGGCTTCCTCACTGAAGCAGACATGGCTCTGATCTTTGTGAAC  
25 GGAAAGAGCTCATCATGTCCAACACGAAGCTGCTGAGGGCCTTGCGGGTG  
AGGAAGAAGACTGGGGGTGAGAAGATGCCAGTTCAGATGATTGGAGACA  
TCCTGGCGGCAGAGCTGTCCCACATGCAGGCCTACATCCGCTTCTGCAGCT  
GTCAGCTTAATGGGGCAACCCTGTTACAGCAGAAGACAGACGAGGACAC  
GGACTTCAAGGAATTTCTAAAGAAGTTGGCATCAGACCCACGATGCAAAG  
30 GGATGCCCTCTCCAGCTTCCTGCTGAAGCCCATGCAGAGGATCACTCGCT  
ACCCGCTGCTCATCCGAAGTATCCTGGAGAACACTCCACAGAGTCATGTT  
GACCACTCCTCCCTGAAGCTGGCCCTAGAACGTGCTGAGGAGCTGTGCTC  
TCAGGTGAACGAGGGAGTCCGGGAGAAGGAAAATTCAGACCGGCTGGAG  
TGGATCCAGGCACACGTGCAGTGC GAAGGCTTGGCAGAGCAACTTATTTT  
35 CAACTCCCTCACCAACTGCCTGGGCCCCCGGAAGCTTCTGCACAGCGGGA  
AGCTGTACAAGACCAAGAGCAATAAGGAGCTGCACGCCTTCCTCTTCAAC  
GACTTCCTGCTGCTCACCTACCTGGTCAGGCAGTTTGCCGCCGCCTCTGGC

-66-

CACGAGAAGCTCTTCAACTCCAAGTCCAGTGCTCAGTTCCGGATGTACAA  
AACGCCCCATTTTCCTGAATGAAGTGTGGTGAACTTCCCACAGACCCTTC  
CGGCGATGAGCCCGTCTTCCACATTTCCCACATTGATCGTGTGTACACACT  
CCGAACAGACAACATCAACGAGAGGACGGCCTGGGTCCAGAAGATCAAG  
5 GGTGCCTCAGAGCAGTACATCGACACTGAGAAGAAGAAACGGGAAAAGG  
CTTACCAAGCCCGTTCTCAAAAGACTTCAGGTATTGGGCGTCTGATGGTGC  
ATGTCATTGAAGCTACAGAATTAAGCCTGCAAACCAAACGGGAAAAGT  
AATCCATACTGTGAAGTCAGCATGGGCTCCCAAAGCTATACCACCAGGAC  
CCTGCAGGACACACTAAACCCCAAGTGGAAGTTCAACTGCCAGTTCTTCA  
10 TCAAGGATCTTTACCAGGACGTTCTGTGTCTCACTATGTTTGACAGAGACC  
AGTTTTCTCCAGATGACTTCTTGGGTCGTAAGTTCCAGTGGCAAAAA  
TCCGAACAGAACAGGAAAGCAAAGGCCCCACCACCCGCGACTACTACTG  
CACGAAGTCCCCACTGGAGAAGTCTGGGTCCGCITTGACCTGCAACTTTTT  
GAACAAAAAACTCTCCTTTGAGGGCCTGGGGAAGCCAGAACCAGGGGAG  
15 CTGCCCACAAGGCTGGGTCTAAAGACAGATTTTGCTCTCCCAGGACAGAG  
GAGCATCACATGGCTTCATCCATCAAACAGCCACACTCGCTGGGCCTGTA  
TTTTATTGCACACTAAATTGCTAGCAATCTATGCAAACATGATCTTTTAAA  
CAAACGCCACAGCACAGTGCCTTGTAAGTTAACCTGTTACAGTGTGT  
TAGATGCCAGGGTTTCCATTTTCAGGGCTATAAAAGTATTATGTGGAAATG  
20 AGGCATCAGACCACCGGACGTTACCACTTGGCAAATCTGTCCACTGTGGA  
GTTGGTGATGTTGGAACCATTCACACTATGTGACCTCTGCTGGGTCACAC  
ACTCAGGAGGTGAAGGGCTGAGATGAAATGCTGCAGCCTTGGGGCTTGTG  
CAGCCTGATACTGAAATAGCATCCACTTGTGCACTGAATAAATAGAACT  
TGATCGTTTTATTCTGACTAGATATTATCATTCTCTGCTAAGACAATATAGT  
25 TTGAAATATTATAGTTTGAATATAAGGAGGAAAGCTTGATGTACTTTAAAT  
ATACTGTGAACTCTAATAATGTGGGGATATTTTCAACTTTAATTTCTTAA  
GTATAAATTATTTATGTAAATCTTTGTTTTGCATATTTATAGAACATGCA  
TCTTTAAGCTTTATCATTGCCAACAAATGTACAGAAAGAGAATAAAAGTAT  
AAGTTTATGAATGTAAAAA

30

Murine Ese2L coding: Sequence ID NO: 26

ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT  
TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC  
CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCTACAGT  
35 CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA  
ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAACTC  
ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC

-67-

ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG  
GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT  
ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA  
ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT  
5 GGAAGTGCCAGTCTCATTACAGCCTTTATCCATTCCCTTATTCTTCTTCAACAT  
TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA  
GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT  
CCTCAACTGCTTCCCTCTCAGGGAACCTAAGACAGGGACCTCAGAG  
TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT  
10 CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC  
CCTTCTTCAGTCAAATCTCTCTCAAACCTCAGCTAGCTACTATTTGGACTCT  
GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG  
CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTG  
ACGTTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTT  
15 GATTCTGTTAATGGAAGTCTGCCTTCATATCAGAAAACACAAGAAGAAGA  
GCCTCAGAAGAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACT  
ATGAACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGA  
GCAGCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGA  
GTGGGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCA  
20 GCTGGAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAG  
CGGGAGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAA  
CAGGAGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCA  
GGAGCTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTG  
AGCTCCAGAAAGAAAAGTCTCCACCTGGAAGTGAAGCAGTGAATGGAA  
25 AACATCAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCA  
AACACAAAAGACTGAGCTAGAAGTTTTTGGATAAACAGTGTGACCTGGAAA  
TTATGGAAATCAAACAACCTTCAACAAGAGCTTAAGGAATATCAAAATAAG  
CTTATCTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTAATAA  
CATGCAGCTCAGTAACACACCTGATTACAGGGATCAGTTTACTTCATAAAA  
30 AGTCATCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGAT  
GCTCTTGAAAAAGAACTGCATCTAAGCTCTCAGAAATGGATTCATTAA  
CAATCAGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCC  
TTGAACAACCTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGA  
AAAAGATTAGAGCAAATTCAAAAAAGAACTAGAAGATGAGGCTGCAA  
35 GGAAAGCAAAGCAAGGAAAAGAAAACCTTGTGGAGAGAAAGTATTAGAAA  
GGAAGAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGA

-68-

CAAAACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACA  
GCCAGTGCTTTGGTG  
AATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCATGATGAGATGAG  
TTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAACTGTAGGAGAGC  
5 CTGGTTGGCTTTATGGTAGTTTTTCAGGGAAAGTTTGGCTGGTTCCCTTGCA  
ACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGTCTCCTAAGAAG  
GCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAACTTCTTCCCAGC  
CACCAGCATCAGTGACTGATTATCACAATGTATCCTTCTCAAACCTTACTG  
TTAATACAACATGGCA  
10 GCAGAAGTCAGCTTTTACCCGCACTGTGTCCCCTGGATCTGTGTCCCCCAT  
TCACGGACAGGGGCAGGCTGTAGAAAACCTGAAAGCCCAGGCCCTTTGTT  
CCTGGACGGCAAAGAAGGAGAACCACCTGAACTTCTCAAAGCACGACGTC  
ATCACTGTCTTGGAGCAGCAGGAAAAGTGGTGGTTTGGGGAGGTGCACGG  
AGGAAGAGGATGGTTCCCCAAGTCTTATGTCAAGCTCATTCTGGGAATG  
15 AAGTACAGCGAGGAGAGCCAGAAGCTTTGTATGCAGCTGTGACTAAGAAA  
CCTACCTCCACAGCCTATCCAGTTACCTCCACAGCCTATCCAGTTGGAGAA  
GACTACATTGCACTTTATTCTACTCAAGTGTAGAGCCCGGGGATTTGACT  
TTCCTGAAGGTGAAGAAATTCTAGTGACCCAGAAAGATGGAGAGTGGTG  
GACAGGAAGTATTGGAGAGAGAACTGGAATCTTCCCGTCCAACTACGTCA  
20 GACCAAAGGATCAAGAGAATTTTGGGAATGCTAGCAAATCTGGAGCATCA  
AACAAAAAACCCGAGATCGCTCAAGTAACTTCAGCATATGCTGCTTCAGG  
GACTGAGCAGCTCAGCCTTGCGCCAGGACAGTTAATATTAATCTTAAAGA  
AAAACACAAGCGGGTGGTGGCAAGGAGAGCTACAGGCCAGAGGGAAGAA  
ACGACAGAAGGGATGGTTTCCTGCCAGCCATGTAAAGCTGCTAGGTCCAA  
25 GCAGTGAAAGAACCATGCCTACTTTTACGCTGTATGTCAAGTGATTGCTA  
TGTATGACTACATGGCGAATAACGAAGATGAGCTCAATTTCTCCAAAGGA  
CAGCTGATTAATGTTATGAACAAAGATGACCCTGACTGGTGGCAAGGAGA  
AACCAATGGTCTGACTGGTCTCTTTCTTCAAACCTATGTAAAGATGACAAC  
AGACTCAGATCCAAGTCAACAGTGGTGTGCTGACCTCCAAGCCCTGGACA  
30 CAATGCAGCCTACGGAGAGGAAGCGACAGGGCTACATTCACGAGCTCATT  
CAGACAGAGGAGCGGTACATGGACGACGACCTGCAGCTGGTCATCGAGG  
TCTTCCAGAAACGGATGGCTGAGGAAGGCTTCCTCACTGAAGCAGACATG  
GCTCTGATCTTTGTGAACTGGAAAGAGCTCATCATGTCCAACACGAAGCT  
GCTGAGGGCCTTGCGGGTGAGGAAGAAGACTGGGGGTGAGAAGATGCCA  
35 GTTCAGATGATTGGAGACATCCTGGCGGCAGAGCTGTCCCACATGCAGGC  
CTACATCCGCTTCTGCAGCTGTCAGCTTAATGGGGCAACCCTGTTACAGCA  
GAAGACAGACGAGGACACGGACTTCAAGGAATTTCTAAAGAAGTTGGCAT

-69-

CAGACCCACGATGCAAAGGGATGCCCCCTCTCCAGCTTCCTGCTGAAGCCC  
 ATGCAGAGGATCACTCGCTACCCGCTGCTCATCCGAAGTATCCTGGAGAA  
 CACTCCACAGAGTCATGTTGACCACTCCTCCCTGAAGCTGGCCCTAGAAC  
 GTGCTGAGGAGCTGTGCTCTCAGGTGAACGAGGGAGTCCGGGAGAAGGA  
 5 AAATTCAGACCGGCTGGAGTGGATCCAGGCACACGTGCAGTGCGAAGGCT  
 TGGCAGAGCAACTTATTTTCAACTCCCTACCAACTGCCTGGGCCCCCGGA  
 AGCTTCTGCACAGCGGGAAGCTGTACAAGACCAAGAGCAATAAGGAGCT  
 GCACGCCTTCCTCTTCAACGACTTCCTGCTGCTCACCTACCTGGTCAGGCA  
 GTTTGCCGCCGCCTCTGGCCACGAGAAGCTCTTCAACTCCAAGTCCAGTGC  
 10 TCAGTTCCGGATGTACAAAACGCCCATTTTCCTGAATGAAGTGTTGGTGAA  
 ACTTCCACAGACCCTTCCGGCGATGAGCCCGTCTTCCACATTTCCACAT  
 TGATCGTGTGTACACACTCCGAACAGACAACATCAACGAGAGGACGGCCT  
 GGGTCCAGAAGATCAAGGGTGCCTCAGAGCAGTACATCGACACTGAGAA  
 GAAGAAACGGGAAAAGGCTTACCAAGCCCGTTCTCAAAGACTTCAGGTA  
 15 TTGGGCGTCTGATGGTGCATGTCATTGAAGCTACAGAATTAAGCCTGC  
 AAACCAAACGGGAAAAGTAATCCATACTGTGAAGTCAGCATGGGCTCCCA  
 AAGCTATACCACCAGGACCCTGCAGGACACACTAAACCCCAAGTGGA  
 TCAACTGCCAGTTCTTCATCAAGGATCTTTACCAGGACGTTCTGTGTCTCA  
 CTATGTTTGACAGAGACCAGTTTTCTCCAGATGACTTCTTGGGTCGTA  
 20 AAGTTCCAGTGGCAAAATCCGAACAGAACAGGAAAGCAAAGGCCCCACC  
 ACCCGCCGACTACTACTGCACGAAGTCCCCACTGGAGAAGTCTGGGTCCG  
 CTTTGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGA

Mouse Ese2L protein: Sequence ID NO:27

25 MAQFPTAMNGGPNMWAITSEERTKHDKQFDNLKPSGGYITGDQARTFFLQS  
 GLPAPVLAELWALSDLNKDGKMDQQEFSIAMKLIKLLQGQQLPVVLPIMK  
 QPPMFSPLISARFGMGSMPLNSIHQPLPPVAPIATPLSSATSGTSIPPLMMPAPL  
 VPSVSTSSLPNGTASLIQPLSIPYSSSTLPHASSYSLMMGGFGGASIQKAQSLID  
 LGSSSSTSSTASLSGNSPKTGTSEWAVPQPSRLKYRQKFNSLDKGMSGYLSGF  
 30 QARNALLQSNLSQTQLATIWTADIDGDGQLKAEEFILAMHLTDMAGQPL  
 PLTLPPELVPPSFRGGKQVDSVNGTLPSYQKTQEEEPQKKLPVTFEDKRKANY  
 ERGNMELEKRRQVLMEQQQREARERKAQKEKEEWERKQRELQEQEWKKQLE  
 LEKRLEKQRELERQREEERRKEIERREAAKQELERQRRLEWERLRRQELLSQK  
 TREQEDIVRLSSRKSLHLELEAVNGKHQQISGRLQDVQIRKQTQKTELEVLD  
 35 KQCDLEIMEIKQLQQELKEYQNKLIYLVPEKQLLNERIKNMQLSNTPDSGISLL  
 HKKSSEKEELCQRLKEQLDALEKETASKLSEMDSFNNQLKELRESYNTQQLA  
 LEQLHKIKRDKLKEIERKRLEQIQKKKLEDEAARKAKQGKENLWRESIRKEEE



-70-

EKQKRLQEEKSQDKTQEEERKAEAKQSETASALVNYRALYPFEARNHDEMS  
FSSGDIIQVDEKTVGEPGWLYGSFQGGKFGWPCNYVEKVLSSSEKALSPKKALL  
PPTVSLSATSTSSQPPASVTDYHNVSFSNLTVNNTTWQQKSAFTRTVSPGSVSPI  
HGQQQAVENLKAQALCSWTAKKENHLNFSKHDVITVLEQQENWWFGEVHG  
5 GRGWFPKSYVKLIPGNEVQRGEPEALYAAVTKKPTSTAYPVTSTAYPVGEDY  
IALYSYSSVEPGDLTFTEGEEILVTQKDGEWWTGSIGERTGIFPSNYVRPKDQE  
NFGNASKSGASNKKPEIAQVTSAYAASGTEQLSLAPGQLILILKKNTSGWWQ  
GELQARGKKRQKGWFPASHVKLLGPSSERTMPTFHAVCQVIAMYDYMANN  
EDELNFSKGQLINVMNKDDPDWWQGETNGLTGLFPSNYVKMTTDS DPSQQ  
10 WCADLQALDTMQPTERKRQGYIHELITQTEERYMDDDLQLVIEVFQKRMAEE  
GFLTEADMALIFVNWKELIMSN TKLLRALRVRKKTGGEKMPVQMIGDILAAE  
LSHMQAYIRFCSCQLNGATLLQQKTDED TDFKEFLKKLASDPRCKGMPLSSF  
LLKPMQRITRYPLLIRSILENTPQSHVDHSSLKLALERAEE LCSQVNEGVREKE  
NSDRLEWIAHVQCEGLAEQLIFNSLTNCLGPRKLLHSGKLYKTKSNKELHA  
15 FLFNDFLLLTYLVRQFAAASGHEKLFNSKSSAQFRMYKTPIFLNEVLVKLPTD  
PSGDEPVFHISHIDRVYTLRTDNINERTAWVQKIKGASEQYIDTEKKKREKAY  
QARSQKTSGIGRLMVHVIEATELKACKPNGKSNPYCEVSMGSQSYTTRTLQD  
TLNPKWNFNCQFFIKDL YQDVLCLTMFDRDQFSPDDFLGRTEVPVAKIRTEQE  
SKGPTTRRLLLHEVPTGEVWVRFDLQLFEQKTLL

### References

1. H. Riezman, P. G. Woodman, G. van Meer, M. Marsh. Molecular  
5 mechanisms of Endocytosis. *Cell* 91: 731-738, 1997.
2. S. L. Schmid. Clathrin-coated vesicle formation and protein sorting: an  
integrated process. *Annu. Rev. Biochem.* 66: 511-548, 1997.
- 10 3. M. S. Robinson. Coats and budding vesicles. *Trends Cell. Biol.* 7: 99-102,  
1997.
4. D. E. Warnock, S. L. Schmid. Dynamin GTPase, a force-generating molecular  
switch. *BioEssays* 18: 885-893, 1996.
- 15 5. R. Urrutia, J. R. Henley, T. Cook, M. A. McNiven. The dynamins: redundant  
or distinct functions for an expanding family of related GTPases? *Proc. Natl. Acad.  
Sci. USA* 94: 377-384, 1997.
- 20 6. P. Wigge, K. Kohler, Y. Vallis, C. A. Doyle, D. Owen, S. P. Hunt, H. T.  
McMahon. Amphiphysin Heterodimers: Potential Role in Clathrin-mediated  
Endocytosis. *Molecular Biology of the Cell* 8: 2003-2015, 1997.
- 25 7. A. L. Munn, B. J. Stevenson, M. I. Geli, H. Riezman. end5, end6 and  
end7: mutations that cause actin delocalization and block the internalization step of  
endocytosis in *Saccharomyces cerevisiae*. *Molecular Biology of the Cell* 6: 1721-  
1742, 1995.
- 30 8. O. Shupliakov, P. Low, D. Grabs, H. Gad, H. Chen, C. David, K. Takei, P. De  
Camilli, L. Brodin. Synaptic vesicle endocytosis impaired by disruption of dynamin-  
SH3 domain interactions. *Science* 276: 259-263, 1997.
9. P. Wigge, Y. Vallis, H. T. McMahon. Inhibition of receptor-mediated  
endocytosis by the amphiphysin SH3 domain. *Current Biology* 7: 554-560, 1997.

35

10. H. McLauchlan, J. Newell, N. Morrice, A. Osborne, M. West, E. Smythe. A novel role for Rab5-GDI in ligand sequestration into clathrin-coated pits. *Current Biology* 8: 34-45, 1997.
- 5 11. P. J. Robinson, J.-M. Sontag, J.-P. Liu, E. M. Fykse, C. Slaughter, H. McMahon, T. C. Sudhof. Dynamin GTPase regulated by protein kinase C phosphorylation in nerve terminals. *Nature* 365: 163-166, 1993.
- 10 12. J.-P. Liu, A. T. R. Sim, P. J. Robinson. Calcineurin inhibition of Dynamin GTPase activity coupled to nerve terminal depolarization. *Science* 265: 970-973, 1994.
- 15 13. A. Wilde, F. M. Brodsky. In vivo phosphorylation of Adaptors regulates their interaction with Clathrin. *The Journal of Cell Biology* 135: 635-645, 1996.
14. R. Bauerfeind, K. Takei, P. De Camilli. Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals. *J. Biol. Chem.* 272: 30984-30992, 1997.
- 20 15. S. van Delft, R. Govers, G. J. Strous, A. J. Verkleij, P. M. P. van Bergen en Henegouwen. Epidermal growth factor induces ubiquitination of Eps15. *Journal of Biological Chemistry* 272: 14013-14016, 1997.
- 25 16. J.-M. Galan, R. Haguenaer-Tsapis. Ubiquitin Lys63 is involved in ubiquitination of a membrane plasma membrane protein. *EMBO J* 16: 5847-5854, 1997.
- 30 17. J. Terrel, S. Shih, R. Dunn, L. Hicke. A function for monoubiquitination in the internalization of a G protein-coupled receptor. *Molecular Cell* 1: 193-202, 1998.
- 35 18. R. Govers, P. van Kerkhof, A. L. Schwartz, G. J. Strous. Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced internalization of the growth hormone receptor. *EMBO J.* 16: 4851-4858, 1997.
19. P. De Camilli, S. D. Emr, P. S. McPherson, P. Novick. Phosphoinositides as regulators in membrane traffic. *Science* 271: 1533-1539, 1996.

20. E. Kubler, H. Riezman. Actin and fimbrin are required for the internalization step of endocytosis in yeast. *EMBO J.* 12: 2855-2862, 1993.
- 5 21. H. Benedetti, S. Raths, F. Crausaz, H. Riezman. The END3 gene encodes a protein that is required for the internalization step of endocytosis and for actin cytoskeleton organization in yeast. *Mol. Biol. Cell.* 5: 1023-1037, 1994.
22. M. I. Geli, H. Riezman. Role of Type I Myosin in receptor-mediated  
10 endocytosis in yeast. *Science* 272: 533-535, 1996.
23. H.-Y. Tang, M. Cai. The EH-domain-containing protein Pan1 is required for normal organization of the actin cytoskeleton in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 16: 4897-4914, 1996.
- 15 24. V. Moreau, J.-M. Galan, G. Devilliers, R. Haguenaue-Tsapis, B. Winsor. The yeast Actin-related protein Arp2p is required for the internalization step of endocytosis. *Molecular Biology of the Cell* 8: 1361-1375, 1997.
- 20 25. B. Wendland, S. D. Emr. Pan1p, Yeast eps15, functions as a multivalent adaptor that coordinates protein-protein interactions essential for endocytosis. *Journal of Cell Biology* 141: 71-84, 1998.
26. F. Fazioli, L. Minichiello, B. Matoskova, W. T. Wong, P. P. Di Fiore. eps15. A novel tyrosine kinase substrate, exhibits transforming activity. *Mol. Cell. Biol.* 13: 5814-5828, 1993.
- 25 27. A. Benmerah, J. Gagnon, B. Begue, B. Megarbane, A. Dautry-Varsat, N. Cerf-Bensussan. The Tyrosine kinase substrate EPS15 is constitutively associated with the plasma membrane adaptor AP2. *J. Cell Biol.* 131: 1831-1838, 1995.
- 30 28. F. Tebar, T. Sorkina, A. Sorkin, M. Ericsson, T. Kirchhausen. Eps15 Is a component of Clathrin-coated Pits and Vesicles and is located at the Rim of Coated Pits. *Journal of Biological Chemistry* 271: 28727-28730, 1996.

-74-

29. F. Tebar, S. Confalonieri, R. E. Carter, P. P. Di Fiore, A. Sorkin. Eps15 is Constitutively Oligomerized due to Homophilic interaction of its Coiled-coil domain. *Journal of Biological Chemistry* 272: 15413-15418, 1997.
- 5 30. R. Carbone, S. Fre, G. Iannolo, F. Belleudi, M. P., P. G. Pelicci, M. R. Torrissi, P. P. Di Fiore. eps15 and eps15R are essential components of the endocytic pathway. *Cancer Research* 57: 5498-5504, 1997.
- 10 31. A. Benmerah, C. Lamaze, B. Begue, S. L. Schmid, A. Dautry-Varsat, N. Cerf-Bensussan. AP-2/Eps15 interaction is required for receptor-mediated endocytosis. *Journal of Cell Biology* 140: 1055-1062, 1998.
- 15 32. W. T. Wong, C. Schumacher, A. E. Salcini, A. Romano, P. Castagnino, P. G. Pelicci, P. P. Di Fiore. A protein-binding domain, EH, identified in the receptor tyrosine kinase substrate EPS15 and conserved in evolution. *Proc. Natl. Acad. Sci. USA* 92: 9530-9534, 1995.
- 20 33. P. P. Di Fiore, P. G. Pelicci, A. Sorkin. EH: a novel protein-protein interaction domain potentially involved in intracellular sorting. *Trends. Biochem. Sci.* 22: 411-413, 1997.
- 25 34. C. Schumacher, B. S. Knudsen, T. Ohuchi, P. P. Di Fiore, R. H. Glassman, H. Hanafusa. The SH3 domain of Crk binds specifically to a conserved proline-rich motif in Eps15 and Eps15R. *Journal of Biological Chemistry* 270: 15341-15347, 1995.
- 30 35. A. Benmerah, B. Begue, A. Dautry-Vasat, N. Cerf-Bensussan. The Ear of alpha-Adaptin interacts with the COOH-terminal domain of the EPS15 protein. *Journal of Biological Chemistry* 271: 12111-12116, 1996.
- 35 36. G. Iannolo, A. E. Salcini, I. Gaidarov, O. B. J. Goodman, J. Baulida, G. Carpenter, P. G. Pelicci, P. P. Di Fiore, J. H. Keen. Mapping of the molecular determinants involved in the interaction between Eps15 and AP2. *Cancer Research* 57: 240-245, 1997.
37. L. Coda, A. E. Salcini, S. Confalonieri, G. Pelicci, T. Sorkina, A. Sorkin, P. G. Pelicci, P. P. Di Fiore. Eps15R is a tyrosine kinase substrate with characteristics of a

-75-

docking protein possibly involved in coated pits-mediated internalization. *Journal of Biological Chemistry* 273: 3003-3012, 1998.

38. B. Wendland, J. M. McCaffery, Q. Xiao, S. D. Emr. A Novel Fluorescence-activated Cell Sorter-based screen for yeast Endocytosis mutants identifies a yeast homologue of mammalian eps15. *J. Cell Biol.* 135: 1485-1500, 1996.
39. S. Raths, J. Rohrer, F. Crausaz, H. Riezman. end3 and end4: Two mutants defective in receptor-mediated and fluid-phase endocytosis in *Saccharomyces cerevisiae*. *The Journal of Cell Biology* 120: 55-65, 1993.
40. H. Y. Tang, A. Munn, M. Cai. EH domain proteins Pan1p and End3p are components of a complex that plays a dual role in organization of the cortical actin cytoskeleton and endocytosis in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 17: 4294-4304, 1997.
41. T. Zoladek, A. Tobiasz, G. Vaduva, M. Boguta, N. C. Martin, A. K. Hopper. MDP1, a *Saccharomyces cerevisiae* gene involved in mitochondrial/cytoplasmic protein distribution, is identical to the ubiquitin-protein ligase gene RSP5. *Genetics* 145: 595-603, 1997.
42. P. S. McPherson, E. P. Garcia, V. I. Slepnev, C. David, X. Zhang, D. Grabs, W. S. Sossin, R. Bauerfeind, Y. Nemoto, P. De Camilli. A presynaptic inositol-5-phosphatase. *Nature* 379: 353-357, 1996.
43. A. E. Salcini, S. Confalonieri, M. Doria, E. Santolini, E. Tassi, O. Minencova, G. Cesareni, P. G. Pelicci, P. P. Di Fiore. Binding specificity and in vivo targets of the EH domain, a novel protein-protein interaction module. *Genes & Development* 11: 2239-2249, 1997.
44. I. Gout, R. Dhand, I. D. Hiles, M. J. Fry, G. Panayotou, P. Das, O. Truong, N. F. Totty, J. Hsuan, G. W. Booker, I. D. Campbell, M. D. Waterfield. The GTPase dynamin binds to and is activated by a subset of SH3 domains. *Cell* 75: 25-36, 1993.

45. C. David, P. S. McPherson, O. Mundigl, P. De Camilli. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. *Proc. Natl. Acad. Sci. USA* 93: 331-335, 1996.
- 5 46. M. H. Butler, C. David, G.-C. Ochoa, Z. Freyberg, L. Daniell, D. Grabs, O. Cremona, P. De Camilli. Amphiphysin II (SH3P9/BIN1), a member of the Amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and Nodes of Ranvier in brain and around T Tubules in skeletal muscle. *Journal of Cell Biology* 137: 1355-1367, 1997.
- 10 47. C. Leprince, F. Romero, D. Cussac, B. Vayssiere, R. Berger, A. Tavitian, J. H. Camonis. A new member of the Amphiphysin family connecting endocytosis and signal transduction pathways. *J. Biol. Chem.* 272: 15101-15105, 1997.
- 15 48. A. R. Ramjaun, K. D. Micheva, I. Bouchelet, P. S. McPherson. Identification and characterization of a nerve terminal-enriched amphiphysin isoform. *J. Biol. Chem.* 272: 16700-16706, 1997.
- 20 49. A. Wesp, L. Hicke, J. Palecek, R. Lombardi, T. Aust, A. L. Munn, H. Riezman. End4p/Sla2p Interacts with Actin-associated proteins for endocytosis in *Saccharomyces cerevisiae*. *Molecular Biology of the Cell* 8: 2291-2306, 1997.
50. E. de Heuvel, A. W. Bell, A. R. Ramjaun, K. Wong, W. S. Sossin, P. S. McPherson. Identification of the major Synaptojanin-binding proteins in the brain. *J. Biol. Chem.* 272: 8710-8716, 1997.
- 25 51. N. Ringstad, Y. Nemoto, P. De Camilli. The SH3p4/SH3p8/SH3p13 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. *Proc. Natl. Acad. Sci. USA* 94: 8569-8574, 1997.
- 30 52. Z. Wang, M. F. Moran. Requirement for the Adapter protein Grb2 in EGF receptor endocytosis. *Science* 272: 1935-1939, 1996.
53. A. B. Sparks, N. G. Hoffman, S. J. McConnel, D. M. Fowlkes, B. K. Kay. Cloning of ligand targets: Sytematic isolation of SH3 domain-containing proteins. *Nature Biotechnology* 14: 741-744, 1996.
- 35

54. P. Cupers, E. ter Haar, W. Boll, T. Kirchhausen. Parallel dimers and anti-parallel tetramers formed by Epidermal Growth Factor Receptor Pathway Substrate Clone 15 (Eps15). *Journal of Biological Chemistry* 272: 33430-33434, 1997.
- 5 55. H. Stenmark, C. Bucci, M. Zerial. Expression of Rab GTPases using recombinant vaccinia virus. *Meth. Enzymol.* 257: 155-164, 1995.
56. S. van Delft, C. Schumacher, W. Hage, A. J. Verkleij, P. M. P. van Bergen en Henegouwen. Association and Colocalization of Eps15 with Adaptor Protein-2 and  
10 Clathrin. *The Journal of Cell Biology* 136: 811-821, 1997.
57. M. Toth, J. Grimsby, G. Buzsaki, G. P. Donovan. Epileptic seizures caused by inactivation of a novel gene, jerky, related to centromere binding protein-B in transgenic mice. *Nature Genetics* 11: 71-75, 1995.
- 15 58. J. Sambrook, E. F. Fritsch, T. Maniatis, *Molecular Cloning, a laboratory manual. Second Edition.* (Cold Spring Harbor Press, Cold Spring Harbor, 1989).
59. Roos, J. and Kelly, R. B. Dap160, a Neural-specific Eps15 homology and  
20 multiple SH3 domain-containing protein that interacts with Drosophila Dynamin. *J. Biol. Chem.* 273, 19108-19119, 1998.
60. Ren, R., Mayer, B.J. Cicchetti, P. and Baltimore, D. Identification of a Ten-Amino Acid Proline-Rich SH3 Binding Site. *Science*, 259, 1157-1161, 1993.
- 25 61. Hall, A. Rho GTPases and the actin cytoskeleton. *Science*, 279, 509-514, 1998.
62. Nalefski, E.A. and Falke, J.J. The C2 domain calcium-binding motif:  
30 Structural and functional diversity. *Protein Science*, 5, 2375-2390, 1996.
63. Chen, H., et al., Epsin is an EH-domain binding protein implicated in clathrin-mediated endocytosis. *Nature*, 394, 793-797.
- 35 64. Stukenberg, P.T. et al., Systematic identification of mitotic phosphoproteins. *Current Biology*, 7, 338-348, 1997.



-78-

65. Tang, H. Y. and Cai, M. The EH-domain containing protein Pan1 is required for normal organization of the actin cytoskeleton in *Saccharomyces cerevisiae*. *Mol. Cell. Biol.* 16, 4897-4914, 1996.

T04240" 46246360



TABLE 1 - Cont'd

	LEAARLKQKEQERKSLE-LEKQKED--AQRRV-QERDKQWLEHVQQEEQP	669
	: : : : : : : : : : : : : : : :	
	HKIKRDKLKEIERKRLEQIQKKKLEDEAAARKAKQGKENLWRESIRKEEEE	687
	RPRKPHEEDRLKREDSVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQ	
	: : : : : : : : : : : : : : : :	
	KQK-----RLQEESQDKTQEEER-KAEA--KQSET-----	
SH3A	APWSTTEKGPLTISAOESVKVVVVYFALYPFEESRSHDEITICPQDIWMVDE	769
	: : : : : : : : : : : : : : : :	
	-----ASALVNRYRALYPFEARNHDEMSESSGDIILVDE	748
	SOTGEPGWLGSELKGKTGFPPANYAEKIPENEVPTPAKPVTDLTSAPAPK	
	: : : : : : : : : : : : : : : :	
	KTVGEPGWLYGSFC GFPGWFPCONYVEKVLSSE-----KALSPK	
	LALRETPAPLPVTSSEPSTTPNNWADFSSTWPSSSNEKPETDNWDTWAAQ	869
	: : : : : : : : : : : : : : : :	
	KALLPPTVSLSATST-SSQPPASVTDYHNV---SFSNLTVTNTTWQ-----	827
	PSLTVPSAGQLRQRSFTPATATGSSPSPVLGGQEKVEGLQAQALYPWFA	
	: : : : : : : : : : : : : : : :	
	-----QKSAFTRTVSPGSV-SPIHGQGQAVENLKAQALCSWTA	
SH3B	KFNHLNFENKSDVITVLELCENWWFGEVHGCGFWFPKSYVKLISGPVRKS	969
	: : : : : : : : : : : : : : : :	
	KKENHLNFKSHDVITVLELCENWWFGEVHGCGFWFPKSYVKLI PGNEVQR	914
	TSIDTGPTESPASLKRVASPAAKPAIP-GEEFIAMYTYESSECOGLTTEL	
	: : : : : : : : : : : : : : : :	
	GEPEALYA AVTKKPTSTAYPVTSTAYPVGEDYIALYSYSSVEPQDITETE	
SH3C	SDVIIVVTKKDGDWMTGTGVGDKSGVFPSNYVRLK DSEGSGTAGKTGSLGKK	1068
	: : : : : : : : : : : : : : : :	
	GEBILVTCFDGEMWTGSLBERTJIFPSNYVRPKDQENFGNASKSGASNKK	1014
SH3D	PEIAQVIASVAATBPILLTLAPGLLILIPKNPBBXWEGELIARGKRPCT	
	: : : : : : : : : : : : : : : :	
	PEIAQVTSAYAASGTETLLSLAPGLLILILKKNNTSGWAGELIARGKHELIF	
	GWEPANYVKLLSPGTSKITPTTEL PKTAVQPAVCQVIGMYDYTAONDELA	1168
	: : : : : : : : : : : : : : : :	
	GWEPASHVKLLGPSSERTMPT-----FHAVCQVIAMYCYMANNEDELN	1107
SH3E	FSKQCLINVLNKDDPDWTFEVSLJWGFLFPSNYVKLT TDMDP SQO	1213
	: : : : : : : : : : : : : : : :	
	FSKQCLINV MNKDDPDWTFGETNGLTG L FPSNYVKMTTDS DP SQOWCADL	1157
	QALDTMQPTERKROGYIH ELIQTEERYMD DLQ LF EQ K T LL	1197

TABLE 2

## Ese Proteins

Mouse Ese1 protein	1	75
Mouse Ese2 protein	1	75
Xenopus Intersectin	1	75
Drosophila Dap160-1	1	68
Mouse Ese1 protein	76	142
Mouse Ese2 protein	76	142
Xenopus Intersectin	76	142
Drosophila Dap160-1	76	135
Mouse Ese1 protein	143	210
Mouse Ese2 protein	143	210
Xenopus Intersectin	143	210
Drosophila Dap160-1	143	183
Mouse Ese1 protein	211	275
Mouse Ese2 protein	211	275
Xenopus Intersectin	211	275
Drosophila Dap160-1	211	245
Mouse Ese1 protein	276	341
Mouse Ese2 protein	276	341
Xenopus Intersectin	276	341
Drosophila Dap160-1	276	310
Mouse Ese1 protein	342	414
Mouse Ese2 protein	342	414
Xenopus Intersectin	342	414
Drosophila Dap160-1	342	354
Mouse Ese1 protein	415	480
Mouse Ese2 protein	415	480
Xenopus Intersectin	415	480
Drosophila Dap160-1	415	469
Mouse Ese1 protein	481	545
Mouse Ese2 protein	481	545
Xenopus Intersectin	481	545
Drosophila Dap160-1	481	544
Mouse Ese1 protein	546	611
Mouse Ese2 protein	546	611
Xenopus Intersectin	546	611
Drosophila Dap160-1	546	614

TABLE 2 - Cont'd

[illegible]

-83-

We Claim:

1. An isolated nucleic acid comprising a nucleotide sequence encoding a mammalian Ese1 protein or a splice variant thereof.
- 5 2. The nucleic acid of claim 1, wherein said nucleotide sequence encodes a murine Ese1 protein or a splice variant thereof.
3. The nucleic acid of claim 1, wherein said nucleotide sequence encodes a human Ese1 protein or a splice variant thereof.
- 10 4. The nucleic acid sequence of claim 1, wherein said nucleic acid comprises a nucleotide sequence selected from the group consisting of a genomic sequence, a cDNA sequence, a polydeoxyribonucleic acid nucleotide sequence, a polyribonucleic acid nucleotide sequence, an allelic variant or homologue thereof.
- 15 5. The nucleic acid of claim 1 encoding a protein comprising the amino acid sequence of Sequence ID No. 3 or Sequence ID No. 24.
- 20 6. The nucleic acid of claim 1 comprising the sequence of Sequence ID No. 1, Sequence ID No. 2, Sequence ID No. 22 or Sequence ID No. 23.
7. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of Sequence ID No. 1, Sequence ID No. 2, Sequence ID No. 22, Sequence ID No. 23 and a sequence complementary to any of these sequences.
- 25 8. The nucleic acid of claim 7, wherein said sequence is used as a probe or a primer.
- 30 9. A recombinant vector comprising the isolated nucleic acid of any of the preceding claims.
- 35 10. A host cell comprising the recombinant vector of claim 9.
11. A substantially pure mammalian Ese1 or Ese1L protein.

-84-

12. A substantially pure murine Ese1 or Ese1L protein.
13. A substantially pure human Ese1 or Ese1L protein.
- 5 14. The protein of claim 11 wherein the protein comprises an Ese1 protein comprising the amino acid sequence of Sequence ID No. 3 or the Ese1L protein comprising the amino acid sequence of Sequence ID No. 24.
- 10 15. A substantially pure polypeptide comprising an amino acid sequence of at least 5 consecutive amino acid residues of Sequence ID No. 3 or Sequence ID No. 24.
- 15 16. A substantially pure polypeptide comprising at least one functional domain of a mammalian Ese1 protein or a mammalian Ese1L protein.
17. A substantially pure polypeptide comprising an antigenic determinant of a mammalian Ese1 protein or a mammalian Ese1L protein.
- 20 18. An antibody which binds specifically to a polypeptide of claim 16.
19. A process for recombinantly producing murine Ese1 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 2, 3 or 4 under conditions whereby the Ese1 protein is expressed and isolating the Ese1 protein therefrom.
- 25 20. An isolated nucleic acid comprising a nucleotide sequence encoding a mammalian Ese2 protein or a splice variant thereof.
- 30 21. The nucleic acid of claim 20, wherein said nucleotide sequence encodes a murine Ese2 protein or a splice variant thereof.
22. The nucleic acid of claim 20, wherein said nucleotide sequence encodes a human Ese2 protein or a splice variant thereof.
- 35 23. The nucleic acid sequence of claim 20, wherein said nucleic acid comprises a nucleotide sequence selected from the group consisting of a genomic

-85-

sequence, a cDNA sequence, a polydeoxyribonucleic acid nucleotide sequence, a polyribonucleic acid nucleotide sequence, an allelic variant or homologue thereof.

- 5     24.     The nucleic acid of claim 20 encoding a protein comprising the amino acid sequence of Sequence ID No. 6 or Sequence ID No. 27.
25.     The nucleic acid of claim 20 comprising the sequence of Sequence ID No. 4, Sequence ID No. 5, Sequence ID No. 25 or Sequence ID No. 26.
- 10     26.     An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of Sequence ID No. 4, Sequence ID No. 5, Sequence ID No. 25, Sequence ID No. 26 and a sequence complementary to any of these sequences.
- 15     27.     The nucleic acid of claim 26, wherein said sequence is used as a probe or a primer.
- 20     28.     A recombinant vector comprising the isolated nucleic acid of any of claims 20 to 26.
29.     A host cell comprising the recombinant vector of claim 28.
30.     A substantially pure mammalian Ese2 or Ese2L protein.
- 25     31.     A substantially pure murine Ese2 or Ese2L protein.
32.     A substantially pure human Ese2 or Ese2L protein.
- 30     33.     The protein of claim 32 wherein the protein comprises an Ese2 protein comprising the amino acid sequence of Sequence ID No. 6 or the Ese2L protein comprising the amino acid sequence of Sequence ID No. 27.
- 35     34.     A substantially pure polypeptide comprising an amino acid sequence of at least 5 consecutive amino acid residues of Sequence ID No. 6 or Sequence ID No. 27.



-86-

35. A substantially pure polypeptide comprising at least one functional domain of a mammalian Ese2 protein or a mammalian Ese2L protein.
36. A substantially pure polypeptide comprising an antigenic determinant of a mammalian Ese2 protein or a mammalian Ese2L protein.
37. An antibody which binds specifically to a polypeptide of claim 36.
38. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 20, 21 or 22 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.
39. A pharmaceutical composition for the treatment of mammalian disorders which involve abnormal endocytosis leading to altered cellular functioning, said composition comprising an active ingredient selected from the group consisting of:
- a) an Ese protein selected from the group consisting of Ese1, Ese1L, Ese2, Ese2L,
  - b) a fragment or mimetic thereof or a non-functional mutant protein, fragment or mimetic thereof of the proteins of a); and
  - c) a pharmaceutically acceptable carrier.
40. A method of screening a candidate compound for efficacy in treating a disorder characterized by an abnormality in the endocytotic pathway, wherein said pathway involves an interaction between an Ese1, Ese1L, Ese2 or Ese2L protein and a binding partner of any one of these proteins, comprising screening said candidate compound for its ability to disrupt or promote said interaction as an indication of its efficacy.
41. A method for preventing or treating a disorder in a mammal characterized by an abnormality in the endocytotic pathway, wherein said pathway involves an interaction between an Ese1, Ese1L, Ese2 or Ese2L protein and a binding partner of any one of these proteins, comprising the step of disrupting or promoting said interaction *in vivo*.

42. The method of claim 40 or 41, wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.
- 5
43. A method for screening a candidate compound for effectiveness as an antagonist of an Ese protein selected from the group consisting of Ese1, Ese1L, Ese2 and Ese2L, said method comprising:
- 10 (a) providing an assay method for determining the endocytotic regulatory capacity of a selected Ese protein; and
- (b) determining the endocytotic regulatory capacity of the selected Ese protein in the presence or absence of the candidate compound, wherein a reduced level of endocytotic regulatory capacity in the presence of the candidate compound indicates effectiveness of the compound as an antagonist.
- 15
44. A method for treating in a mammal a disorder associated with an undesired level of endocytotic activity of an Ese protein selected from the group consisting of Ese1, Ese1L, Ese2 and Ese2L, said method comprising administering to the mammal
- 20 an effective amount of a substance selected from the group consisting of:
- (a) an Ese protein antagonist;
- (b) an antibody which binds specifically to an Ese protein;
- (c) an antisense strand comprising a nucleic acid sequence complementary to a sequence or fragment of the sequence represented by Sequence ID Nos. 1, 2, 4, 5, 22, 23, 25 and 26 and capable of hybridizing to the nucleic acid
- 25 sequence encoding an Ese protein;
- (d) an agent which down regulates the expression of an Ese gene encoding for an Ese protein;
- (e) an antagonist of an Ese protein binding partner; and
- 30 (f) an Ese agonist.
45. A method for suppressing in a mammal, abnormal proliferation of a cell capable of being stimulated to proliferate by a growth factor receptor, the method comprising administering to the mammal an effective amount of a Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein,
- 35 wherein the Ese protein is selected from the group consisting of Ese1, Ese1L, Ese2 and Ese2L.

-88-

46. A method for preventing viral infection in a mammal, said method comprising administering to the mammal an effective amount of an Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein or an Ese mutant protein not capable of regulating endocytosis, wherein the Ese protein is selected from the group consisting of Ese1, Ese1L, Ese2 and Ese2L.

47. A method for promoting endocytosis in selected cells in a mammal in need of such treatment, said method comprising administering to the mammal an effective amount of an Ese protein or an active analogue, mimic or fragment thereof, wherein the Ese protein is selected from the group consisting of Ese1, Ese1L, Ese2 and Ese2L.

48. A method for blocking clathrin-mediated endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising overexpressing Ese1 protein or an active analogue, mimic or fragment thereof in said cells.

49. A method for regulating endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising providing an Ese1-Esps 15 complex and further binding dynamin to said complex to regulate components of the endocytic pathway.




FIGURE 1




FIGURE 2A

Ese 11.

EH EH P<sub>n</sub>

DBL PH C2

ES62L.    DBL PH C2

[illegible]

FIGURE 2B

A) Yeast two hybrid screen: Eps15 and Eps15R bind the Ese1 coiled-coil domain




FIGURE 3A




FIGURE 3B






FIGURE 4

7/9

A) Yeast two hybrid screen: Dynamin binds the Ese1 SH3 domains




FIGURE 5A

B) Ese1 overexpression recruits endogenous Dynamin




FIGURE 5B




FIGURE 6

Model: The Eps:Ese complex recruits critical components for coated pit formation and scission




FIGURE 7

# DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 3477-89

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **ESE GENES AND PROTEINS**,

the specification of which

☐ is attached hereto

OR

☒ was filed on **April 27, 1999** as PCT International Application Number **PCT/CA99/00375** and was amended on

\_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

2,230,201	CA	04/27/1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

None	
Application Number(s)	Filing Date (MM/DD/YYYY)
Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

60/118,739	02/05/1999	Pending
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
PCT/CA99/00375	04/27/1999	Published
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned
Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

**Customer Number 20792**

Send correspondence to: Karen A. Magri  
Myers Bigel Sibley & Sajovec  
Post Office Box 37428  
Raleigh, NC 27627

Direct telephone calls to: Karen A. Magri  
(919)854-1400

Facsimile: (919) 854-1401

Full name of (first/sole) inventor: **Sean E. Egan**

Inventor's  
Signature: Sean Egan Date: June 28, 2001

Residence: Canada

Citizenship: Canada

Post Office Address: c/o The Hospital for Sick Children  
555 University Avenue  
Toronto, Ontario M5G 1X8  
Canada CAY

Full name of second inventor: Wei Wang

Inventor's  
Signature: *Wei Wang* Date: Jun 28, 2001

Residence: Canada

Citizenship: Canada

Post Office Address: c/o The Hospital for Sick Children  
555 University Avenue  
Toronto, Ontario M5G 1X8  
Canada CAK



Full name of second inventor: **Ameet Sengar**

Inventor's

Signature: Ameet Sengar

Date: June 28/01

Residence:

Canada

Citizenship:

Canada

Post Office Address:

c/o The Hospital for Sick Children


555 University Avenue

Toronto, Ontario M5G 1X8

Canada

CAK

United States Patent & Trademark Office  
Office of Initial Patent Examination – Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ **Scanned copy is best available.** Drawings Fig. 4, Fig. 5B  
and Fig. 6 are very dark.